WO2019114666A1 - 生物活性物偶联物及其制备方法和用途 - Google Patents
生物活性物偶联物及其制备方法和用途 Download PDFInfo
- Publication number
- WO2019114666A1 WO2019114666A1 PCT/CN2018/120125 CN2018120125W WO2019114666A1 WO 2019114666 A1 WO2019114666 A1 WO 2019114666A1 CN 2018120125 W CN2018120125 W CN 2018120125W WO 2019114666 A1 WO2019114666 A1 WO 2019114666A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- integer
- conjugate
- pharmaceutically acceptable
- Prior art date
Links
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 238000010168 coupling process Methods 0.000 claims abstract description 84
- 238000005859 coupling reaction Methods 0.000 claims abstract description 80
- 230000008878 coupling Effects 0.000 claims abstract description 79
- 239000003814 drug Substances 0.000 claims abstract description 52
- 229940079593 drug Drugs 0.000 claims abstract description 50
- 230000000694 effects Effects 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 230000001413 cellular effect Effects 0.000 claims abstract description 10
- 230000002159 abnormal effect Effects 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 228
- -1 Cit Chemical compound 0.000 claims description 214
- 206010028980 Neoplasm Diseases 0.000 claims description 133
- 210000004027 cell Anatomy 0.000 claims description 122
- 125000000217 alkyl group Chemical group 0.000 claims description 92
- 229910052739 hydrogen Inorganic materials 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 76
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 64
- 150000003839 salts Chemical class 0.000 claims description 64
- 239000001257 hydrogen Substances 0.000 claims description 63
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 58
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 52
- 230000008685 targeting Effects 0.000 claims description 48
- 125000000623 heterocyclic group Chemical group 0.000 claims description 47
- 229950001460 sacituzumab Drugs 0.000 claims description 47
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 43
- 229910052757 nitrogen Inorganic materials 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 40
- 125000004432 carbon atom Chemical group C* 0.000 claims description 37
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 150000002367 halogens Chemical class 0.000 claims description 28
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 28
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 27
- 206010017758 gastric cancer Diseases 0.000 claims description 27
- 201000011549 stomach cancer Diseases 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 25
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 239000003446 ligand Substances 0.000 claims description 23
- 150000002923 oximes Chemical class 0.000 claims description 23
- 206010006187 Breast cancer Diseases 0.000 claims description 22
- 208000026310 Breast neoplasm Diseases 0.000 claims description 22
- 229960000575 trastuzumab Drugs 0.000 claims description 22
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 21
- 125000005647 linker group Chemical group 0.000 claims description 21
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 20
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 229960002087 pertuzumab Drugs 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 229940024606 amino acid Drugs 0.000 claims description 18
- 210000004881 tumor cell Anatomy 0.000 claims description 18
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 17
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 16
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 230000000259 anti-tumor effect Effects 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 15
- 150000003384 small molecules Chemical class 0.000 claims description 15
- YQAIUOWPSUOINN-IUCAKERBSA-N Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN YQAIUOWPSUOINN-IUCAKERBSA-N 0.000 claims description 14
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 230000005764 inhibitory process Effects 0.000 claims description 14
- 108010017391 lysylvaline Proteins 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 13
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 12
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 12
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 12
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims description 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 201000005202 lung cancer Diseases 0.000 claims description 12
- 208000020816 lung neoplasm Diseases 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 11
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 10
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 10
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 10
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 10
- 230000004071 biological effect Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims description 9
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- AAQGRPOPTAUUBM-ZLUOBGJFSA-N Ala-Ala-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O AAQGRPOPTAUUBM-ZLUOBGJFSA-N 0.000 claims description 8
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical group [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 8
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 claims description 8
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims description 8
- 125000002723 alicyclic group Chemical group 0.000 claims description 8
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 108010073969 valyllysine Proteins 0.000 claims description 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 7
- 108700012457 TACSTD2 Proteins 0.000 claims description 7
- 125000004419 alkynylene group Chemical group 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- 150000003852 triazoles Chemical class 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 claims description 6
- 101150054149 ANGPTL4 gene Proteins 0.000 claims description 6
- 102000045205 Angiopoietin-Like Protein 4 Human genes 0.000 claims description 6
- 108700042530 Angiopoietin-Like Protein 4 Proteins 0.000 claims description 6
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims description 6
- 108010085074 Brevican Proteins 0.000 claims description 6
- 102100032312 Brevican core protein Human genes 0.000 claims description 6
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 6
- 102100024220 CD180 antigen Human genes 0.000 claims description 6
- 102100025221 CD70 antigen Human genes 0.000 claims description 6
- 102100032768 Complement receptor type 2 Human genes 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 102100031517 Fc receptor-like protein 1 Human genes 0.000 claims description 6
- 101710120224 Fc receptor-like protein 1 Proteins 0.000 claims description 6
- 102100031511 Fc receptor-like protein 2 Human genes 0.000 claims description 6
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 6
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 6
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 claims description 6
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims description 6
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 6
- 101000980829 Homo sapiens CD180 antigen Proteins 0.000 claims description 6
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 6
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims description 6
- 101000846911 Homo sapiens Fc receptor-like protein 2 Proteins 0.000 claims description 6
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 6
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 6
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 claims description 6
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 6
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 claims description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 6
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 claims description 6
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 claims description 6
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims description 6
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 6
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- 102100037603 P2X purinoceptor 5 Human genes 0.000 claims description 6
- 101710189969 P2X purinoceptor 5 Proteins 0.000 claims description 6
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 6
- 108091006938 SLC39A6 Proteins 0.000 claims description 6
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 claims description 6
- 102100026160 Tomoregulin-2 Human genes 0.000 claims description 6
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 6
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims description 6
- 102100023144 Zinc transporter ZIP6 Human genes 0.000 claims description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 102000006495 integrins Human genes 0.000 claims description 6
- 108010044426 integrins Proteins 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 125000000101 thioether group Chemical group 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 101150029707 ERBB2 gene Proteins 0.000 claims description 5
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000003368 amide group Chemical group 0.000 claims description 5
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 229940043355 kinase inhibitor Drugs 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 5
- 125000003375 sulfoxide group Chemical group 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 claims description 4
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 claims description 4
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 3
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 claims description 3
- 102100036732 Actin, aortic smooth muscle Human genes 0.000 claims description 3
- 102100026439 Adhesion G protein-coupled receptor E1 Human genes 0.000 claims description 3
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 claims description 3
- 108010003133 Aldo-Keto Reductase Family 1 Member C2 Proteins 0.000 claims description 3
- 102100026446 Aldo-keto reductase family 1 member C1 Human genes 0.000 claims description 3
- 102100024089 Aldo-keto reductase family 1 member C2 Human genes 0.000 claims description 3
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 claims description 3
- 102000013918 Apolipoproteins E Human genes 0.000 claims description 3
- 108010025628 Apolipoproteins E Proteins 0.000 claims description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 3
- 108010055400 Aspartate kinase Proteins 0.000 claims description 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- 108010051479 Bombesin Proteins 0.000 claims description 3
- 102000013585 Bombesin Human genes 0.000 claims description 3
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 claims description 3
- 101800004538 Bradykinin Proteins 0.000 claims description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 3
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims description 3
- 108010008629 CA-125 Antigen Proteins 0.000 claims description 3
- 102100031168 CCN family member 2 Human genes 0.000 claims description 3
- 108010017987 CD30 Ligand Proteins 0.000 claims description 3
- 108010029697 CD40 Ligand Proteins 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 102100035350 CUB domain-containing protein 1 Human genes 0.000 claims description 3
- 108050007957 Cadherin Proteins 0.000 claims description 3
- 102000000905 Cadherin Human genes 0.000 claims description 3
- 102100024155 Cadherin-11 Human genes 0.000 claims description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 3
- 102100036369 Carbonic anhydrase 6 Human genes 0.000 claims description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 3
- 102100032219 Cathepsin D Human genes 0.000 claims description 3
- 102100035654 Cathepsin S Human genes 0.000 claims description 3
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 claims description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 3
- 108050009302 Claudin Proteins 0.000 claims description 3
- 102000002029 Claudin Human genes 0.000 claims description 3
- 102100024335 Collagen alpha-1(VII) chain Human genes 0.000 claims description 3
- 102100024338 Collagen alpha-3(VI) chain Human genes 0.000 claims description 3
- 102100037077 Complement C1q subcomponent subunit A Human genes 0.000 claims description 3
- 102100037085 Complement C1q subcomponent subunit B Human genes 0.000 claims description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- 102100026139 DNA damage-inducible transcript 4 protein Human genes 0.000 claims description 3
- 230000006820 DNA synthesis Effects 0.000 claims description 3
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 3
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- 102100036466 Delta-like protein 3 Human genes 0.000 claims description 3
- 102100033553 Delta-like protein 4 Human genes 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 102000000820 Enterotoxin Receptors Human genes 0.000 claims description 3
- 108010001687 Enterotoxin Receptors Proteins 0.000 claims description 3
- 102100033942 Ephrin-A4 Human genes 0.000 claims description 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 3
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 3
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- 102100022629 Fructose-2,6-bisphosphatase Human genes 0.000 claims description 3
- 102100030385 Granzyme B Human genes 0.000 claims description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 3
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 3
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 3
- 102100028006 Heme oxygenase 1 Human genes 0.000 claims description 3
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 claims description 3
- 101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 claims description 3
- 101000718225 Homo sapiens Adhesion G protein-coupled receptor E1 Proteins 0.000 claims description 3
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 claims description 3
- 101000718028 Homo sapiens Aldo-keto reductase family 1 member C1 Proteins 0.000 claims description 3
- 101000890626 Homo sapiens Allograft inflammatory factor 1 Proteins 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 claims description 3
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 claims description 3
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 3
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 3
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims description 3
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims description 3
- 101000737742 Homo sapiens CUB domain-containing protein 1 Proteins 0.000 claims description 3
- 101000762236 Homo sapiens Cadherin-11 Proteins 0.000 claims description 3
- 101000714525 Homo sapiens Carbonic anhydrase 6 Proteins 0.000 claims description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 3
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 claims description 3
- 101000947086 Homo sapiens Cathepsin S Proteins 0.000 claims description 3
- 101000909498 Homo sapiens Collagen alpha-1(VII) chain Proteins 0.000 claims description 3
- 101000909506 Homo sapiens Collagen alpha-3(VI) chain Proteins 0.000 claims description 3
- 101000740726 Homo sapiens Complement C1q subcomponent subunit A Proteins 0.000 claims description 3
- 101000740680 Homo sapiens Complement C1q subcomponent subunit B Proteins 0.000 claims description 3
- 101000912753 Homo sapiens DNA damage-inducible transcript 4 protein Proteins 0.000 claims description 3
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims description 3
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims description 3
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims description 3
- 101000925259 Homo sapiens Ephrin-A4 Proteins 0.000 claims description 3
- 101000823463 Homo sapiens Fructose-2,6-bisphosphatase Proteins 0.000 claims description 3
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 claims description 3
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 3
- 101001079623 Homo sapiens Heme oxygenase 1 Proteins 0.000 claims description 3
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 3
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 claims description 3
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims description 3
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims description 3
- 101000604590 Homo sapiens Keratin, type I cuticular Ha3-I Proteins 0.000 claims description 3
- 101001039113 Homo sapiens Leucine-rich repeat-containing protein 15 Proteins 0.000 claims description 3
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 3
- 101001065609 Homo sapiens Lumican Proteins 0.000 claims description 3
- 101001038507 Homo sapiens Ly6/PLAUR domain-containing protein 3 Proteins 0.000 claims description 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 3
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 claims description 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 3
- 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 claims description 3
- 101001011886 Homo sapiens Matrix metalloproteinase-16 Proteins 0.000 claims description 3
- 101000798109 Homo sapiens Melanotransferrin Proteins 0.000 claims description 3
- 101000956317 Homo sapiens Membrane-spanning 4-domains subfamily A member 4A Proteins 0.000 claims description 3
- 101001014567 Homo sapiens Membrane-spanning 4-domains subfamily A member 7 Proteins 0.000 claims description 3
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 3
- 101000604123 Homo sapiens Noggin Proteins 0.000 claims description 3
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 3
- 101000897042 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 claims description 3
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 claims description 3
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 claims description 3
- 101000935642 Homo sapiens Phosphoinositide 3-kinase adapter protein 1 Proteins 0.000 claims description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 3
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 3
- 101000595907 Homo sapiens Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Proteins 0.000 claims description 3
- 101000881678 Homo sapiens Prolyl hydroxylase EGLN3 Proteins 0.000 claims description 3
- 101000804792 Homo sapiens Protein Wnt-5a Proteins 0.000 claims description 3
- 101000835984 Homo sapiens SLIT and NTRK-like protein 6 Proteins 0.000 claims description 3
- 101000701446 Homo sapiens Stanniocalcin-2 Proteins 0.000 claims description 3
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 claims description 3
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 claims description 3
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 claims description 3
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 claims description 3
- 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 claims description 3
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 claims description 3
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 3
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims description 3
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 claims description 3
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 claims description 3
- 101000808114 Homo sapiens Uroplakin-1b Proteins 0.000 claims description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 3
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 claims description 3
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 3
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 claims description 3
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims description 3
- 102100037850 Interferon gamma Human genes 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 102100038185 Keratin, type I cuticular Ha3-I Human genes 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 102100035792 Kininogen-1 Human genes 0.000 claims description 3
- 102000011743 Kisspeptin-1 Receptors Human genes 0.000 claims description 3
- 108010076800 Kisspeptin-1 Receptors Proteins 0.000 claims description 3
- 101710159002 L-lactate oxidase Proteins 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 102000017578 LAG3 Human genes 0.000 claims description 3
- 102100040645 Leucine-rich repeat-containing protein 15 Human genes 0.000 claims description 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 3
- 102100032114 Lumican Human genes 0.000 claims description 3
- 102100040281 Ly6/PLAUR domain-containing protein 3 Human genes 0.000 claims description 3
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 claims description 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 3
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 claims description 3
- 102100030200 Matrix metalloproteinase-16 Human genes 0.000 claims description 3
- 101150031009 Mcpt8 gene Proteins 0.000 claims description 3
- 102100032239 Melanotransferrin Human genes 0.000 claims description 3
- 102100032512 Membrane-spanning 4-domains subfamily A member 7 Human genes 0.000 claims description 3
- 108090000015 Mesothelin Proteins 0.000 claims description 3
- 102000003735 Mesothelin Human genes 0.000 claims description 3
- 108010008707 Mucin-1 Proteins 0.000 claims description 3
- 102100034256 Mucin-1 Human genes 0.000 claims description 3
- 102100023123 Mucin-16 Human genes 0.000 claims description 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 102100035486 Nectin-4 Human genes 0.000 claims description 3
- 101710043865 Nectin-4 Proteins 0.000 claims description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 3
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 claims description 3
- 102000004473 OX40 Ligand Human genes 0.000 claims description 3
- 108010042215 OX40 Ligand Proteins 0.000 claims description 3
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 claims description 3
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 claims description 3
- 102100028238 Phosphoinositide 3-kinase adapter protein 1 Human genes 0.000 claims description 3
- 102100035194 Placenta growth factor Human genes 0.000 claims description 3
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 3
- 102100035198 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Human genes 0.000 claims description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 3
- 102100037247 Prolyl hydroxylase EGLN3 Human genes 0.000 claims description 3
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 3
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 102100025504 SLIT and NTRK-like protein 6 Human genes 0.000 claims description 3
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims description 3
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims description 3
- 102000005157 Somatostatin Human genes 0.000 claims description 3
- 108010056088 Somatostatin Proteins 0.000 claims description 3
- 102100030510 Stanniocalcin-2 Human genes 0.000 claims description 3
- 102100028848 Stromelysin-2 Human genes 0.000 claims description 3
- 101710172711 Structural protein Proteins 0.000 claims description 3
- 102100035721 Syndecan-1 Human genes 0.000 claims description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 claims description 3
- 108010000499 Thromboplastin Proteins 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 102100030859 Tissue factor Human genes 0.000 claims description 3
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 3
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 3
- 102100023489 Transcription factor 4 Human genes 0.000 claims description 3
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 3
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 claims description 3
- 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 claims description 3
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims description 3
- 101710190034 Trophoblast glycoprotein Proteins 0.000 claims description 3
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 3
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 3
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 102100038853 Uroplakin-1b Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 3
- 102000043366 Wnt-5a Human genes 0.000 claims description 3
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 claims description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- 108700004675 bleomycetin Proteins 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 claims description 3
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims description 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 3
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 3
- 229960001573 cabazitaxel Drugs 0.000 claims description 3
- 229940127093 camptothecin Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 3
- 229960004630 chlorambucil Drugs 0.000 claims description 3
- 229960002436 cladribine Drugs 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 229960000640 dactinomycin Drugs 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- 229940127276 delta-like ligand 3 Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- 229940116977 epidermal growth factor Drugs 0.000 claims description 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- 229960000390 fludarabine Drugs 0.000 claims description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 229940014144 folate Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 3
- 229960001924 melphalan Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 230000017074 necrotic cell death Effects 0.000 claims description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
- 229960001756 oxaliplatin Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 3
- 229960001237 podophyllotoxin Drugs 0.000 claims description 3
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 3
- 239000003207 proteasome inhibitor Substances 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 229960000553 somatostatin Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- 239000003744 tubulin modulator Substances 0.000 claims description 3
- 230000005747 tumor angiogenesis Effects 0.000 claims description 3
- 230000004565 tumor cell growth Effects 0.000 claims description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- KJWNKJWHMQSPNZ-UHFFFAOYSA-N 1-methylpiperidin-2-amine Chemical compound CN1CCCCC1N KJWNKJWHMQSPNZ-UHFFFAOYSA-N 0.000 claims description 2
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 claims description 2
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 claims description 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 229940121959 Carbonic anhydrase IX inhibitor Drugs 0.000 claims description 2
- 108050006400 Cyclin Proteins 0.000 claims description 2
- 102000016736 Cyclin Human genes 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims description 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 2
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims description 2
- 102000046202 Sodium-Phosphate Cotransporter Proteins Human genes 0.000 claims description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 2
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000001345 alkine derivatives Chemical group 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
- 125000005361 aryl sulfoxide group Chemical group 0.000 claims description 2
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 2
- 150000002224 folic acids Chemical class 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 229960004198 guanidine Drugs 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 229940127126 plasminogen activator Drugs 0.000 claims description 2
- 150000003057 platinum Chemical class 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 150000003230 pyrimidines Chemical group 0.000 claims description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 2
- 108091006284 sodium-phosphate co-transporters Proteins 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 125000001174 sulfone group Chemical group 0.000 claims description 2
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229930002839 ionone Natural products 0.000 claims 1
- 150000002499 ionone derivatives Chemical class 0.000 claims 1
- 150000004291 polyenes Chemical class 0.000 claims 1
- AFCCDDWKHLHPDF-UHFFFAOYSA-M metam-sodium Chemical compound [Na+].CNC([S-])=S AFCCDDWKHLHPDF-UHFFFAOYSA-M 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 150
- 230000015572 biosynthetic process Effects 0.000 description 99
- 238000003786 synthesis reaction Methods 0.000 description 99
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 95
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
- 239000000243 solution Substances 0.000 description 57
- 239000000562 conjugate Substances 0.000 description 55
- 239000000611 antibody drug conjugate Substances 0.000 description 46
- 229940049595 antibody-drug conjugate Drugs 0.000 description 46
- 238000006243 chemical reaction Methods 0.000 description 46
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 43
- 241000699670 Mus sp. Species 0.000 description 42
- 235000019439 ethyl acetate Nutrition 0.000 description 40
- 238000000746 purification Methods 0.000 description 37
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 36
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 36
- 239000000047 product Substances 0.000 description 35
- 239000011541 reaction mixture Substances 0.000 description 33
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 30
- 229950000143 sacituzumab govitecan Drugs 0.000 description 29
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 description 29
- 101150034590 DAR1 gene Proteins 0.000 description 28
- 101100393304 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GPD1 gene Proteins 0.000 description 28
- 239000012071 phase Substances 0.000 description 26
- 239000003053 toxin Substances 0.000 description 26
- 231100000765 toxin Toxicity 0.000 description 26
- 108700012359 toxins Proteins 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 0 C*=Nc1ccc(COC(SC)=O)cc1 Chemical compound C*=Nc1ccc(COC(SC)=O)cc1 0.000 description 24
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 238000002953 preparative HPLC Methods 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
- 238000010586 diagram Methods 0.000 description 19
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 18
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 18
- 238000010172 mouse model Methods 0.000 description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 17
- 125000004122 cyclic group Chemical group 0.000 description 17
- 125000006413 ring segment Chemical group 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 101100330723 Arabidopsis thaliana DAR2 gene Proteins 0.000 description 15
- 101100330724 Arabidopsis thaliana DAR3 gene Proteins 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 230000004614 tumor growth Effects 0.000 description 15
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 12
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 238000007920 subcutaneous administration Methods 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 239000013078 crystal Substances 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 125000004434 sulfur atom Chemical group 0.000 description 10
- 210000003462 vein Anatomy 0.000 description 10
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 9
- KOABBLJRZNHNOS-UHFFFAOYSA-N 6-(2-methylsulfonylpyrimidin-5-yl)hex-5-ynoic acid Chemical compound CS(=O)(=O)C1=NC=C(C=N1)C#CCCCC(=O)O KOABBLJRZNHNOS-UHFFFAOYSA-N 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000010253 intravenous injection Methods 0.000 description 9
- 125000003003 spiro group Chemical group 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 8
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 239000012046 mixed solvent Substances 0.000 description 8
- 239000012085 test solution Substances 0.000 description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- 230000003698 anagen phase Effects 0.000 description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 description 7
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000004580 weight loss Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 206010070863 Toxicity to various agents Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000004262 preparative liquid chromatography Methods 0.000 description 6
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 101100330725 Arabidopsis thaliana DAR4 gene Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 5
- 229940127121 immunoconjugate Drugs 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 5
- KJJITHAVZJBOHG-NSHDSACASA-N (2s)-2-amino-5-(carbamoylamino)-n-[4-(hydroxymethyl)phenyl]pentanamide Chemical compound NC(=O)NCCC[C@H](N)C(=O)NC1=CC=C(CO)C=C1 KJJITHAVZJBOHG-NSHDSACASA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 4
- PWWZVPARKBBOQV-UHFFFAOYSA-N CSC1=NC=C(C=N1)C#CCCCC(=O)O Chemical compound CSC1=NC=C(C=N1)C#CCCCC(=O)O PWWZVPARKBBOQV-UHFFFAOYSA-N 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- 238000006845 Michael addition reaction Methods 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000004579 body weight change Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 239000002274 desiccant Substances 0.000 description 4
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 4
- 238000013365 molecular weight analysis method Methods 0.000 description 4
- 229960005190 phenylalanine Drugs 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229940037001 sodium edetate Drugs 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- DNVALMNMVGZIQM-UHFFFAOYSA-N CS(=O)(=O)C1=NC=C(C=N1)C#CCCCCN Chemical compound CS(=O)(=O)C1=NC=C(C=N1)C#CCCCCN DNVALMNMVGZIQM-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- GAGSACJPEXLTCF-UHFFFAOYSA-N 2-(2-methylsulfonylpyrimidin-5-yl)-N-prop-2-ynyl-1,3-oxazole-4-carboxamide Chemical compound CS(=O)(=O)C1=NC=C(C=N1)C=1OC=C(N=1)C(=O)NCC#C GAGSACJPEXLTCF-UHFFFAOYSA-N 0.000 description 2
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 2
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 2
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 2
- WJICIUARICPBPE-UHFFFAOYSA-N 6-(2-methylsulfonylpyrimidin-5-yl)hex-5-ynamide Chemical compound CS(=O)(=O)C1=NC=C(C=N1)C#CCCCC(=O)N WJICIUARICPBPE-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100368708 Homo sapiens TACSTD2 gene Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 101150117918 Tacstd2 gene Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 2
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 2
- 239000012964 benzotriazole Substances 0.000 description 2
- QIXRWIVDBZJDGD-UHFFFAOYSA-N benzyl (4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OCC1=CC=CC=C1 QIXRWIVDBZJDGD-UHFFFAOYSA-N 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 229960000455 brentuximab vedotin Drugs 0.000 description 2
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical class C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 150000004651 carbonic acid esters Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutanoic acid Natural products NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- NHEPKQDGPJQVOO-UHFFFAOYSA-N hex-1-yn-1-amine Chemical compound CCCCC#CN NHEPKQDGPJQVOO-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229950004101 inotuzumab ozogamicin Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- IODCOTMMYYOZDW-SFHVURJKSA-N tert-butyl N-[4-[[[(2S)-2-amino-3-phenylpropanoyl]amino]methyl]phenyl]carbamate Chemical compound C(C)(C)(C)OC(NC1=CC=C(C=C1)CNC([C@H](CC1=CC=CC=C1)N)=O)=O IODCOTMMYYOZDW-SFHVURJKSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- WVHYSQPIGWZPAZ-ZETCQYMHSA-N (2S)-2-amino-N-[4-(hydroxymethyl)phenyl]propanamide Chemical compound C[C@H](N)C(=O)NC1=CC=C(CO)C=C1 WVHYSQPIGWZPAZ-ZETCQYMHSA-N 0.000 description 1
- ZYJPUMXJBDHSIF-LLVKDONJSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-LLVKDONJSA-N 0.000 description 1
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 1
- VEGGTWZUZGZKHY-GJZGRUSLSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)-n-[4-(hydroxymethyl)phenyl]pentanamide Chemical compound NC(=O)NCCC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)NC1=CC=C(CO)C=C1 VEGGTWZUZGZKHY-GJZGRUSLSA-N 0.000 description 1
- NBMSMZSRTIOFOK-SFHVURJKSA-N (2s)-5-(carbamoylamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCNC(=O)N)C(O)=O)C3=CC=CC=C3C2=C1 NBMSMZSRTIOFOK-SFHVURJKSA-N 0.000 description 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 1
- HCPKEHXHZCCCGP-HYXAFXHYSA-N (Z)-6-(2-methylsulfonylpyrimidin-5-yl)hex-5-enoic acid Chemical compound CS(=O)(=O)C1=NC=C(C=N1)\C=C/CCCC(=O)O HCPKEHXHZCCCGP-HYXAFXHYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- PQQRHWFRZHFGFM-UHFFFAOYSA-N 1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC=N1 PQQRHWFRZHFGFM-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- BQHWATVEWGHHHF-UHFFFAOYSA-N 2,2-dimethyl-3-phenylpropanoic acid Chemical compound OC(=O)C(C)(C)CC1=CC=CC=C1 BQHWATVEWGHHHF-UHFFFAOYSA-N 0.000 description 1
- JDEUUKYNTHHAQH-UHFFFAOYSA-N 2,2-dimethylbutanamide Chemical compound CCC(C)(C)C(N)=O JDEUUKYNTHHAQH-UHFFFAOYSA-N 0.000 description 1
- OGDSZJXKUNAQBN-UHFFFAOYSA-N 2-(2-methylsulfanylpyrimidin-5-yl)-1,3-oxazole-4-carboxylic acid Chemical compound CSC1=NC=C(C=N1)C=1OC=C(N=1)C(=O)O OGDSZJXKUNAQBN-UHFFFAOYSA-N 0.000 description 1
- YAZRYGKUWWEYAA-UHFFFAOYSA-N 2-(2-methylsulfanylpyrimidin-5-yl)-1,3-thiazole-4-carboxylic acid Chemical compound CSc1ncc(cn1)-c1nc(cs1)C(O)=O YAZRYGKUWWEYAA-UHFFFAOYSA-N 0.000 description 1
- JOOWKFWUSRWHOM-UHFFFAOYSA-N 2-(2-methylsulfonylpyrimidin-5-yl)-1,3-oxazole-4-carboxylic acid Chemical compound CS(=O)(=O)c1ncc(cn1)-c1nc(co1)C(O)=O JOOWKFWUSRWHOM-UHFFFAOYSA-N 0.000 description 1
- KUVAOBJQGQJHOF-UHFFFAOYSA-N 2-(2-methylsulfonylpyrimidin-5-yl)-1,3-thiazole-4-carboxylic acid Chemical compound CS(=O)(=O)c1ncc(cn1)-c1nc(cs1)C(O)=O KUVAOBJQGQJHOF-UHFFFAOYSA-N 0.000 description 1
- BEGREHRAUWCAHV-UHFFFAOYSA-N 2-bromo-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(Br)=N1 BEGREHRAUWCAHV-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- IHQLDONSQYPRJN-UHFFFAOYSA-N 4,6-dihydro-1H-thieno[3,4-d]imidazole Chemical compound N1C=NC2=C1CSC2 IHQLDONSQYPRJN-UHFFFAOYSA-N 0.000 description 1
- RTJLJCPSZXRGLW-UHFFFAOYSA-N 4-(2-methylsulfanylpyrimidin-5-yl)benzoic acid Chemical compound CSC1=NC=C(C=N1)C1=CC=C(C(=O)O)C=C1 RTJLJCPSZXRGLW-UHFFFAOYSA-N 0.000 description 1
- AJJPACDDUIBVGL-UHFFFAOYSA-N 4-(2-methylsulfonylpyrimidin-5-yl)-N-prop-2-ynylbenzamide Chemical compound CS(=O)(=O)C1=NC=C(C=N1)C1=CC=C(C(=O)NCC#C)C=C1 AJJPACDDUIBVGL-UHFFFAOYSA-N 0.000 description 1
- MQLHTRVWEATIKS-UHFFFAOYSA-N 4-(2-methylsulfonylpyrimidin-5-yl)benzoic acid Chemical compound CS(=O)(=O)C1=NC=C(C=N1)C1=CC=C(C(=O)O)C=C1 MQLHTRVWEATIKS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- BFWYZZPDZZGSLJ-UHFFFAOYSA-N 4-(aminomethyl)aniline Chemical compound NCC1=CC=C(N)C=C1 BFWYZZPDZZGSLJ-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- WFLSPLBDSJLPFW-UHFFFAOYSA-N 5-bromo-2-methylsulfanylpyrimidine Chemical compound CSC1=NC=C(Br)C=N1 WFLSPLBDSJLPFW-UHFFFAOYSA-N 0.000 description 1
- JMVIGARDVHRAKT-UHFFFAOYSA-N 6-(2-methylsulfonylpyrimidin-5-yl)-N-prop-2-ynylhex-5-yn-1-amine Chemical compound CS(=O)(=O)C1=NC=C(C=N1)C#CCCCCNCC#C JMVIGARDVHRAKT-UHFFFAOYSA-N 0.000 description 1
- 241000134916 Amanita Species 0.000 description 1
- 241000156724 Antirhea Species 0.000 description 1
- WSUCXGDWYKJQHB-UHFFFAOYSA-N Bc(cn1)cnc1SC Chemical compound Bc(cn1)cnc1SC WSUCXGDWYKJQHB-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- OTAQHUVZWFGGKK-UHFFFAOYSA-N CC(C)(CCC1=CC=C(C=C1)NC)OC(=O)N Chemical compound CC(C)(CCC1=CC=C(C=C1)NC)OC(=O)N OTAQHUVZWFGGKK-UHFFFAOYSA-N 0.000 description 1
- UBDSSBKQHAVPBR-QCDSWUKFSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C=O)=O)NC(COCC(NCCOCC[n]1nnc(CNC(CCCC#Cc(cn2)cnc2S(C)(=O)=O)=O)c1)=O)=O Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C=O)=O)NC(COCC(NCCOCC[n]1nnc(CNC(CCCC#Cc(cn2)cnc2S(C)(=O)=O)=O)c1)=O)=O UBDSSBKQHAVPBR-QCDSWUKFSA-N 0.000 description 1
- MQWUTZXPWCPGCY-HYSPUSHZSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)C1(C)C([C@@H](C)C(N[C@@H](Cc1ccccc1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)C1(C)C([C@@H](C)C(N[C@@H](Cc1ccccc1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O MQWUTZXPWCPGCY-HYSPUSHZSA-N 0.000 description 1
- YLCALJUVUMZWCQ-AIUALCAISA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(NC(Cc1ccccc1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(NC(Cc1ccccc1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O YLCALJUVUMZWCQ-AIUALCAISA-N 0.000 description 1
- CITZOXNBHKSONK-MQIDTILOSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(NC(Cc1ccccn1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(NC(Cc1ccccn1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O CITZOXNBHKSONK-MQIDTILOSA-N 0.000 description 1
- GSCFBPLYQQTAIU-PXDAZRQKSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(NCC(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(NCC(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O GSCFBPLYQQTAIU-PXDAZRQKSA-N 0.000 description 1
- YLCALJUVUMZWCQ-DTJOLGTLSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O YLCALJUVUMZWCQ-DTJOLGTLSA-N 0.000 description 1
- FPAMGZUIMMPDMZ-YVCFKVKBSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(NCc(cc1)ccc1NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCC#Cc(cn1)cnc1S(C)(=O)=O)=O)=O)=O)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(NCc(cc1)ccc1NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCC#Cc(cn1)cnc1S(C)(=O)=O)=O)=O)=O)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O FPAMGZUIMMPDMZ-YVCFKVKBSA-N 0.000 description 1
- CITZOXNBHKSONK-FONBTESGSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccn1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccn1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O CITZOXNBHKSONK-FONBTESGSA-N 0.000 description 1
- CTLMWXLEIGKVJF-DJOZAEGOSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](CC(NCc(cc1)ccc1N)=O)Cc1ccccc1)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](CC(NCc(cc1)ccc1N)=O)Cc1ccccc1)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O CTLMWXLEIGKVJF-DJOZAEGOSA-N 0.000 description 1
- YLCALJUVUMZWCQ-WRLCLDKHSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](Cc1ccccc1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](Cc1ccccc1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O YLCALJUVUMZWCQ-WRLCLDKHSA-N 0.000 description 1
- CITZOXNBHKSONK-CVLGSZOTSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](Cc1ccccn1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](Cc1ccccn1)C(NCc(cc1)ccc1N)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C)=O)=O CITZOXNBHKSONK-CVLGSZOTSA-N 0.000 description 1
- GFWHLXXRLTZAEJ-UHFFFAOYSA-N COC(CCCC#Cc(cn1)cnc1SC)=O Chemical compound COC(CCCC#Cc(cn1)cnc1SC)=O GFWHLXXRLTZAEJ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229940122560 Cyclin inhibitor Drugs 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010072039 Histidine kinase Proteins 0.000 description 1
- 108010064711 Homoserine dehydrogenase Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 241000546273 Lindera <angiosperm> Species 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- HNZZQRFFPLRAFU-UHFFFAOYSA-N cyclopentadecanecarboxylic acid Chemical compound OC(=O)C1CCCCCCCCCCCCCC1 HNZZQRFFPLRAFU-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229950001902 dimevamide Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- TZBLICQZVLFLRD-UHFFFAOYSA-N ethyl 2-(2-methylsulfanylpyrimidin-5-yl)-1,3-oxazole-4-carboxylate Chemical compound CCOC(=O)c1coc(n1)-c1cnc(SC)nc1 TZBLICQZVLFLRD-UHFFFAOYSA-N 0.000 description 1
- SGIBUKNPAQMWAP-UHFFFAOYSA-N ethyl 2-bromo-1,3-oxazole-4-carboxylate Chemical compound CCOC(=O)C1=COC(Br)=N1 SGIBUKNPAQMWAP-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- ONUHRYKLJYSRMY-UHFFFAOYSA-N hex-5-yn-1-amine Chemical compound NCCCCC#C ONUHRYKLJYSRMY-UHFFFAOYSA-N 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 102000051957 human ERBB2 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- PVAVYBJZPZPIGW-UHFFFAOYSA-N methyl 4-(2-methylsulfanylpyrimidin-5-yl)benzoate Chemical compound CSC1=NC=C(C=N1)C1=CC=C(C(=O)OC)C=C1 PVAVYBJZPZPIGW-UHFFFAOYSA-N 0.000 description 1
- CZNGTXVOZOWWKM-UHFFFAOYSA-N methyl 4-bromobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1 CZNGTXVOZOWWKM-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical compound OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- HJEZRYIJNHAIGY-UHFFFAOYSA-N tert-butyl 4-bromobutanoate Chemical compound CC(C)(C)OC(=O)CCCBr HJEZRYIJNHAIGY-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- UXWQXBSQQHAGMG-UHFFFAOYSA-N tert-butyl n-[(4-aminophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(N)C=C1 UXWQXBSQQHAGMG-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
- A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the present disclosure pertains to the field of medical technology, and relates to bioactive conjugates, methods for their preparation, and diseases for preventing and/or treating disorders associated with abnormal cellular activities, including but not limited to use in the prevention and/or treatment of neoplastic diseases.
- Chemotherapy was once the standard treatment for cancer, but high-killing bioactive molecules can kill normal cells and cause serious side effects.
- Targeted anti-tumor drugs have become a hot spot in the field of cancer research due to their simultaneous targeting and anti-tumor activity.
- biomacromolecules such as therapeutic antibodies or antibody fragments
- targeted small molecule ligands have been used for the development of antitumor drugs and tumor targeted therapy.
- biomacromolecules although highly targeted, have limited therapeutic effects on solid tumors; while bioactive molecules have high killing efficacy against cancer cells, they often lack targeting and often accidentally injure normal cells, causing serious toxic side effect.
- ADC antibody-drug conjugates
- the ADC combines the targeting of antibodies with the activity of biologically active molecules to become a "bio-missile".
- the antibody directs the ADC to bind to the target cell, which is then internalized by the cell, releasing the drug, and treating the disease. Because the antibody has specificity and targeting to tumor cell related targets, its application value is not only reflected in the treatment, but also becomes an ideal carrier for drug targeted delivery, which reduces the side effects of the drug.
- Small molecule drug conjugation SMDC
- ADC antibody-drug conjugate
- ADCs already on the market: Mylotarg (Gemtuzumab Ozogamicin, gemtuzumab oxazometh), Adcetris (Brentuximab Vedotin, CD30 mAb-MMAE), Kadcyla (Trastuzumab Emtansine, trastuzumab- ⁇ Dessert alkaloids and Besponsa (Inotuzumab ozogamicin, CD22 mAb-caccimycin).
- ADC drugs consist of antibodies, biologically active molecules, and linkers.
- the bioactive molecule is covalently coupled to the antibody via a linker;
- the antibody eg, a monoclonal antibody
- the antibody is capable of specifically recognizing a specific target on the surface of the tumor cell, thereby directing the ADC to the surface of the cancer cell and allowing the ADC to pass through the endocytosis
- the effect enters the cancer cells; then the bioactive molecules are released in the cancer cells, achieving the effect of specifically killing the cancer cells without damaging the normal tissue cells.
- Lysine is the most common attachment site in antibodies, and its ⁇ -amino group can react with the activated carboxyl group of the linker to form an amide bond.
- site-directed coupling that is, activating a group to activate a carboxyl group of a linker, and then forming an amide bond with a specific lysine ⁇ -amino group in the antibody to complete the coupling.
- an amide bond is prone to hydrolysis under the action of an enzyme in the body, causing the bioactive molecule and the antibody to fall off when the target cell is not reached, and the toxicity of the ADC is increased while the targeting of the ADC is lost.
- the thio group of the antibody cysteine is present in the form of a disulfide bond. Opening the disulfide bond in the antibody provides multiple free sulfhydryl groups as coupling sites. Coupling with an antibody thiol group, one method is a Michael addition reaction of a free sulfhydryl group on the antibody with maleimide, or a specific substrate and a free sulfhydryl group on the antibody can be formed by two Michael addition reactions. A uniquely structured sulfur bridge.
- the ADC obtained by the thiol Michael addition method will undergo an inverse Michael addition in the systemic circulation, resulting in a toxic reaction.
- the present invention has discovered a novel class of bioactive conjugates obtained by improving the manner in which the drug is coupled to a targeting moiety in an ADC or SMDC drug.
- the conjugate has higher stability, very high coupling efficiency (90%) and higher drug loading (DAR value 5-8), and the present disclosure is based on the above findings.
- the ADC of the present invention such as BT001021 (Example 32)
- the bioactive small molecule toxin is significantly exposed in tumor tissue above plasma tissue exposure.
- the Immu-132 ADC has significantly higher plasma exposure than tumor tissue exposure under the same route of administration, the ADC of the present invention therefore has a better therapeutic window than Immu-132.
- the ADC of the present invention has a better therapeutic effect than Immu-132 in animal models of gastric cancer, breast cancer and non-small cell lung cancer tumors.
- a first aspect of the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof,
- T is a biologically active molecular fragment, preferably a molecular fragment having antitumor biological activity
- L 1 is selected from the group consisting of amino acids, peptides of 2-10 amino acids, oligosaccharides, -(CH 2 ) t1 -, -(CH 2 CH 2 O) t1 -(CH 2 ) t2 -, Wherein each of R, R', R 1 and R 2 is independently H (hydrogen), D (oxime), halogen, carboxylic acid, sulfonic acid, cyano, C 1-6 alkyl, halogenated C 1- 6 alkyl (eg -CF 3 ), cyano substituted C 1-6 alkyl (eg -CH 2 CN), C 1-6 alkoxy, C 2-10 alkenyl, C 2-10 alkynyl, a C 3-6 cycloalkyl group, a 6-10 membered aryl group or a 5-12 membered heteroaryl group, each of Z 1 being independently an amino acid or a peptide of 2 to 10 amino acids, each of t 1 and t 2
- L 2 is selected from the group consisting of amino acids, peptides of 2-10 amino acids, oligosaccharides, -(CH 2 ) t1 -, -(CH 2 CH 2 O) t1 -(CH 2 ) t2 -,
- R 3 , R 4 , R 5 and R 6 are each independently selected from the group consisting of H (hydrogen), D (oxime), halogen, carboxylic acid, sulfonic acid, CN, C 1-6 alkyl, halogenated C 1- 6 alkyl, cyano substituted C 1-6 alkyl, C 1-6 alkoxy, C 2-10 alkenyl, C 2-10 alkynyl and C 3-6 cycloalkyl, or, R 3 , R 4 or R 5 , R 6 or R 3 , R 5 together with the carbon atom to which they are attached form a 3-8 membered ring, and t 1 and t 2 are each independently 0, 1 , 2 , 3, 4, 5 or 6
- L 4 is selected from Wherein, Z 5 is preferably selected from C 2-6 alkenylene, C 2-6 alkynylene hydrocarbon, an amide group, a sulfone group, a sulfoxide group, 6-10-membered aryl, 5-6 membered heteroaryl; Z 2 is selected from C 1-6 alkylene, C 2-10 alkenylene, C 2-10 alkynylene, C 3-8 cycloalkylene, 6-10 membered aryl and 5-14 membered heteroaryl; R 9 Selected from H (hydrogen), C 1-6 alkyl; Z 3 is absent or selected from C 1-6 alkylene, halogenated C 1-6 alkylene and alkoxy substituted C 1-6 alkylene Or R 9 and Z 3 together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; ⁇ is independently 0, 1 , 2, 3, 4, 5 or 6; and 2 positions of L 4 Connected to E;
- E is selected from the group consisting of optionally substituted by one or more R 12 : 6-10 membered aryl, 5-14 membered heteroaryl; wherein R 12 is independently selected from H (hydrogen), D ( ⁇ ) , halogen, CN, nitro, C 1-6 alkyl and halogenated C 1-6 alkyl;
- G is a leaving group for a nucleophilic substitution reaction; such as a halogen, a sulfonyl group, a sulfonate group, a nitro group, and the like;
- n 1 , m 2 and m 3 are each independently 0, 1 , 2 , 3 , 4, 5, 6, 7, 8, 9, or 10.
- L 1 is selected from the group consisting of Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, a peptide consisting of 2-5 amino acids, Wherein each of R, R', R 1 and R 2 is independently H (hydrogen), D ( ⁇ ), C 1-6 alkyl, C 2-10 alkenyl, C 2-10 alkynyl or C 3 -6 cycloalkyl, Z 1 is Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Cit-Ala, Val-Ala, Lys-Val, Val -Lys(Ac), Phe-Lys, Phe-Lys(Ac), D-Val-Leu-Lys, Gly-Gly-Arg or Ala-Ala-Asn, x 1 is 0, 1, 2 or 3, x 3 It is 0, 1, 2, 3 or 4.
- L 1 is selected from the group consisting of Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Cit-Val, Val-Ala, Lys-Val, Val-Lys (Ac), Phe-Lys, Phe-Lys (Ac), D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn, Wherein R, R' and R 1 are each independently H (hydrogen), D ( ⁇ ), C 1-6 alkyl, C 2-10 alkenyl, C 2-10 alkynyl or C 3-6 naphthenic Base, Z 1 is Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Cit-Ala, Val-Ala, Lys-Val, Val-Lys (Ac ), Phe-Lys, Phe-Lys (Ac), D-Val-Leu-Lys
- L 1 is selected from the group consisting of Lys, Cit, Cit-Val, Val-Ala, Lys-Val, Wherein R, R' and R 1 are each independently H (hydrogen), D ( ⁇ ) or C 1-4 alkyl, and Z 1 is Cit, Lys, Cit-Val, Cit-Ala, Val-Ala or Lys -Val, x 1 and x 3 are each independently 0, 1, or 2.
- L 1 is selected from the group consisting of Lys, Cit, Cit-Val, Val-Ala, Lys-Val,
- L 1 is selected from
- L 2 is selected from the group consisting of Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, a peptide consisting of 2-5 amino acids,
- R 3 , R 4 , R 5 and R 6 are each independently selected from the group consisting of H (hydrogen), D (oxime), halogen, carboxylic acid, sulfonic acid, CF 3 , CN, CH 2 CN, C 1-4 alkane.
- y 1 and y 2 are each independently 0, 1 , 2 , 3, 4 , 6, 7 or 8, and at a position L 1 L 2 is connected;
- n 1 0, 1, 2 or 3.
- L 2 is selected from the group consisting of Val, Cit, Phe, Lys, D-Val, Leu, Gly, Ala, Asn, Val-Cit, Cit-Val, Val-Ala, Lys-Val, Val-Lys (Ac), Phe-Lys, Phe-Lys (Ac), D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn,
- R 3 , R 4 , R 5 and R 6 are each independently selected from the group consisting of H (hydrogen), D (oxime), halogen, carboxylic acid, sulfonic acid, CF 3 , CN, CH 2 CN, C 1-4 alkane.
- y 1 and y 2 are each independently 0, 1 , 2 , 3, 4 , 6, 7 or 8, and at a position L 1 L 2 is connected;
- n 1 0, 1, or 2.
- L 2 is selected from Wherein R 3 , R 4 , R 5 and R 6 are each independently selected from the group consisting of H (hydrogen), D ( ⁇ ) and C 1-4 alkyl, and y 1 and y 2 are each independently 0, 1, 2 3,4,5,6,7 or 8, and L 2 at a position connected to the L 1;
- L 2 is selected from
- L 2 is selected from
- L 3 is selected from the group consisting of, optionally substituted by one or more R 7 : amino, 3-8 membered cycloalkyl, 3-8 membered heteroheterocyclyl, 6-12.
- W is oxygen or NR 8
- n 2 0, 1, 2 or 3.
- n 2 0, 1, or 2.
- L 3 is selected from the group consisting of triazole; m 2 is 0 or 1.
- L 3 is selected from m 2 is 0 or 1; preferably, the 1 position of L 3 is bonded to L 2 .
- L 3 is selected from the group consisting of, optionally substituted by one or more R 7 : amino,
- W is NR 8 and R 8 is selected from the group consisting of H (hydrogen), D (oxime), C 1-6 alkyl, C 2-6 alkenyl, C 3-6 alkynyl and C 3-6 cycloalkyl.
- L 3 is selected from
- R q is each independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 3-6 alkynyl and C 3-8 cycloalkyl; ⁇ 1 is 0, 1 or 2; ⁇ 2 is 1, 2 or 3.
- L 3 is selected from
- L 4 is selected from Wherein Z 4 is a 6-10 membered aryl group, a 5-6 membered heteroaryl group; R 10 is selected from the group consisting of H (hydrogen) and C 1-6 alkyl; and Z 2 is selected from the group consisting of C 1-6 alkylene, C 2 10 alkenylene, C 2-10 alkynylene, C 3-8 cycloalkyl; R 9 is selected from H (hydrogen), C 1-6 alkyl; Z 3 is absent or selected from C 1-6 Or an alkyl group; or, R 9 and Z 3 together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; ⁇ is independently 0, 1 , 2, 3, 4 , 5 or 6, and 2 positions of L 4 Connected to E;
- n 3 is selected from 0, 1, 2 or 3.
- L 4 is selected from Wherein Z 4 is a benzene ring, R 10 is selected from H (hydrogen), C 1-6 alkyl; Z 2 is selected from C 1-6 alkylene, C 2-10 alkenylene, C 2-10 alkyne a C 3-8 cycloalkylene group; R 9 is selected from H (hydrogen), C 1-6 alkyl; Z 3 is absent or selected from a C 1-6 alkylene group, or R 9 together with Z 3 The nitrogen atom to which it is bonded forms a 4-8 membered heterocyclic group; ⁇ is independently 0, 1 , 2, 3, 4 , 5 or 6, and the 2 position of L 4 is bonded to E;
- n 3 is selected from 0, 1, 2 or 3.
- L 4 is selected from Wherein Z 4 is a 5-6 membered heteroaryl; R 10 is selected from H (hydrogen), C 1- 6 alkyl; Z 2 is selected from C 1-6 alkylene, C 2-10 alkenylene, C 2 -10 alkynylene, C 3-8 cycloalkylene; R 9 is selected from H (hydrogen), C 1-6 alkyl; Z 3 is absent or selected from C 1-6 alkylene; or, R 9 Forming a 4-8 membered heterocyclic group with Z 3 together with the nitrogen atom to which it is attached; ⁇ is independently 0, 1 , 2, 3, 4 , 5 or 6, and the 2 position of L 4 is bonded to E;
- n 3 is selected from 0, 1, 2 or 3.
- L 4 is selected from
- L 4 is selected from
- L 4 is selected from
- E is selected from a 5-10 membered heteroaryl optionally substituted with one or more R 12 ; wherein R 12 is independently selected from H (hydrogen), D (oxime), halogen, CN, nitro, C 1-4 alkyl and halo C 1-4 alkyl.
- E is selected from the group consisting of, optionally substituted by one or more R 12 : pyrimidine, quinazoline, and pyrrolo[2,3-d]pyrimidine; wherein R 12 is independently selected From H (hydrogen), D (oxime), halogen, CN, nitro, C 1-2 alkyl and halo C 1-2 alkyl.
- E is selected from pyrimidines optionally substituted with one or more R 12 ; wherein R 12 is independently selected from H (hydrogen) and D (oxime).
- G is selected from the group consisting of halogen, OMs, OTs, OTf, nitro, and the following groups optionally substituted with one or more R 13 : alkyl sulfide group, aryl sulfide group, hetero An aryl sulfide group, an alkyl sulfoxide group, an aryl sulfoxide group, a heteroaryl sulfoxide group, an alkylsulfonyl group, an arylsulfonyl group, a heteroarylsulfonyl group; wherein R 13 is independently selected from H (hydrogen), D( ⁇ ), halogen, CN, nitro, C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, 6-10 membered aryl and 5-12 Meta-heteroaryl.
- G is selected from the group consisting of F, Cl, Br, I, OMs, OTs, OTf, methylsulfonyl, ethylsulfonyl, p-toluenesulfonyl, and naphthalenesulfonyl.
- G is selected from the group consisting of F, Cl, Br, OMs, OTs, methylsulfonyl, and p-toluenesulfonyl.
- G is selected from the group consisting of Cl and methylsulfonyl.
- G is preferably a methylsulfonyl group
- E is preferably a pyrimidine
- m 3 is 1.
- m 4 is preferably an integer of 0 to 6
- the methylsulfonyl group is a substituent of a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
- m 5 is preferably an integer of 0 to 6
- the methylsulfonyl group is a substituent of a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
- m 6 is preferably an integer from 0 to 6
- the methylsulfonyl group is a substituent of a carbon atom adjacent to the nitrogen atom in the pyrimidine ring.
- m 7 is an integer selected from 1 to 5
- the methylsulfonyl group is a substituent of a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
- m 8 is an integer selected from 1 to 5
- the methylsulfonyl group is a substituent of a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
- m 9 is an integer selected from 1 to 5
- R 13 is selected from hydrogen, C 1-6 alkyl, and the methylsulfonyl group is a substituent of a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
- m 10 is selected from an integer of 0-6, and Z 4 is selected from a 5-6 membered heteroaryl group; the methylsulfonyl group is a substituent of a carbon atom adjacent to a nitrogen atom in the pyrimidine ring.
- a methylsulfonyl group is a substituent of a carbon atom adjacent to a nitrogen atom in the pyrimidine ring. More preferably, m 10 is selected from an integer from 0-6.
- n 10 is selected from an integer from 0-6.
- n is derived from oxazole and thiazole, which is a substituent of a carbon atom adjacent to a nitrogen atom in the pyrimidine ring. More preferably, m 10 is selected from an integer from 0-6.
- m 10 is selected from an integer of 0-6, Z 4 is selected from a 6-10 membered aryl group; and the methylsulfonyl group is a carbon atom substituent adjacent to the nitrogen atom. More preferably, m 10 is selected from an integer from 0-6.
- m 10 is an integer selected from 0 to 6
- Z 4 is a benzene ring.
- T is a biologically active molecular fragment.
- the bioactive molecule is selected from the group consisting of a metal complex, such as a metal platinum complex (eg, oxaliplatin), a metal gold complex; a glycopeptide antibiotic, such as bleomycin or pingyangmycin DNA topoisomerase inhibitors, such as topoisomerase I inhibitors (eg camptothecin, hydroxycamptothecin, 9-aminocamptothecin, SN-38, irinotecan, topotecan, beloate) Kang or rupibine), topoisomerase II inhibitors (eg actinomycin D, doxorubicin, doxorubicin, doxymethine, daunorubicin, mitoxantrone, podophyllotoxin or Etoposide); interfering with DNA synthesis drugs, such as methotrexate, 5-fluorouracil, cy
- the biologically active molecule is selected from Wherein R 14 is selected from R 15 substituted acyl or sulfonyl, R 15 is selected from C 1-6 alkyl, halo C 1-6 alkyl, 6-10 membered aryl and 5-12 membered heteroaryl; 16 is selected from the group consisting of H (hydrogen), D (oxime), C 1-6 alkyl, R 17 substituted C 1-6 alkyl, and R 17 is selected from aryl, heteroaryl including, but not limited to, phenyl , pyridyl, m 11 is selected from 0, 1, 2.
- the biologically active molecule is selected from Wherein R 14 is selected from R 15 substituted acyl or sulfonyl, R 15 is selected from C 1-6 alkyl, halo C 1-6 alkyl, 6-10 membered aryl and 5-12 membered heteroaryl; 16 is selected from the group consisting of H (hydrogen), D (oxime), C 1-6 alkyl, R 17 substituted C 1-6 alkyl, and R 17 is selected from aryl, heteroaryl including, but not limited to, phenyl , pyridyl, m 11 is selected from 0, 1, 2.
- the biologically active molecule is selected from
- the biologically active molecule is selected from
- the biologically active molecule is selected from
- the biologically active molecule is selected from
- the biologically active molecule is selected from
- T is selected from
- T is selected from
- T is selected from
- T is selected from
- T is selected from
- the compound of formula (I) is selected from:
- the compound is selected from:
- the present disclosure provides a conjugate comprising a biologically active molecule, a linker, and a targeting moiety.
- the targeting moiety is linked to the linker via its reactive group (eg, a thiol group) to form a conjugate.
- the conjugate structure is as shown in formula (II):
- A is a targeting moiety (eg, a small molecule ligand, a protein, a polypeptide, a non-proteinaceous agent (eg, sugar, RNA, or DNA));
- ⁇ is selected from an integer or a fraction between 1 and 10; preferably, ⁇ is selected from An integer or fraction between 5-8 (for example, 5, 6, 7, or 8);
- the target of A is selected from the group consisting of epidermal growth factor, Trop-2, CD37, HER2, CD70, EGFRvIII, Mesothelin, Folate eceoptor1, Mucin 1, CD138, CD20, CD19, CD30, SLTRK6, Nectin 4, Tissue Factor, Mucin16, Endothelinreceoptor, STEAP1, SLC39A6, Guanylylcyclase C, PSMA, CCD79b, CD22, Sodium phosphate cotransporter2B, GPNMB, Trophoblast glycoprotein, AGS-16, EGFR, CD33, CD66e, CD74, CD56, PD-L1, TACSTD2, DR5, E16, STEAP1, 0772P, MPF, Napi3b, Sema 5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcRH2, NCA, MDP,
- A is a small molecule ligand, such as a folic acid derivative, a glutamate urea derivative, a somatostatin derivative, an aryl sulfonamide derivative (eg, a carbonic anhydrase IX inhibitor), linked Two aliphatic fluorene polyenes, cyanine dyes or IR-783 or derivatives thereof.
- a small molecule ligand such as a folic acid derivative, a glutamate urea derivative, a somatostatin derivative, an aryl sulfonamide derivative (eg, a carbonic anhydrase IX inhibitor), linked Two aliphatic fluorene polyenes, cyanine dyes or IR-783 or derivatives thereof.
- A is selected from
- A is an antibody, such as a monoclonal antibody or antigen-binding fragment thereof, wherein the monoclonal antibody or antigen-binding fragment thereof comprises Fab, Fab', F(ab') 2 , Fd, Fv, dAb, a complementarity determining region fragment, a single chain antibody (eg, scFv), a non-human antibody, a humanized antibody, a chimeric antibody, a fully human antibody, a probody, a bispecific antibody, or a multispecific antibody.
- a monoclonal antibody or antigen-binding fragment thereof comprises Fab, Fab', F(ab') 2 , Fd, Fv, dAb, a complementarity determining region fragment, a single chain antibody (eg, scFv), a non-human antibody, a humanized antibody, a chimeric antibody, a fully human antibody, a probody, a bispecific antibody, or a multispecific antibody.
- A is a monoclonal antibody against Her 2 , such as trastuzumab, Pertuzumab or a monoclonal antibody against Trop-2, such as Sacituzumab.
- A is a monoclonal antibody against Trop-2, such as M1, M2, and M3.
- Lys at the end of the heavy chain is readily deleted, but this deletion does not affect biological activity, see Dick, L. W. et al, Biotechnol. Bioeng., 100: 1132-1143.
- the above M1, M2, M3 mAb and its heavy chain-terminal Lys deleted sequence or fragments thereof belong to the M1, M2, M3 mAbs of the present invention.
- A is selected from the group consisting of an RGD peptide that recognizes a cell surface integrin receptor; a growth factor that recognizes a cell surface growth factor receptor such as EGF, PDGF, or VEGF; and a functional cell surface plasminogen A peptide of activator, bombesin, bradykinin, somatostatin or prostate specific membrane antigen receptor.
- A is selected from the group consisting of a CD40 ligand, a CD30 ligand, an OX40 ligand, a PD-1 ligand, an ErbB ligand, a Her2 ligand, a TACSTD2 ligand, and a DR5 ligand.
- the conjugate is selected from the group consisting of
- ⁇ is selected from an integer or a decimal between 1-10
- the mAb is a monoclonal antibody against Trop-2 or a monoclonal antibody against Her 2; preferably, the monoclonal antibody against Trop-2 is selected from Sacituzumab, M1 , M2 and M3 antibodies, monoclonal antibodies against Her 2 are selected from trastuzumab, pertuzumab; preferably, ⁇ is selected from integers or decimals between 5-8 (eg 5, 6, 7 or 8).
- the conjugate is selected from the group consisting of
- ⁇ is selected from an integer or a decimal between 1-10
- the mAb is a monoclonal antibody against Trop-2 or a monoclonal antibody against Her 2; preferably, the monoclonal antibody against Trop-2 is selected from the group consisting of Sacituzumab,
- the monoclonal antibody to Her 2 is selected from trastuzumab, pertuzumab; preferably, ⁇ is selected from an integer or a fraction between 5-8 (eg, 5, 6, 7, or 8).
- the conjugate is:
- A1 is a Sacituzumab antibody
- ⁇ is selected from an integer or a decimal between 1-10; and preferred ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6-8, 6.5- An integer or fraction between 7,6.5-7.5, 6.5-8, 7-8, or 7.5-8.
- the conjugate is:
- A1 is a Sacituzumab antibody
- ⁇ is selected from an integer or a decimal between 1-10; and preferred ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6-8, 6.5- An integer or fraction between 7,6.5-7.5, 6.5-8, 7-8, or 7.5-8.
- the conjugate is:
- A1 is a Sacituzumab antibody
- ⁇ is selected from an integer or a decimal between 1-10; and preferred ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6-8, 6.5- An integer or fraction between 7,6.5-7.5, 6.5-8, 7-8, or 7.5-8.
- the conjugate is:
- A1 is a fragment of a Sacituzumab antibody
- ⁇ is selected from an integer or a decimal between 1-10; preferably ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6-8, An integer or fraction between 6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
- the conjugate is:
- A2 is trastuzumab, and ⁇ is selected from an integer or a decimal between 1-10; preferably, ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6- An integer or fraction between 8,6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
- the conjugate is:
- A2 is trastuzumab, and ⁇ is selected from an integer or a decimal between 1-10; preferably, ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6- An integer or fraction between 8,6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
- the conjugate is:
- A2 is trastuzumab, and ⁇ is selected from an integer or a decimal between 1-10; preferably, ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6- An integer or fraction between 8,6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
- the conjugate is:
- A3 is pertuzumab, and ⁇ is selected from an integer or a decimal between 1-10; preferably, ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6- An integer or fraction between 8,6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
- the conjugate is:
- A3 is pertuzumab, and ⁇ is selected from an integer or a decimal between 1-10; preferably, ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6- An integer or fraction between 8,6.5-7, 6.5-7.5, 6.5-8, 7-8 or 7.5-8.
- the conjugate is:
- A4 is an M1 antibody, and ⁇ is selected from an integer or a decimal between 1-10; preferably, ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6-8, 6.5 An integer or fraction between -7, 6.5-7.5, 6.5-8, 7-8, or 7.5-8.
- the conjugate is:
- A4 is an M1 antibody, and ⁇ is selected from an integer or a decimal between 1-10; preferably, ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6-8, 6.5 An integer or fraction between -7, 6.5-7.5, 6.5-8, 7-8, or 7.5-8.
- the conjugate is:
- A5 is an M2 antibody
- ⁇ is selected from an integer or a decimal between 1-10; preferably, ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6-8, 6.5 An integer or fraction between -7, 6.5-7.5, 6.5-8, 7-8, or 7.5-8.
- the conjugate is:
- A5 is an M2 antibody
- ⁇ is selected from an integer or a decimal between 1-10; preferably, ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6-8, 6.5 An integer or fraction between -7, 6.5-7.5, 6.5-8, 7-8, or 7.5-8.
- the conjugate is:
- A6 is an M3 antibody, and ⁇ is selected from an integer or a decimal between 1-10; preferably, ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6-8, 6.5 An integer or fraction between -7, 6.5-7.5, 6.5-8, 7-8, or 7.5-8.
- the conjugate is:
- A6 is an M3 antibody, and ⁇ is selected from an integer or a decimal between 1-10; preferably, ⁇ is selected from an integer or a decimal between 5-8, such as 6-7, 6-7.5, 6-8, 6.5 An integer or fraction between -7, 6.5-7.5, 6.5-8, 7-8, or 7.5-8.
- the present disclosure provides a method of preparing a conjugate of the second aspect, comprising the step of coupling a linker of a compound of formula (I) with a reactive moiety of a targeting moiety.
- the method comprises opening a disulfide bond of the targeting moiety using a reducing agent (eg, TCEP) to provide a thiol group.
- a reducing agent eg, TCEP
- the method comprises the step of forming a linker of a compound of formula (I) with a thiol group of a targeting moiety to form a C-S bond.
- the targeting moiety is a monoclonal antibody against Her 2 (eg, trastuzumab, Pertuzumab) or a monoclonal antibody against Trop-2 (eg, Sacituzumab, M1, M2 or M3), or an active fragment or variant thereof.
- Her 2 eg, trastuzumab, Pertuzumab
- Trop-2 eg, Sacituzumab, M1, M2 or M3
- the ratio of the amount of the targeting moiety to the substance of the compound of formula (I) is 1: (1-20); preferably, the coupling is carried out in water and/or an organic solvent;
- the organic solvent is selected from the group consisting of N,N-dimethylformamide, dimethyl sulfoxide, N-methylpyrrolidone, nitriles (such as acetonitrile), alcohols (such as methanol, ethanol), and any combination thereof.
- the method further comprises the step of purifying the coupled product; preferably, by chromatography (eg, ion exchange chromatography, hydrophobic chromatography, reversed phase chromatography, or affinity chromatography) One or more) purified the coupled product.
- chromatography eg, ion exchange chromatography, hydrophobic chromatography, reversed phase chromatography, or affinity chromatography
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the first aspect of the present disclosure or a pharmaceutically acceptable salt thereof, or the conjugate of the second aspect, and one or A variety of pharmaceutical excipients.
- the present disclosure provides the compound of the first aspect, or a pharmaceutically acceptable salt thereof, or the conjugate of the second aspect, for the preparation of a medicament for treating a disease associated with abnormal cell activity (eg, a cancer disease) Use in.
- a disease associated with abnormal cell activity eg, a cancer disease
- the cancer disease is a solid tumor or a non-solid tumor, such as selected from the group consisting of esophageal cancer (eg, esophageal adenocarcinoma and esophageal squamous cell carcinoma), brain tumor, lung cancer (eg, small cell lung cancer, and non-small) Cellular lung cancer), squamous cell carcinoma, bladder cancer, stomach cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, colorectal cancer, liver cancer, kidney cancer, non Hodgkin's lymphoma, central nervous system tumors (eg, glioma, glioblastoma multiforme, glioma or sarcoma), prostate cancer, and thyroid cancer.
- esophageal cancer eg, esophageal adenocarcinoma and esophageal squamous cell carcinoma
- brain tumor eg,
- the present disclosure provides the compound of the first aspect, or a pharmaceutically acceptable salt thereof, or the conjugate or pharmaceutical composition of the second aspect, for use in the treatment of a disease associated with abnormal cellular activity (eg, cancer) Use in disease).
- a disease associated with abnormal cellular activity eg, cancer
- the present disclosure provides a method of treating a disease associated with abnormal cellular activity, such as a cancer disease, comprising providing a compound of the first aspect, or a pharmaceutically acceptable thereof, to an effective dosage of an individual in need thereof A salt or a conjugate or pharmaceutical composition of the second aspect.
- the medicinal excipient refers to an excipient and an additive used in the production of a drug and a formulation, and refers to a reasonable evaluation of safety in addition to the active ingredient, and is included in the drug.
- the substance in the preparation In addition to prototyping, acting as a carrier and improving stability, pharmaceutical excipients also have important functions such as solubilization, solubilization, and controlled release, which are important components that may affect the quality, safety and effectiveness of drugs. According to its source, it can be divided into natural materials, semi-synthetic materials and total synthetic materials.
- solvent propellant
- solubilizer cosolvent
- emulsifier colorant
- binder disintegrant
- filler filler
- lubricant wetting agent
- osmotic pressure regulator stabilizer
- Glidants flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, antioxidants, chelating agents, penetration enhancers, pH adjusters, buffers, plasticizers, surface active agents Agent, foaming agent, antifoaming agent, thickener, inclusion agent, moisturizer, absorbent, diluent, flocculant and deflocculant, filter aid, release retardant, etc.
- solvent propellant
- solubilizer cosolvent
- emulsifier colorant
- binder disintegrant
- filler filler
- lubricant wetting agent
- osmotic pressure regulator stabilizer
- Glidants osmotic pressure regulator
- flavoring agents preservatives
- suspending agents coating materials
- fragrances anti
- the pharmaceutical composition can be formulated into various suitable dosage forms depending on the route of administration. For example, tablets, capsules, granules, oral solutions, oral suspensions, oral emulsions, powders, elixirs, syrups, injections, suppositories, ointments, creams, pastes, ophthalmic preparations, pills, implants Agents, aerosols, powders, sprays, and the like.
- the pharmaceutical composition or a suitable dosage form may contain 0.01 mg to 1000 mg of the compound of the present disclosure or a pharmaceutically acceptable salt or conjugate thereof, suitably containing 0.1 mg to 800 mg, preferably 0.5-500 mg, preferably It contains 0.5 to 350 mg, particularly preferably 1 to 250 mg.
- the pharmaceutical composition can be administered in the form of an injection, including an injection, a sterile powder for injection, and a concentrated solution for injection.
- carriers and solvents which can be used include water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils may also be employed as a solvent or suspension medium such as a monoglyceride or a diglyceride.
- the term "individual” includes human or non-human animals.
- Exemplary human individuals include a human individual (referred to as a patient) or a normal individual having a disease, such as the disease described herein.
- non-human animal in the present disclosure includes all vertebrate animals, such as non-mammals (eg, birds, amphibians, reptiles) and mammals, such as non-human primates, domestic animals, and/or domesticated animals (eg, sheep, Dogs, cats, cows, pigs, etc.).
- the term "effective amount” refers to the amount of a compound that, after administration, will relieve to some extent one or more symptoms of the condition being treated.
- the term "conjugate” refers to a substance obtained by linking a biologically active molecule to a targeting moiety.
- the bioactive molecule is linked to the targeting moiety via a linker.
- the linker is capable of cleavage in a particular environment (e.g., an intracellular low pH environment) or a specific action (e.g., the action of a lysosomal protease) to separate the biologically active molecule from the targeting moiety.
- the linker comprises a cleavable or non-cleavable unit, such as a peptide or a disulfide bond.
- the bioactive molecule is linked directly to the targeting moiety by a covalent bond that is capable of cleavage under a particular environment or action, thereby separating the biologically active molecule from the targeting moiety.
- biologically active and “biologically active molecule” refer to a substance that inhibits or prevents the function of a cell and/or causes cell death or destruction.
- biological activity in the conjugate is a molecule having antitumor biological activity.
- radioisotopes such as At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and Lu radioisotopes; metal complexes such as metal platinum complexes , metal gold complexes, oxaliplatin, etc.; glycopeptide antibiotics, such as bleomycin, pingyangmycin; DNA topoisomerase inhibitors, such as topoisomerase I inhibitors, camptothecin, hydroxyl Alkaloid, 9-aminocamptothecin, SN-38, irinotecan, topotecan, belocommide, rupeticon, topoisomerase II inhibitor, actinomycin D, doxorubicin, Resorcin, doxymethine, daunorubicin, mitoxantrone, podophyllotoxin, etoposide, etc.; interfere with DNA
- small molecule refers to a small molecule drug having biological activity.
- linker refers to a fragment that links a biologically active molecule to a targeting moiety.
- targeting moiety refers to a moiety in a conjugate that is capable of specifically binding to a target (or portion of a target) of a cell surface.
- the conjugate can be delivered to a particular cell population by interaction of the targeting moiety with the target.
- the conjugate when the targeting moiety in the conjugate is an antibody, the conjugate may be referred to as a "drug-antibody conjugate.”
- drug-antibody conjugate and “immunoconjugate” are used interchangeably.
- antibody in its broadest sense and includes intact monoclonal antibodies, polyclonal antibodies, and multispecific antibodies (eg, bispecific antibodies) formed from at least two intact antibodies, as long as they have The biological activity required.
- antibody and “immunoglobulin” are used interchangeably.
- the term "monoclonal antibody” refers to an antibody from a population of substantially homogeneous antibodies, ie, the individual antibodies comprising the cluster are identical except for a small number of natural mutations that may be present.
- Monoclonal antibodies have high specificity for one determinant (epitope) of the antigen, while polyclonal antibodies relative thereto contain different antibodies for different determinants (epitopes).
- monoclonal antibodies have the advantage of being free from contamination by other antibodies during synthesis.
- the modifier "monoclonal” as used herein means that the antibody is characterized by a substantially homogeneous population of antibodies and is not to be construed as being prepared by a particular method.
- the monoclonal antibody also specifically includes a chimeric antibody, ie, a portion of the heavy and/or light chain is identical or homologous to a certain, certain or a subset of antibodies, and the remainder is One, another or another subclass of antibodies are identical or homologous as long as they have the desired biological activity (see, for example, US 4,816,567; and Morrison et al., 1984, PNAS, 81:6851-6855).
- Chimeric antibodies useful in the present disclosure include primatized antibodies comprising variable region antigen binding sequences from non-human primates (e.g., ancient monkeys, orangutans, etc.) and human constant region sequences.
- antibody fragment refers to a portion of an antibody, preferably an antigen binding or variable region.
- antibody fragments include Fab, Fab', F(ab') 2 , Fd, Fv, dAb and complementarity determining region fragments, diabodies, linear antibodies and single chain antibody molecules.
- bispecific antibody is also referred to as "bifunctional antibody conjugate” and refers to a conjugate formed by a first antibody (fragment) and a second antibody (fragment) by a coupling arm, the conjugate The activity of the respective antibodies is retained, so they are bifunctional and bispecific.
- multispecific antibody includes, for example, trispecific antibodies and tetraspecific antibodies, the former being antibodies having three different antigen binding specificities and the latter being antibodies having four different antigen binding specificities.
- the term "intact antibody” refers to an antibody comprising an antigen binding variable region and a light chain constant region (CL), a heavy chain constant region (CH1, CH2, and CH3).
- the constant region can be a native sequence (eg, a human native constant region sequence) or an amino acid sequence variant thereof.
- An intact antibody is preferably an intact antibody having one or more effector functions.
- the term "Probody” is a modified antibody comprising an antibody or an antibody fragment that specifically binds to its target and is capable of coupling to a masking group, wherein the masking group refers to an antibody or antibody fragment thereof
- the cleavage constant of the binding ability of the target is at least 100-fold or 1000-fold, or 10,000-fold greater than the cleavage constant of the binding ability of the antibody or antibody fragment without the coupling masking group to its target.
- a "humanized" form of a non-human (eg, murine) antibody refers to a chimeric antibody comprising a minimal amount of non-human immunoglobulin sequences.
- Most humanized antibodies are human receptors.
- the hypervariable region residues of immunoglobulins are replaced by non-humans (eg, mice, rats, rabbits, or non-human primates) with the desired specificity, affinity, and function. Hypervariable region residues (donor antibodies).
- the framework region (FR) residues of the human immunoglobulin are also replaced with non-human residues.
- the humanized antibody may also comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are intended to further optimize the performance of the antibody.
- Humanized antibodies generally comprise at least one, usually two variable regions, wherein all or nearly all of the hypervanable loops correspond to non-human immunoglobulins, while FR is completely or almost entirely human immunoglobulin.
- a humanized antibody can also comprise at least a portion of an immunoglobulin constant region (Fc, typically a human immunoglobulin Fc).
- Fc immunoglobulin constant region
- Intact antibodies can be divided into different "classes” based on the amino acid sequence of the heavy chain constant region.
- the main five classes are IgA, IgD, IgE, IgG and IgM, several of which can also be divided into different "subclasses” (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.
- the heavy chain constant regions of different classes of antibodies are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
- Subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known in the art.
- amino acid substitution in an antibody is substituted by an L-amino acid in most cases, it is not limited thereto.
- one or more D-amino acids can be included in the antibody peptide chain. Peptides comprising D-amino acids are more stable and less susceptible to degradation in the oral, intestinal or plasma than peptides comprising only L-amino acids.
- the monoclonal antibodies used in the present disclosure can be produced by a number of methods.
- monoclonal antibodies for use in the present disclosure can be obtained by hybridoma methods using a variety of species including cells of mice, hamsters, rats, and humans (see, eg, Kohler et al, 1975, Nature, 256:495).
- Monoclonal antibodies useful in the present disclosure include, but are not limited to, monoclonal antibodies against Her 2, such as trastuzumab, Pertuzumab, or monoclonal antibodies against Trop-2, such as Sacituzumab (That is, Isactuzumab or hRS7 antibody), M1, M2 or M3.
- Her 2 such as trastuzumab, Pertuzumab, or monoclonal antibodies against Trop-2, such as Sacituzumab (That is, Isactuzumab or hRS7 antibody), M1, M2 or M3.
- the target of the targeting moiety A is selected from the group consisting of: epidermal growth factor, Trop-2, CD37, HER2, CD70, EGFRvIII, Mesothelin, Folate eceoptor1, Mucin 1, CD138, CD20, CD19, CD30, SLTRK6, Nectin 4, Tissue factor, Mucin16, Endothelinreceoptor, STEAP1, SLC39A6, Guanylylcyclase C, PSMA, CCD79b, CD22, Sodium phosphate cotransporter 2B, GPNMB, Trophoblast glycoprotein, AGS-16, EGFR, CD33, CD66e, CD74, CD56 , PD-L1, TACSTD2, DR5, E16, STEAP1, 0772P, MPF, Napi3b, Sema5b, PSCA hlg, ETBR, MSG783, STEAP2, TrpM4, CRIPTO, CD21, CD79b, FcR
- the target of the targeting moiety A is selected from the group consisting of: an RGD peptide that recognizes a cell surface integrin receptor; a growth factor that recognizes a cell surface growth factor receptor such as EGF, PDGF, VEGF; A peptide capable of recognizing functional cell surface plasminogen activator, bombesin, bradykinin, somatostatin, prostate specific membrane antigen receptor.
- the target of the targeting moiety A is selected from the group consisting of: a CD40 ligand, a CD30 ligand, an OX40 ligand, a PD-1 ligand, an ErbB ligand, a Her2 ligand, a TACSTD2 ligand, and DR5 ligand.
- the targeting moiety A is a monoclonal antibody against Her 2 , such as trastuzumab, Pertuzumab; or the targeting moiety is anti-Trop- A monoclonal antibody of 2, such as Sacituzumab, M1, M2 or M3.
- the targeting moiety is trastuzumab or Pertuzumab.
- Trastuzumab is a monoclonal antibody against Her 2 whose amino acid sequence is known to those skilled in the art, the schematic sequence of which can be found, for example, CN 103319599.
- the heavy chain distal Lys of the targeting moiety is readily deleted but does not affect biological activity, see Dick, L. W. et al, Biotechnol. Bioeng., 100: 1132-1143.
- the targeting moiety is a monoclonal antibody against Trop-2, such as a Sacituzumab, M1, M2 or M3 heavy chain last Lys deletion, for example, the targeting moiety is a monoclonal antibody against Her 2 , such as a song. Tombuzumab, Pertuzumab, is missing at the last heavy chain of Lytuzumab.
- Exemplary heavy chain sequences and light chain sequences of trastuzumab can be found, for example, in SEQ ID No.: 17 and SEQ ID No.: 18.
- the heavy chain sequence and the light chain sequence of trastuzumab they are described using the sequences shown in SEQ ID No.: 17 and SEQ ID No.: 18, respectively.
- Exemplary heavy chain and light chain sequences of pertuzumab can be found in SEQ ID No.: 16 and SEQ ID No.: 15 of US7560111.
- the targeting moiety anti-Trop-2 antibody is RS7 (i.e., the present disclosure Sacituzumab) as described in U.S. Patent No. 7,517,964; and hRS7 (i.e., the present disclosure Sacituzumab) as described in US 2012/0237518.
- Anti-Trop-2 antibodies useful in the present disclosure can also be screened by methods for designing, constructing, and constructing antibody libraries displaying antibodies, as disclosed in CN103476941A, or by Sorrento Therapeutics, Inc. The library was obtained by screening.
- the heavy chain sequence and the light chain amino acid sequence of Sacituzumab mAb can be found, for example, in SEQ ID No.: 19 and SEQ ID No.: 20, respectively.
- the K (or lys) at the end of the heavy chain is readily deleted, but this deletion does not affect biological activity, see Dick, L. W. et al, Biotechnol. Bioeng., 100: 1132-1143.
- ErbB2 and Her2/neu are used interchangeably, both of which represent the native sequence human HER2 protein (Genebank Accession No.: X03363, see, eg, Semba et al, 1985, PNAS, 82: 6497-6501; and Yamamoto) Et al., 1986, Nature, 319: 230-234) and functional derivatives thereof, such as amino acid sequence variants.
- ErbB2 represents the gene encoding human Her2, and neu represents the gene encoding rat pl85neu.
- the compounds or conjugates of the present disclosure are capable of inhibiting or killing cells expressing the ErbB2 receptor, such as breast cancer cells, ovarian cancer cells, gastric cancer cells, endometrial cancer cells, salivary gland cancer cells, lung cancer cells, Renal cancer cells, colon cancer cells, thyroid cancer cells, pancreatic cancer cells, bladder cancer cells or liver cancer cells.
- cells expressing the ErbB2 receptor such as breast cancer cells, ovarian cancer cells, gastric cancer cells, endometrial cancer cells, salivary gland cancer cells, lung cancer cells, Renal cancer cells, colon cancer cells, thyroid cancer cells, pancreatic cancer cells, bladder cancer cells or liver cancer cells.
- Trop-2 or TROP2 refers to human trophoblast cell surface antigens 2, also known as TACSTD2, M1S1, GA733-1, EGP-1, which are composed of many human tumors.
- Cell surface receptors expressed by cells such as breast cancer, colorectal cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer, cervical cancer.
- a compound or conjugate of the present disclosure is capable of inhibiting or killing a cell that expresses a TROP2 receptor, such as a breast cancer cell, a colorectal cancer cell, a lung cancer cell, a pancreatic cancer cell, an ovarian cancer cell, a prostate cancer cell, or Cervical cancer cells.
- conjugate present in the present invention The specific manner of linking the thiol group to the linker in the antibody when the targeting moiety is an antibody.
- C 1-6 alkyl means a straight or branched alkyl group having 1 to 6 carbon atoms, and includes, for example, "C 1-4 alkyl", "C 1-3 alkyl”. Etc. Specific examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methyl Butyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl Base, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl Base, 2-e
- C 2-6 alkenyl refers to a straight-chain, branched or cyclic alkenyl group containing at least one double bond and having 2 to 6 carbon atoms, including, for example, "C 2-4 alkenyl”. "Wait.
- Examples thereof include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentyl Alkenyl, 3-pentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,4-hexyl Dienyl, cyclopentenyl, 1,3-cyclopentadienyl, cyclohexenyl, 1,4-cyclohexadienyl and the like.
- C 2-6 alkynyl refers to a straight or branched alkynyl group containing at least one triple bond and having 2 to 6 carbon atoms, including, for example, "C 2-4 alkynyl” and the like. Examples thereof include, but are not limited to, ethynyl, propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 4-methyl-2-pentynyl, 2-hexynyl, 3 - hexynyl, 5-methyl-2-hexynyl and the like.
- halogen includes fluoro, chloro, bromo, iodo.
- 3-8 membered cycloalkyl or “C 3-8 cycloalkyl” refers to a saturated cyclic alkyl group containing from 3 to 8 carbon atoms, including, for example, “3-6 membered cycloalkyl”", 4-6 membered cycloalkyl", “5-7 membered cycloalkyl” or “5-6 membered cycloalkyl” and the like. Specific examples include, but are not limited to, cyclopropyl, cyclobutane, cyclopentyl, cyclohexane, cycloheptyl, cyclooctyl, and the like.
- C1-6 alkoxy refers to a group having a C1-6 alkyl-O- structure wherein C1-6 alkyl is as defined above. Specific examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxide Base, hexyloxy, and the like.
- 3-8 membered heteroheterocyclyl refers to a cyclic group containing from 3 to 8 ring atoms, at least one of which is a hetero atom such as a nitrogen atom, an oxygen atom or a sulfur atom.
- a ring atom eg, a carbon atom, a nitrogen atom, or a sulfur atom
- oxo e.g., a carbon atom, a nitrogen atom, or a sulfur atom
- the "3-8 membered aliphatic heterocyclic group” includes, for example, “3-8 membered nitrogen-containing aliphatic heterocyclic group”, “3-8 membered oxyalicyclic group”, “3-6 membered aliphatic heterocyclic group”, “ 3-6 yuan oxygen-containing heterocyclic group”, “4-7-membered aliphatic heterocyclic group”, “4-6-membered aliphatic heterocyclic group”, “5-7-membered aliphatic heterocyclic group”, “5-6 yuan” "Heteroheterocyclyl", “5-6 membered nitrogen-containing heterocyclic group”, including but not limited to oxiranyl, oxocyclobutane, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl , tetrahydropyranyl, homopiperazinyl and the like.
- 6-12 membered spirocyclyl refers to a cyclic structure containing 6 to 12 ring-forming carbon atoms formed by the sharing of one carbon atom by two or more cyclic structures.
- the carbon atoms in the cyclic structure can be replaced by oxo.
- the "6-12 membered spiro group” includes, for example, “6-11 membered spiro group”, “6-10 membered spiro group”, “7-10 membered spiro group”, and “7-9 membered spiro group”", 7-8 yuan spiro ring base”, “9-10 yuan spiro ring base”, “3-10 yuan spiro ring base” and so on. Specific examples include, but are not limited to: Wait.
- 6-12 membered bridged ring group refers to a ring of 6 to 12 ring carbon atoms formed by two or more ring structures sharing two non-adjacent carbon atoms with each other. structure.
- the carbon atoms in the cyclic structure can be replaced by oxo.
- "6-12 Yuan Bridged Ring Group” includes, for example, “6-11 Yuan Bridged Ring Group”, “5-10 Yuan Bridged Ring Group”, “7-10 Yuan Bridged Ring Group”, “7-9 Yuan Bridged Ring Group” , "7-8 yuan bridge ring base”, “9-10 yuan bridge ring base”, “3-10 yuan bridge ring base” and so on. Specific examples include, but are not limited to: Wait.
- 6-12 membered fused ring group refers to a cyclic structure having 6 to 12 ring carbon atoms formed by two or more ring structures sharing two adjacent atoms with each other. , including “6-11 membered fused ring group”, “6-10 membered fused ring group”, “6-8 membered fused ring group”, “10-12 membered fused ring group”, “7-10 membered fused ring group””. Examples include, but are not limited to: Wait.
- the term "6-12 membered spiroheterocyclyl” refers to a ring atom formed by the sharing of one ring atom with two or more cyclic structures, wherein at least one of the ring atoms is A cyclic structure of a hetero atom such as a nitrogen atom, an oxygen atom or a sulfur atom.
- a ring atom eg, a carbon atom, a nitrogen atom, or a sulfur atom
- oxo e.g, a carbon atom, a nitrogen atom, or a sulfur atom
- the "6-12 membered spiroheterocyclyl” includes, for example, “6-11 membered spiroheterocyclyl", “5-10 membered spiroheterocyclyl”, “7-11 membered spiroheterocyclyl”, and “7-10"Spiroheterocyclyl”,”7-9 membered spiroheterocyclyl", “7-8 membered spiroheterocyclyl”, “9-10 membered spiroheterocyclyl", “3-10 membered spiroheterocyclyl”, etc. . Specific examples include, but are not limited to: Wait.
- the term "6-12 membered bridged heterocyclyl” refers to a group of 6 to 12 ring atoms formed by two or more ring structures sharing two non-adjacent ring atoms with each other (wherein The ring structure in which at least one ring atom is a hetero atom such as a nitrogen atom, an oxygen atom or a sulfur atom.
- a ring atom eg, a carbon atom, a nitrogen atom, or a sulfur atom
- oxo e.g, a carbon atom, a nitrogen atom, or a sulfur atom
- the "6-12 membered bridged heterocyclic group” includes, for example, "6-11 membered bridged heterocyclic group", “6-9 membered bridged heterocyclic group”, “6-10 membered bridged heterocyclic group”, and “7-10 member” Bridged heterocyclic group”, “7-9 membered bridged heterocyclic group”, “7-8 membered bridged heterocyclic group”, “8-membered bridged heterocyclic group”, “9-10 membered bridged heterocyclic group", "3 -10-membered bridge heterocyclic group” and the like. Specific examples include, but are not limited to: Wait.
- the term "6-12 membered fused heterocyclyl” refers to a group of 6 to 12 ring atoms formed by two or more ring structures sharing two adjacent atoms with each other (at least one of which The ring atom is a cyclic structure of a hetero atom such as a nitrogen atom, an oxygen atom or a sulfur atom.
- a ring atom eg, a carbon atom, a nitrogen atom, or a sulfur atom
- oxo e.g, a carbon atom, a nitrogen atom, or a sulfur atom
- the "6-12 membered fused heterocyclic group” includes, for example, "6-11 membered fused heterocyclic group", “5-10 membered fused heterocyclic group”, “7-10 membered fused heterocyclic group”, and "3-10 member”. "Heteroheterocyclic group”, “3-10 membered nitrogen-containing fused heterocyclic group”, “9-10 membered fused heterocyclic group”, “9-10 membered nitrogen-containing fused heterocyclic group”, "6-12 yuan oxygenated” A fused heterocyclic group” and the like.
- Specific examples include, but are not limited to, tetrahydroimidazo[4,5-c]pyridyl, 3,4-dihydroquinazolinyl, 1,2-dihydroquinoxalinyl, benzo[d][1 , 3]dioxolyl, 1,3-dihydroisobenzofuranyl, 4H-1,3-benzoxazinyl, 4,6-dihydro-1H-furo[3,4 -d]imidazolyl, 3a,4,6,6a-tetrahydro-1H-furo[3,4-d]imidazolyl, 4,6-dihydro-1H-thieno[3,4-d]imidazole , 4,6-dihydro-1H-pyrrolo[3,4-d]imidazolyl, benzimidazolylalkyl, octahydro-benzo[d]imidazolyl, decahydroquinolyl, hexahydr
- aryl refers to a monocyclic or polycyclic hydrocarbon group having an aromatic character, such as a 6-20 membered aryl group, a 6-10 membered aryl group, a 5-8 membered aryl group, and the like. Specific examples include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthryl, and the like.
- the "6-20 membered aryl group” means an aryl group having 6 to 20 ring atoms.
- heteroaryl refers to a cyclic group having an aromatic character wherein at least one of the ring atoms is a hetero atom such as a nitrogen atom, an oxygen atom or a sulfur atom.
- a ring atom eg, a carbon atom, a nitrogen atom, or a sulfur atom
- oxo a ring atom in the cyclic structure
- Specific examples include, but are not limited to, a 5-10 membered heteroaryl group, a 5-10 membered nitrogen-containing heteroaryl group, a 6-10 membered oxygen-containing heteroaryl group, a 6-8 membered nitrogen-containing heteroaryl group, and a 5-8 membered oxygen group.
- a heteroaryl group or the like such as furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl, pyrazolyl, 1, 2,3-Triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl 1,3,4-oxadiazolyl, pyridyl, 2-pyridinone, 4-pyridinone, pyrimidinyl, 1,4-dioxadienyl, 2H-1,2-oxa Azinyl, 4H-1,2-oxazinyl, 6H-1,2-oxazinyl, 4H-1,3-oxazinyl, 6H-1,3-oxazinyl, 4H-1,4- Azinyl,
- the present disclosure obtains a novel class of biologically active molecular conjugates by improving the manner in which the drug is coupled to the targeting moiety in the ADC or SMDC.
- the bioactive molecule conjugate is obtained by nucleophilic substitution reaction of a heteroaromatic ring on an ADC drug linker with a free sulfhydryl group in an antibody molecule.
- the conjugate obtained by the above coupling method can achieve at least one of the following technical effects:
- the conjugate of the conjugate can reach 5-8;
- the coupling efficiency can reach 90%
- the conjugate obtained according to the above coupling method can effectively improve the stability of the drug molecule in the circulation, and reduce the detachment of the non-target drug in the non-target cell;
- the conjugate can also increase the effective release of the bioactive molecule in the cell to achieve the purpose of synergistic effect and attenuation;
- the conjugate has a good therapeutic effect on a tumor animal model.
- the coupling mode described in the present disclosure has a high application range and can be widely used for coupling biologically active molecules with antibodies or targeting small molecule ligands.
- Figure 1 shows the TIC diagram (total ion chromatogram) of BT001002.
- Figure 2 is a BT001002 coupled light chain deconvolution diagram.
- Figure 3 is a BT001002 coupled heavy chain deconvolution diagram.
- Figure 4 is a TIC diagram (total ion chromatogram) of BT001004.
- Figure 5 is a BT001004 coupled light chain deconvolution diagram.
- Figure 6 is a BT001004 coupled heavy chain deconvolution plot.
- Figure 7 is an SEC chromatogram of BT001002.
- Figure 8 is a molecular weight Marker SEC chromatogram of BT001002.
- Figure 9 is an SEC chromatogram of BT001004.
- Figure 10 is a BT001012 coupled light chain deconvolution diagram.
- Figure 11 is a BT001012 coupled heavy chain deconvolution diagram.
- Figure 12 is a BT001013 coupled light chain deconvolution diagram.
- Figure 13 is a BT001013 coupled heavy chain deconvolution plot.
- Figure 14 is a BT001018 coupled light chain deconvolution diagram.
- Figure 15 is a BT001018 coupled heavy chain deconvolution plot.
- Figure 16 is a BT001021 coupled light chain deconvolution diagram.
- Figure 17 is a BT001021 coupled heavy chain deconvolution plot.
- Figure 18 is a BT001023 coupled light chain deconvolution diagram.
- Figure 19 is a BT001023 coupled heavy chain deconvolution plot.
- Figure 20 is a BT001040 coupled light chain deconvolution diagram.
- Figure 21 is a BT001040 coupled heavy chain deconvolution plot.
- Figure 22 is a BT001041 coupled light chain deconvolution diagram.
- Figure 23 is a BT001041 coupled heavy chain deconvolution diagram.
- Figure 24 is a BT001042 coupled light chain deconvolution diagram.
- Figure 25 is a BT001042 coupled heavy chain deconvolution plot.
- Figure 26 is a BT001043 coupled light chain deconvolution diagram.
- Figure 27 is a BT001043 coupled heavy chain deconvolution plot.
- Figure 28 is a BT001044 coupled light chain deconvolution diagram.
- Figure 29 is a BT001044 coupled heavy chain deconvolution diagram.
- Figure 30 is a BT001046 coupled light chain deconvolution plot.
- Figure 31 is a BT001046 coupled heavy chain deconvolution plot.
- Figure 32 is a BT001047 coupled light chain deconvolution diagram.
- Figure 33 is a BT001047 coupled heavy chain deconvolution plot.
- Figure 34 is an SEC chromatogram of BT001012.
- Figure 35 shows the SEC chromatogram of BT001013.
- Figure 36 is a SEC chromatogram of BT001018.
- Figure 37 is the SEC chromatogram of BT001021.
- Figure 38 is an SEC chromatogram of BT001023.
- Figure 39 is an SEC chromatogram of BT001042.
- Figure 40 is an SEC chromatogram of BT001043.
- Figure 41 is an SEC chromatogram of BT001044.
- Figure 42 is an SEC chromatogram of BT001046.
- Figure 43 is a SEC chromatogram of BT001047.
- Fig. 44 shows the growth of tumor volume in each group of mice in the NCI-N87 human gastric cancer model.
- Figure 45 Changes in body weight of mice in each group of NCI-N87 human gastric cancer models.
- Figure 46 Growth of tumor volume in each group of mice in the HCC1806 human breast cancer model.
- Figure 47A shows the growth of tumor volume in each group of mice in the HCC827 human non-small cell lung cancer xenograft model.
- Figure 47B Changes in body weight of mice in each group of HCC827 human non-small cell lung cancer xenograft models.
- Figure 48A Growth of tumor volume in each group of mice in the NCI-N87 human gastric cancer xenograft model.
- Figure 48B Changes in body weight of mice in each group of NCI-N87 human gastric cancer xenograft models.
- Figure 49A Growth of tumor volume in mice of each group in the MDA-MB-231 human breast cancer-bearing mouse model.
- Figure 49B Changes in body weight of mice in each group of MDA-MB-231 human breast cancer-bearing mice model.
- the nuclear magnetic resonance ( 1 H NMR) measuring instrument was performed using a Bruker 400 MHz nuclear magnetic resonance apparatus; the solvent was determined to be deuterated methanol (CD 3 OD), deuterated chloroform (CDCl 3 ) or hexamethyl dimethyl sulfoxide (DMSO-d 6). ); the internal standard substance is tetramethylsilane (TMS).
- NMR nuclear magnetic resonance
- MS mass spectrometer
- ESI Agilent 6120B
- the preparative liquid chromatography method is as follows:
- Mobile phase A water; mobile phase B: acetonitrile
- Mobile phase A water; mobile phase B: acetonitrile
- Mobile phase A water containing 0.1% trifluoroacetic acid
- mobile phase B acetonitrile
- Method D Column: Waters SunFire C18 5 ⁇ m 19x250mm
- Mobile phase A acetonitrile
- mobile phase B water containing 0.05% formic acid
- Step 1 (4-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2) -(dimethylamino)-3-methylbutyryl)-N,3-dimethylbutyryl)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3 Synthesis of tert-butyl ester of -methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)carbamate
- Step 2 (2S)-N-((3R,4S,5S)-1-((2S)-2-((1R,2R)-3-((1-((4-aminobenzyl))amino)) -1-oxo-3-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-propionyl)pyrrolidin-1-yl)-3-methoxy-5
- Step 2 Synthesis of (S)-(4-((2-amino-3-phenylpropionamido)methyl)phenyl)carbamic acid tert-butyl ester
- Lithium hydroxide monohydrate (21 mg, 0.51 mmol) was dissolved in water (1 mL) and added to (S)-(4-((2-((9))))) A solution of tert-butyl carbonyl)amino)-3-phenylpropionamido)methyl)phenyl)carbamate (102 mg, 0.17 mmol) in tetrahydrofuran (2 mL). Water (20 mL) was added to the mixture and the mixture was evaporated. The organic phase was combined and the organic layer was washed with brine (30 mL? The desiccating agent was filtered off, and the solvent was evaporated. ESI-MS (m/z): 370.2 [M+H] + .
- Step 3 (4-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-3-(methyl) Amino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy Synthesis of -2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)carbamate
- Step 4 (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-((S)-1-((4-aminobenzyl) Amino)-1-oxo-3-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3- Methoxy-5-methyl-1-oxoheptan-4-yl)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3- Synthesis of dimethylbutyramide
- Methanesulfonyl chloride (462 mg, 12.77 mmol, about 70% purity) was added dropwise to a solution of beclotilone hydrochloride (3 g, 6.38 mmol) and triethylamine (2.58 g, 25.54 mmol) in dichloromethane (40 mL). The reaction was carried out for 2 h under the conditions. After suction filtration, the cake was washed with dichloromethane (3 mL)
- Step 3 (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-((tert-butoxycarbonyl))amino)methyl)phenyl) Amino)-1-oxo-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl-2-yl)-carbamate (compounds 1-5) Synthesis
- Step 4 (9H-fluoren-9-yl)-methyl-((S)-1-(((S)-1-((4-(aminomethyl)phenyl))amino)-1-oxo Synthesis of 5-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl-2-yl)-carbamate (Compound 1-6)
- Trifluoroacetic acid (15 mL) was added to compound 1-5 (3.0 g, 4.29 mmol). The solvent was evaporated to drynessnessnessnessnessnessnessnessnessnessnessnessnessnessnessnessnessnessnessnesssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssssss
- Step 5 (9H- ⁇ -9-yl)-methyl-((S)-1-(((S)-1-((4-(((R)))) Amino)-3-phenylpropionamido)methyl)phenyl)amino-1-oxo-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl- Synthesis of 2-yl)-carbamate (Compound 1-7)
- Boc-D-phenylalanine (1.1 g, 4.2 mmol), trifluoroacetate salt of compound 1-6 (3.0 g, 4.2 mmol) was dissolved in N,N-dimethylformamide (40 mL) , cooling to 0 ° C, then adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.2 g, 6.3 mmol), 1-hydroxybenzotriazole ( 0.9 g, 6.3 mmol), N-methylmorpholine (1.7 g, 16.8 mmol), and the reaction system was stirred for 1.0 h. The reaction mixture was poured into ice water (400 mL). ESI-MS (m/z): 848.4 [M+H] + .
- Step 6 (9H- ⁇ -9-yl)-methyl-((S)-1-(((S)-1-((4-((())))) Amido)methyl)phenyl)amino)-1-oxo-5-ureidopentyl-2-yl)amino)-3-methyl-1-oxobutyl-2-yl)-aminomethyl
- Step 7 (9H- ⁇ -9-yl)-methyl-((S)-1-(((S)-1-((4-((())))) 3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-butanamide)-N, 3-dimethylbutyryl)-3-methoxy-5-methylheptanoyl)pyrrol-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropanamide Methyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (compound) Synthesis of 1-9)
- Step 8 (S)-2-((S)-2-Amino-3-butyrylamino)-N-(4-((S)-2-((2R,3R)-3-((S) )-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-butylamido)-N,3-dimethyl Butyramide)-3-methoxy-5-methylheptanoyl)pyrrol-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl) Synthesis of Phenyl)-5-ureidovaleramide (Compound 1-10)
- Step 9 (S)-2-((S)-2-(4-(4-Chloro-7H-pyrrole[2,3-d]pyrimidin-7-yl)butanamide)-3-methylbutyl Amido)-N-(4-(((S)))((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2) -((S)-2-(dimethylamino)-3-methylbutyryl)-N,3-dimethylbutyryl)-3-methoxy-5-methylheptanoyl)pyrrole Synthesis of alk-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-5-ureidovaleramide (Compound TL001)
- Step 2 (S)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S) )-2-((S)-2-(Dimethylamino)-3-methylbutyryl)-N,3-dimethylbutyryl)-3-methoxy-5-methyl Heptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-2-((S)-3- Methyl-2-(4-(4-(methylthio)-7H-pyrrole[2,3-d]pyrimidin-7-yl)-butyryl)butylamido)-5-ureidovaleramide Synthesis of (Compound 2-3)
- Step 3 (S)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S) )-2-((S)-2-(Dimethylamino)-3-methylbutyryl)-N,3-dimethylbutyryl)-3-methoxy-5-methyl Heptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)-2-((S)-3- Methyl-2-(4-(4-(methylsulfonyl)-7H-pyrrole[2,3-d]pyrimidin-7-yl)-butyryl)-butanamide)-5-ureidovaleramide Synthesis of (Compound TL002)
- Step 4 N-((S)-1-(((S)-1-((4R,3R)-3-((S)-1-(())) 3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3-dimethylbutyrylamino) 3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoylamino)-3-phenylpropionamido)methyl)phenyl Amino)-1-oxo-5-ureido-2-yl)amino)-3-methyl-1-oxybutan-2-yl)-6-(2-(methylsulfonyl)pyrimidine- Synthesis of 5-yl)-5-hexynylamide (Compound TL003)
- Step 3 (S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30-oxaoxa-6-azatriacetamide Synthesis of s-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide (Compound 19-4)
- Step 4 4-((S)-35-azido-4,8-dioxo-2-(3-ureidopropyl)-6,12,15,18,21,24,27,30 , 33-decyloxy-3,9-azatetradecane)benzyl ((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonylamino)ethyl) -3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4',6,7]pyridazino[1,2-b]quinoline- Synthesis of 4-yl)carbonate (Compound 19-5)
- Step 5 4-((S)-35-Amino-4,8-dioxo-2-(3-ureidopropyl)-6,12,15,18,21,24,27,30,33 -decyloxy-3,9-azatetradecane)benzyl ((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonylamino)ethyl)-3 ,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4',6,7]indolizine[1,2-b]quinoline-4- Synthesis of a base carbonate (compound 19-6)
- Step 6 (S)-4-Ethyl-11-(2-(N-isopropylmethylsulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro -1H-pyrano[3',4',6,7]pyridazino[1,2-b]quinolin-4-yl (4-((S)-42-(2-(methyl)) Sulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-2-(3-ureidopropyl)-6,12,15,18,21,24,27,30,33- ⁇ Synthesis of Oxy-3,9,36-azadocosane-41-amido)benzyl)carbonate (Compound TL019)
- Step 1 ((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino) )-3-methyl-butyramido-2-yl)-(9H-indenyl)methyl-carbamate
- Step 3 N-((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)) Amino)-3-methyl-1-oxobutan-2-yl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamide (Compound 28-4) synthesis
- Benzotriazol-1-yl-oxytripyrrolidinyl hexafluorophosphate (313 mg, 0.6 mmol) and N,N-diisopropylethylamine (194 mg, 1.50 mmol) were added to 6-( 2-Methylsulfonylpyrimidin-5-yl)-5-hexynoic acid (135 mg, 0.5 mmol) and (2S)-2-((2S)-2-amino-3-methyl-butanoyl)amino -N-(4-(Hydroxymethyl)phenyl)-5-ureido-pentanamide (190 mg, 0.5 mmol) in N,N-dimethylformamide (10 mL). Purification by preparative high performance liquid chromatography (Method D) gave the title compound. ESI-MS (m/z): 630.3 [M+H] + .
- Step 4 (S)-4-Ethyl-11-(2-(N-isopropylmethanesulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro- 1H-pyrano[3',4',6,7]pyridazino[1,2-b]quinolin-4-yl-(4-((S)-2-((S)-3) -Methyl-2-(6-(2-(methylsulfonyl)pyrimidin-5-yl))-5-hexynamido)butyramido)-5-ureidopentanoamide)benzyl)carbonate Synthesis of ester (compound TL028)
- Step 1 (S)-2-((S)-35-azido-2-isopropyl-4,8-dioxo-6,12,15,18,21,24,27,30, Synthesis of 33-decyloxy-3,9-azatetradecane)-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide (Compound 29-1)
- Step 2 4-((2S,5S)-38-azido-5-isopropyl-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18 ,21,24,27,30,33,36-decyloxy-3,6,12-triazatridecylamide)benzyl ((S)-4-ethyl-11-(2- (N-isopropylmethylsulfonylamino)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4',6,7 Synthesis of pyridazine[1,2-b]quinolin-4-yl)carbonate (Compound 29-2)
- Step 3 (S)-4-Ethyl-11-(2-(N-isopropylmethylsulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro -1H-pyrano[3',4',6,7]pyridazino[1,2-b]quinolin-4-yl-(4-((2S,5S)-5-isopropyl) -38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamido)methyl)-1H-1,2,3-triazol-1-yl -4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27,30,33,36-decyloxy-3,6,12 Synthesis of tris(triazatridecylamino)benzyl)carbonate (compound TL029)
- Step 1 (S)-2-((S)-35-Amino-2-isopropyl-4,8-dioxo-6,12,15,18,21,24,27,30,33- Synthesis of decyloxy-3,9-diazatridecylamide)-N-(4-(hydroxymethyl)phenyl)-5-ureidovaleramide
- Step 2 N-((6S,9S)-1-amino-6-((4-(hydroxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,15-tetra Oxo-13,19,22,25,28,31,34,37,40-decyloxy-2,7,10,16-tetraazatetradodecane-42-yl)-6-(2 Synthesis of -(Methanesulfonyl)pyrimidin-5-yl)hex-5-ynylamide
- Step 3 (S)-4-Ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro -1H-pyrano[3',4':6,7]indolizine[1,2-b]quinolin-4-yl(4-((2S,5S)-5-isopropyl- 45-(2-(Methylsulfonyl)pyrimidin-5-yl)-4,7,11,40-tetraoxo-2-(3-ureidopropyl)-9,15,18,21,24 Synthesis of 27,30,33,36-decyloxy-3,6,12,39-tetraazatetradecane-44-carbamoyl)benzyl)carbonate (Compound TL022)
- Example 12 4-((S)-2-(4-Aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6, 12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazatetradecyl-41-ynylamido)benzyl-((S)-4 -ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone [3' , 4':6,7]oxazino[1,2-b]quinolin-4-yl)carbonate
- Step 1 (S)-4-Ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro- 1H-pyrone [3',4':6,7]pyridazino[1,2-b]quinolin-4-yl (4-((S)-2-(4-((4) -Methoxyphenyl)diphenylmethyl)amino)butyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15 Synthesis of 18,21,24,27,30,33-nonaoxa-3,9,36-triazatetradodecyl-41-alkylamido)benzyl carbonate
- 6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynoic acid (12 mg, 0.045 mmol) was dissolved in dichloromethane (2 mL) at rt.
- Azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (21.2 mg, 0.056 mmol) and N,N-diisopropylethylamine (8.6 mg, 0.067) (mmol)
- stirring for 10 min compound 24-1 (35 mg, 0.022 mmol) was added and the reaction was stirred for 1 h.
- Purification by preparative high performance liquid chromatography (Method B) gave the title compound.
- ESI-MS (m/z): 1821.8 [M+H] + .
- Step 2 4-((S)-2-(4-Aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12 ,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazatetradecyl-41-ynylamido)benzyl-((S)-4- Ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone [3', Synthesis of 4':6,7]oxazino[1,2-b]quinolin-4-yl)carbonate (Compound TL024)
- Step 3 (9H-fluoren-9-yl)-methyl ((S)-1-((())-1-((4-(hydroxymethyl)phenyl)amino)-1-oxopropane Preparation of 2-yl)amino)-3-methyl-1-oxobutan-2-yl)-carbamate
- Step 5 (S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30-decyloxy-6-diaza thirty Preparation of Pentadecylamino)-N-((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxopropan-2-yl)-3-methylbutanamide
- Step 6 4-((2S,5S)-38 azido-5-isopropyl-2-methyl-4,7,11-trioxo-9,15,18,21,24,27, 30,33,36-decyloxy-3,6,12-triazatriaconamido)benzyl ((S)-4-ethyl-11-(2-(N-isopropylmethyl) Sulfonylamino)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]pyridazine[1, Preparation of 2-b]quinolin-4-yl)carbonate
- Step 7 (S)-4-Ethyl-11-(2-(N-isopropylmethylsulfonamide)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro -1H-pyrano[3',4':6,7]pyridazino[1,2-b]quinolin-4-yl-4-((2S,5S)-5-isopropyl- 2-Methyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)yl)hex-5-ynylamino)methyl)-1H-1,2,3 -triazol-1-yl)-4,7,11-trioxo-9,15,18,21,24,27,30,33,36-decyloxy-3,6,12-triaza Preparation of triacontanido)benzyl carbonate (compound TL030)
- Example XIV 4-((S)-2-(4-Aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-amide) Methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nineoxy Hetero-3,9-diazatridecanoylamino)benzyl ((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3 ,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline-4- Carbonate
- Step 1 Synthesis of 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)hex-5-ynylamide
- Step 2 4-((S)-35-azido-2-(4-((4-(methoxyphenyl))diphenylmethyl)amino)butyl)-4,8-dioxo -6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazatridecanoylamino)benzyl ((S)-4-ethyl-11 -(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-2H-pyrano[2,3-b] Synthesis of -1H-pyrano[3',4':6,7]oxazino[1,2-b]quinolin-4-yl)carbonate
- T-030 (250 mg, 0.49 mmol) was dissolved in dichloromethane (10 mL), and then cooled to 0 ° C, then added to 4-dimethylaminopyridine (478 mg, 3.91 mmol) in dichloromethane (3 mL) The solution was then slowly added dropwise a solution of triphosgene (72 mg, 0.24 mmol) in dichloromethane (10 mL), and the mixture was stirred and stirred at 0 ° C for 20 min.
- Step 3 (S)-4-Ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro -1H-pyrano[3',4':6,7]pyridazino[1,2-b]quinolin-4-yl (4-((S)-2-(4-((4) -Methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hexyl-5-amide) Methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-decyloxy- Synthesis of 3,9-diazatridecanoylamino)benzyl)carbonate
- Step 4 4-((S)-2-(4-Aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hexyl-5-amide) )methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-hexaoxa -3,9-diazatridecanoylamino)benzyl ((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3, 14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizine[1,2-b]quinolin-4-yl Synthesis of Carbonate (Compound TL033)
- Step 1 4-((S)-35-azido-2-(4-((4-methoxyphenyl)diphenylmethyl)amino)butyl)-4,8-dioxo 6,6,15,18,21,24,27-decyloxy-((S)-9-((tert-butyldimethylsilyl)oxy)-4,11-diethyl- 3,14-dioxo-3,4,12,14-tetrahydro-1,2,3,4-tetrahydroquinoline-1H-pyrano[3',4':6,7]pyridazine Synthesis of [1,2-b]quinolin-4-yl)carbonate
- Step 2 (S)-9-(tert-Butyldimethylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro- 1H-pyrano[3',4':6,7]pyridazine[1,2-b]quinolin-4-yl-4-((S)-2-(4-((6(6) -(methylsulfonyl)pyrimidin-5-yl)-35-(4-((6-2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynylamide)methyl)-1H- 1,2,3-triazol-1-yl)-dioxo 6,12,15,18,21,24,27,30,33-decyloxy-3,9-diazatrifene Synthesis of alkanoamido)carbonate
- Step 3 4-((S)-2-(4-Aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynylamide) )methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-oxime -3,9-diazatridecanoylamino)benzyl ((S)-11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetra Synthesis of Hydrogen-1H-pyrano[3',4':6,7]oxazino[1,2-b]quinoline-4-carbonate (Compound TL034)
- Step 1 ((S)-35-azido-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-4,8-dioxo- 6,12,15,18,21,24,27,30,33-decyloxy-3,9-diazatridecylamide)benzyl ((S)-4-ethyl-11- (2-(N-Isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1,2,3,6-triazepane- Synthesis of 1H-pyrano[3',4':6,7]oxazino[1,2-b]quinolin-4-yl)carbonate
- Step 2 (S)-4-Ethyl-11-(2-(N-isopropylacetylamino)ethyl)-3,14-dioxo 3,4,12,14-tetrahydro-1H- Nitraindolo[1,2-b]quinolin-4-yl)-4-((S)-2-(4-(((4-) in pyrano[3',4':6,7] Methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((6-2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynylamide)methyl -1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-decyloxy-3, Synthesis of 9-diazatridecanoylamino]carbonate
- Step 3 4-((S)-2-(4-Aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynylamide) )methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-hexaoxa -3,9-diazatridecanoylamino)benzyl ((S)-4-ethyl-11-(2-(N-isopropylacetylamino)ethyl)-3,14-di Oxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)carbonate Synthesis of (Compound TL035)
- Step 2 (S)-4-Ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H -pyrone [3',4':6,7]pyridazino[1,2-b]quinolin-4-yl(4-((S,Z)-2-(4-((( 4-methoxyphenyl)diphenylmethyl)amino)butyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12, Synthesis of 15,18,21,24,27,30,33-nonaoxa-3,9,36-triazatetradodecyl-41-enamido)benzyl carbonate
- Step 3 4-((S,Z)-2-(4-Aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6 ,12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazatetradecyl-41-enamide)benzyl-((S)- 4-ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone [3' Synthesis of 4':6,7]oxazino[1,2-b]quinolin-4-yl)carbonate (Compound TL045)
- Example 18 4-((S)-2-(4-Aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6, 12,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazatetradecyl-41-ynylamido)benzyl-((S)-4 -ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone [3', 4':6,7]oxazino[1,2-b]quinolin-4-yl)carbonate
- Step 1 (S)-4-Ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H -pyrone [3',4':6,7]pyridazino[1,2-b]quinolin-4-yl(4-((S)-2-(4-(((4- Methoxyphenyl)diphenylmethyl)amino)butyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12,15, Synthesis of 18,21,24,27,30,33-nonaoxa-3,9,36-triazatetradodecyl-41-alkylamido)benzyl carbonate
- Step 2 4-((S)-2-(4-Aminobutyl)-42-(2-(methylsulfonyl)pyrimidin-5-yl)-4,8,37-trioxo-6,12 ,15,18,21,24,27,30,33-nonaoxa-3,9,36-triazatetradecyl-41-ynylamido)benzyl-((S)-4- Ethyl-11-(2-(N-isopropylacetamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone [3',4 Synthesis of ':6,7]oxazino[1,2-b]quinolin-4-yl)carbonate (Compound TL048)
- a compound 48-2 was used in place of the compound 24-2 by a similar synthetic procedure as in Example 12, Step 2.
- the title compound was obtained as the trifluoroacetic acid salt, 11.35 mg.
- Example 19 4-((S)-2-(4-Aminobutyl)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)thiazole-4-carboxamide) Methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nineoxy Hetero-3,9-diazatridecylamino)benzyl-((S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3 ,14-dioxo-3,4,12,14-tetrahydro-1H-pyrone [3',4':6,7]pyridazino[1,2-b]quinoline-4- Carbonate
- reaction solution was cooled to room temperature, dripped into water, suction filtered, and the filtrate was collected, ethyl acetate was extracted (10 mL ⁇ 3), the aqueous phase was collected, the pH was adjusted to pH 3 with dilute hydrochloric acid, and the solid was precipitated. , 70mg. ESI-MS (m/z): 254.0 [M+H] + .
- Step 3 Synthesis of 2-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(propyl-2-alkyn-1-yl)thiazole-4-carboxamide
- Step 4 (S)-4-Ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro -1H-pyrone [3',4':6,7]pyridazino[1,2-b]quinolin-4-yl-(4-((S)-2-(4-(( (4-methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)thiazol-4-carboxamide) )methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-hexaoxa Synthesis of -3,9-diazatripentadecylamino)benzyl)carbonate
- Step 5 4-((S)-2-(4-Aminobutyl)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)thiazol-4-carboxamide) )methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-hexaoxa -3,9-diazatridecylamino)benzyl-((S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3, 14-dioxo-3,4,12,14-tetrahydro-1H-pyrone [3',4':6,7]pyridazino[1,2-b]quinolin-4-yl ) Synthesis of carbonate
- Step 1 Synthesis of ethyl 2-(2-(methylthio)pyrimidin-5-yl)oxazole-4-carboxylate
- Ethyl 2-bromooxazole-4-carboxylate 100 mg, 0.45 mmol
- compound 49-1 126 mg, 0.50 mmol
- a mixed solvent of 1,4-dioxane and water 25 °C. (4 mL / 2 mL)
- potassium carbonate 125 mg, 0.9 mmol
- [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride 33 mg, 0.05 mmol
- Step 4 Synthesis of 2-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)-oxazole-4-carboxamide
- Step 5 (S)-4-Ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro -1H-pyrano[3',4':6,7]indolizine[1,2-b]quinolin-4-yl 4-((S)-2-(4-((4) -Methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)oxazole-4-carbonyl) Amino)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-oxime Synthesis of benzyl-3,9-diazatridecylamidobenzyl) benzyl) carbonate
- Step 6 4-((S)-2-(4-Aminobutyric acid)-35-(4-((2-(2-(methylsulfonyl)pyrimidin-5-yl)oxazole-4-) Amido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33- ⁇ Oxy-3,9-diazatridecanoylamino)benzyl-((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl) -3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizine[1,2-b]quinoline- Synthesis of 4-yl)carbonate
- Step 1 ((S)-1-(((S)-1-((4-((()))((()))) 4S,5S)-4-((S)-2-((S)-2-(Dimethylamino)-3-butyryl)-N,3-dimethylbutyryl)-3-methoxy 5--5-methylheptanoyl)pyrrol-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)phenyl)amino)-1-oxo Synthesis of 5-5-pentylureto-2-yl)amino)-3-methyl-1-oxobutan-2-yl)amino-(9H-indol-9yl)methyl-formate
- Step 2 (S)-2-((S)-2-Amino-3-butanamide)-N-(4-((())((2R,3R)-3-((S) )-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-butylamido)-N,3-dimethylbutyl Amido)-3-methoxy-5-methylheptanoyl)pyrrol-2-yl)-3-methoxy-2-methylpropionamido)-3-phenylpropionamido)methyl)benzene Synthesis of 5-)-ureidovaleramide
- Step 3 (S)-2-((S)-35-azido-2-isopropyl-4,8-dioxo-6,12,15,18,21,24,27,30,33- Nonaza-3,9-diazatridecylamino)-N-(4-(((S)-2-((2R,3R)-3-((S)-1-(( 3R,4S,5S)-4-((S)-2-((S)-2-((S)-2-((S)-2-(Dimethylamino)-3-methylbutanamide)-N,3-dimethylbutanamide)-3- Methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamide)-3-phenylpropanamide)methyl)phenyl)-5-ureido Synthesis of valeramide
- Step 4 N-((1-((6S,9S)-1-amino-6-((4-((()))((2))) ((3R,4S,5S)-4-((S)-2-((S)-2-(Dimethylamino)-3-methylbutanamide)-N,3-dimethylbutyramide)- 3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamide)-3-phenylpropanamide)methyl)phenyl)carbamoyl )-9-isopropyl-1,8,11,15-tetraoxy-13,19,22,25,28,31,34,37,40-nonoxa-2,7,10,16- Tetraazanonane-42-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(2-(methylsulfonyl)pyrimidin-5-yl)-5- Synthesis of he
- Step 1 4-((2S,5S)-38-azido-5-isopropyl-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18, 21,24,27,30,33,36-nonaoxa-3,6,12-triazatetradecyl)benzyl-((S)-1-((())-1-((()) ((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino) )-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl) (A Synthesis of (amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl
- Step 2 4-((2S,5S)-5-isopropyl-38-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexyn)amide) )-1H-1,2,3-triazol-1-yl)-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18,21,24,27 ,30,33,36-nonaoxa-3,6,12-triazatetradecyl)benzyl-((S)-1-(((S)-1-(((3R,4S) ,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-) Oxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan
- Step 1 4-((2S,5S)-38-azido-5-isopropyl-4,7,11-trioxo-2-(3-ureidopropyl)-9,15,18 Synthesis of 21,24,27,30,33,36-decyloxy-3,6,12-triazatridecylamide)benzyl-(4-nitrophenyl)-carbonate
- Step 2 (S)-2-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-) (((4-((S)-2-((S)-2-(32-azido-5-oxo-3,9,12,15,18,21,24,27,30- ⁇ oxy-6-azatriaconamido)-3-methylbutyrylamino)-5-ureidopentanoylamino)benzyl)oxy)carbonyl)(methyl)amino)-3-methyl Butyrylamino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropane Synthesis of acyl)-L-phenylalanine
- Step 3 (S)-2-((2R,3R)-3-((2S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2) -((S)-3-methyl 2-(methyl(((4-((S))-2-((S)-3-methyl-2-(32-(4-((6-) 2-(Methylsulfonyl)pyrimidin-5-yl)hex-5-carbamoyl)methyl)-1H-1,2,3-triazol-1-yl)-5-oxo-3,9 ,12,15,18,21,24,27,30-decyloxy-6-azatridecylamido)butyrylamino)-5-ureidopentanoylamino)benzyl)oxy)carbonyl) Amino) Butyrylamino) Butyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl
- Step 1 (S)-4-(35-azido-2-(4-(((4-methoxyphenyl))))phenyl)amino)butanoyl)-4,8-dioxy-6 ,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazatridecylamino)benzyl-(4-nitrophenyl)-carbonate synthesis
- Step 2 4-((S)-35-azido-2-(4-(((4-methoxyphenyl))diphenylmethyl)amino)butanoyl)-4,8-dioxo- 6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazatripentadecylamino)benzyl ((S)-1-((((S)) -1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropane-2) -yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptane-4- (M)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-
- Step 3 4-((S)-2-(4-(((4-methoxyphenyl))diphenylmethyl)amino)butanoyl)-35-(4-((6-(2-) Methanesulfonyl)pyrimidin-5-yl)-5-hexynamide)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15 ,18,21,24,27,30,33-nonaoxa-3,9-diazatridecylamino)benzyl ((S)-1-(((S)-1-(((())) (3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino) 1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5
- Step 4 4-((S)-2-(4-Aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)-5-hexynamide) Methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa- 3,9-diazatridecylamino)benzyl-((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2) -((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropane Pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino
- Step 1 Synthesis of methyl 4-(2-(methylthio)pyrimidin-5-yl)benzoate
- Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate 100 mg, 0.26 mmol was added to compound 55-3 (50 mg, 0.18 mmol) in dichloromethane at 25 °C.
- a (10 mL) solution the reaction was stirred for 30 min, and propargylamine (10 mg, 0.2 mmol) and N,N-diisopropylethylamine (70 mg, 0.5 mmol) were added to the reaction mixture, and the reaction was stirred for 2.5 h. Purification by column chromatography on silica gel ESI-MS (m/z): 316.0 [M+H] + .
- Step 5 (S)-4-Ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro -1H-pyrano[3',4':6,7]indolizine[1,2-b]quinolin-4-yl(4-((S)-2-(4-((( 4-methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((4-(2-(methylsulfonyl)pyrimidin-5-yl)benzamide)) -1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-decyloxy-3 Synthesis of 9-diazatridecanoylamino)benzyl)carbonate
- Step 6 4-((S)-2-(4-Aminobutyl)-35-(4-((4-(2-(methylsulfonyl)pyrimidin-5-yl)benzamide)) -1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-decyloxy-3 , 9-diazatridecanoylamino)benzyl ((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14- Dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)carbonic acid Ester synthesis
- Step 1 32-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hex-5-ynylamide)methyl)-1H-1,2,3-triazole-1 Synthesis of 5-yloxy-3,9,12,15,18,21,24,27,30-decyloxy-6-azatridodecanoic acid
- Step 2 (9H- ⁇ -9-yl)methyl ((S)-1-(((S)-1-((4-((S))-3-azido-2-((2R, 3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyryl) Amino)-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido) Propyl)phenyl)amino)-1-oxo-5-ureidopentanoylamino-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate synthesis
- Step 3 (S)-2-((S)-2-Amino-3-methylbutyrylamino)-N-(4-((S)-3-azido-2-((2R,3R) )-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino) )-N,3-dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido) Synthesis of phenyl)phenyl)-5-ureidovaleramide
- Step 4 N-((1-((6S,9S)-1-amino-6-((4-((S))-3-azido-2-((2R,3R)-3-(( S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutyrylamino)-N,3- Dimethylbutyrylamino)-3-methoxy-5-methylheptyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionamido)propyl)phenyl)amino Formyl)-9-isopropyl-1,8,11,15-tetraoxo-13,19,22,25,28,31,34,37,40-decyloxy-2,7,10, 16-tetraazatetradodecane-42-yl)-1H-1,2,3-triazol-4-yl)methyl)-6-(2-(
- Sacituzumab antibody (anti-Trop-2, 33.5 mg/mL) was diluted with 0.25 mL of a solution containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate (pH 7.6), followed by 0.45 mL containing 20 mM PB and 150 mM NaCl.
- the solution (pH 7.6) was mixed, adjusted to pH 7.4 with a 1 M K 2 HPO 4 solution, and mixed with 10 mM TCEP (tris(2-carboxyethyl)phosphine) solution, and allowed to stand at room temperature for 30 min.
- TCEP tris(2-carboxyethyl)phosphine
- TL003 dissolved in dimethyl sulfoxide was added in an amount of 15 times the substance, and the mixture was allowed to stand at room temperature for 2 hours. After completion, 6.1 ⁇ l of 100 mM cysteine was added to terminate the reaction. Finally, the buffer was replaced with a 20 mM PB buffer solution of pH 6.44 using a G-25 gel column to obtain a product of TL003 coupled with Sacituzumab antibody, which was named BT001002.
- Sacituzumab antibody (anti-Trop-2, 17.6 mg/mL) was diluted with 0.095 mL of a dilution (solution containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate, pH 7.6); then 1 M Na 2 HPO 4 The solution was adjusted to pH 7.4, mixed with 10 mM TCEP solution, and allowed to stand at room temperature for 30 min.
- TL 019 dissolved in dimethyl sulfoxide was added in an amount of 9 times the substance, and the mixture was allowed to stand at room temperature for 2 h.
- the buffer was replaced with a PBS buffer solution of pH 6.5 using a G-25 gel column to obtain a product of TL019 coupled with Sacituzumab antibody, which was named BT001004.
- TL003 was replaced with the trifluoroacetate salt of TL024 to obtain the product of TL024 coupled with the Sacituzumab antibody, designated BT001012.
- TL003 was replaced with the trifluoroacetate salt of TL048 to obtain the product of TL048 coupled with the Sacituzumab antibody, designated BT001013.
- TL003 was replaced with TL030 to obtain the product of TL030 coupled with the Sacituzumab antibody, designated BT001018.
- Sacituzumab antibody (anti-Trop-2, 33.5 mg/mL) was diluted with 0.25 mL of a solution containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate (pH 7.6), followed by 0.45 mL containing 20 mM PB and 150 mM NaCl.
- the solution (pH 7.6) was mixed, adjusted to pH 7.4 with a 1 M Na 2 HPO 4 solution, and mixed with 10 mM TCEP (tris(2-carboxyethyl)phosphine) solution, and allowed to stand at room temperature for 30 min.
- TCEP tris(2-carboxyethyl)phosphine
- TL033 trifluoroacetate dissolved in dimethyl sulfoxide was added in an amount of 10 times the substance, and the mixture was allowed to stand at room temperature for 2 hours. After completion, 6.1 ⁇ l of 100 mM cysteine was added to terminate the reaction. Finally, the buffer was replaced with a PBS buffer solution of pH 6.5 using a G-25 gel column to obtain a product of TL033 coupled with Sacituzumab antibody, which was named BT001021.
- TL003 was replaced with the trifluoroacetate salt of TL034 to obtain the product of TL034 coupled with the Sacituzumab antibody, designated BT001022.
- TL003 was replaced with the trifluoroacetate salt of TL035 to obtain the product of TL035 coupled with the Sacituzumab antibody, designated BT001023.
- TL003 was replaced with the trifluoroacetate salt of TL045 to obtain the product of TL045 coupled with the Sacituzumab antibody, designated BT001032.
- TL003 was replaced with the trifluoroacetate salt of TL033, and the Sacituzumab antibody was replaced with the M1 antibody to obtain a product of TL033 coupled with the M1 antibody, designated BT001033.
- TL003 was replaced with the trifluoroacetate salt of TL033, and the Sacituzumab antibody was replaced with the M2 antibody to obtain the product of TL033 coupled with the M2 antibody, designated BT001034.
- M3 antibody anti-Trop-2, 33.5 mg/mL
- a solution containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate (pH 7.6) was diluted with 0.25 mL of a solution containing 20 mM PB, 150 mM NaCl and 20 mM sodium edetate (pH 7.6), followed by 0.45 mL containing 20 mM PB and 150 mM.
- the solution of NaCl pH 7.6 was mixed, adjusted to pH 7.4 with a 1 M Na 2 HPO 4 solution, and mixed with 10 mM TCEP (tris(2-carboxyethyl)phosphine) solution, and allowed to stand at room temperature for 30 min.
- TCEP tris(2-carboxyethyl)phosphine
- a trifluoroacetic acid salt of TL033 dissolved in dimethyl sulfoxide was added in an amount of 10 times the substance, and the mixture was allowed to stand at room temperature for 2 hours. After completion, the reaction was terminated by adding 6.1 ⁇ l of 100 mM cysteine. Finally, the buffer was replaced with a PBS buffer solution of pH 6.5 using a G-25 gel column to obtain a product of TL033 coupled with the M3 antibody, which was named BT001035.
- TL003 was replaced with trifluoroacetate salt of TL033
- Sacituzumab antibody was replaced with trastuzole antibody to obtain a product of TL033 coupled to trastuzole antibody, designated BT001036.
- TL003 was replaced with the trifluoroacetic acid salt of TL049 to give the product of TL049 and Sacituzumab antibody, BT001040.
- TL003 was replaced with the trifluoroacetate salt of TL050 to obtain the product of TL050 coupled with the Sacituzumab antibody, designated BT001041.
- TL003 was replaced with TL051 to obtain the product of TL051 coupled with the Sacituzumab antibody, designated BT001042.
- TL003 was replaced with TL052 to obtain the product of TL052 coupled with the Sacituzumab antibody, designated BT001043.
- TL003 was replaced with TL053 to obtain the product of TL053 coupled with the Sacituzumab antibody, designated BT001044.
- TL003 was replaced with the trifluoroacetate salt of TL054 to obtain the product of TL054 coupled with the Sacituzumab antibody, designated BT001045.
- TL003 was replaced with the trifluoroacetate salt of TL055 to obtain the product of TL055 coupled with the Sacituzumab antibody, designated BT001046.
- TL003 was replaced with TL056 to obtain the product of TL056 coupled with the Sacituzumab antibody, designated BT001047.
- Mobile phase A 0.1% FA/98% H 2 O/2% ACN
- mobile phase B 0.1% FA/2% H 2 O/98% ACN
- mAb represents a monoclonal antibody
- LC represents an antibody light chain
- HC represents an antibody heavy chain
- DAR1 represents a conjugate comprising an antibody light chain/heavy chain and a cellular biologically active molecule
- DAR2 represents an antibody light chain/ a conjugate of a heavy chain and two cellular bioactive molecules
- DAR3 represents a conjugate comprising one antibody light/heavy chain and three cellular bioactive molecules
- DAR4 is expressed as comprising one antibody light/heavy chain and four cells
- a glycoform represents a sugar chain structure on two heavy chains: G0F indicates fucosylation without galactose.
- mAb, LC, HC, DAR1, DAR2, DAR3, DAR4, and G0F are as described above.
- Mobile phase A 0.1% FA/98% H 2 O/2% ACN
- mobile phase B 0.1% FA/2% H 2 O/98% ACN
- LC stands for antibody light chain and HC stands for antibody heavy chain.
- the antibody light chain of BT001004 is coupled with 0 ⁇ 1 cell bioactive molecules (LC, DAR1 ratio is 14%, 86%, respectively), and heavy chain is coupled with 1-3 cell bioactive molecules (DAR1).
- the ratio of DAR2 to DAR3 was 13%, 19%, and 68%, respectively, and the coupling ratio (DAR) of the entire antibody to the cell bioactive molecule was calculated to be 7.0.
- the antibody light chain is coupled with 0 to 1 toxin (LC, DAR1 ratio is 12.9%, 87.1%, respectively), and the heavy chain is coupled with 1 to 3 toxins (DAR1, DAR2, DAR3 ratios, respectively).
- the ratio of the antibody to toxin (DAR) was 7.0, which was 13.4%, 10.8%, and 75.8%.
- the antibody light chain is coupled with 0 to 1 toxin (LC, DAR1 ratio is 6.8%, 93.2%, respectively), and the heavy chain is coupled with 1-4 toxins (DAR1, DAR2, DAR3, DAR4).
- the ratios were 12.8%, 12.8%, 64.9%, 9.5%, respectively, and the coupling ratio (DAR) of the antibody to the toxin was calculated to be 7.3.
- the light chain of BT001018 is coupled with 0 to 1 toxin (LC, DAR1 ratio is 55.3%, 44.7%, respectively), and heavy chain is coupled with 1 to 3 toxins (DAR1, DAR2, DAR3 ratios, respectively).
- the ratio of the antibody to toxin (DAR) was 5.2, which was 19.6%, 23.3%, and 49.6%.
- Mobile phase A 0.1% FA/98% H 2 O/2% ACN
- mobile phase B 0.1% FA/2% H 2 O/98% ACN
- the antibody light chain is coupled with 0 to 1 toxin (LC, DAR1 ratio is 4.5%, 95.5%, respectively), and heavy chain is coupled with 1 to 3 toxins (DAR1, DAR2, DAR3 ratios, respectively).
- the ratio of the antibody to toxin (DAR) was 6.9, which was 15.3%, 17.6%, and 67.1%).
- the antibody light chain is coupled with 0 to 1 toxin (LC, DAR1 ratio is 15%, 85%, respectively), and the heavy chain is coupled with 0 to 3 toxins (HC, DAR1, DAR2, DAR3).
- the ratios were 6.7%, 16.7%, 12.7%, and 63.9%, respectively, and the coupling ratio (DAR) of the antibody to the toxin was calculated to be 6.4.
- Liquid chromatography column Thermo MabPacTM RP 4 ⁇ m, 3.0mm*100mm
- Mobile phase A 0.1% FA/98% H 2 O/2% ACN
- mobile phase B 0.1% FA/2% H 2 O/98% ACN
- Mobile phase A (% by volume) 80 60 10 10 80 80 Mobile phase B (% by volume) 20 40 90 90 20 20
- the antibody light chain is coupled with 0 to 1 cell bioactive molecule (LC, DAR1 ratio is 4.9%, 95.1%, respectively), and heavy chain is coupled with 1-4 cell bioactive molecules (DAR1).
- the ratios of DAR2, DAR3, and DAR4 were 16.5%, 14.3%, 52.6%, and 16.6%, respectively, and the coupling ratio (DAR) of the antibody to the cell bioactive molecule was calculated to be 7.3.
- Example 55 A method similar to that of Example 55 was employed, and the results are shown in Figs. 22 and 23.
- the antibody light chain is coupled with 0 to 1 cell bioactive molecule (LC, DAR1 ratio is 10.5%, 89.5%, respectively), and heavy chain is coupled with 1-4 cell bioactive molecules (DAR1).
- the ratio of DAR2, DAR3, and DAR4 was 21.3%, 14.8%, 57.9%, and 6.0%, respectively, and the coupling ratio (DAR) of the antibody to the cell bioactive molecule was calculated to be 6.8.
- the antibody light chain is coupled with 0 to 1 cell bioactive molecule (LC, DAR1 ratio is 14.9%, 85.1%, respectively), and heavy chain is coupled with 1-3 cell bioactive molecules (DAR1).
- the ratio of DAR2 to DAR3 was 19.7%, 9.4%, and 70.9%, respectively, and the coupling ratio (DAR) of the antibody to the cell bioactive molecule was calculated to be 6.7.
- the antibody light chain is coupled with 0 to 1 cell bioactive molecule (LC, DAR1 ratio is 9.1%, 90.9%, respectively), and the heavy chain is coupled with 1-3 cell bioactive molecules (DAR1).
- the ratio of DAR2 to DAR3 was 20.1%, 11.4%, and 68.4%, respectively, and the coupling ratio (DAR) of the antibody to the cell bioactive molecule was calculated to be 6.8.
- the antibody light chain is coupled with 0 to 1 cell bioactive molecule (LC, DAR1 ratio is 23.0%, 77.0%, respectively), and heavy chain is coupled with 1-3 cell bioactive molecules (DAR1).
- the ratio of DAR2 to DAR3 was 19.4%, 11.4%, and 69.3%, respectively, and the coupling ratio (DAR) of the antibody to the cell bioactive molecule was calculated to be 6.5.
- the antibody light chain is coupled with 0 to 1 cell bioactive molecule (LC, DAR1 ratio is 33.8%, 66.2%, respectively), and heavy chain is coupled with 0 to 3 cell bioactive molecules (DAR0).
- the ratio of DAR1, DAR2, and DAR3 was 21.9%, 6.1%, 9.6%, and 62.3%, respectively, and the coupling ratio (DAR) of the antibody to the cell bioactive molecule was calculated to be 5.6.
- the antibody light chain of BT001047 is coupled with 0 to 1 cell bioactive molecule (LC, DAR1 ratio is 13.7%, 86.3%, respectively), and heavy chain is coupled with 1-3 cell bioactive molecules (DAR1).
- the ratio of DAR2 to DAR3 was 22.2%, 13.5%, and 64.3%, respectively, and the coupling ratio (DAR) of the antibody to the cell bioactive molecule was calculated to be 6.6.
- the coupling reaction was monitored by SEC-HPLC and the conjugate was subjected to SEC detection.
- Liquid chromatography column TOSOH TSKgel SuperSW mAb, 4 ⁇ m, 7.8 mm x 300 mm;
- Mobile phase 100 mmol/L Na 2 HPO 4 , 100 mmol/L NaCl, 5% isopropanol, pH 7.0;
- Injection volume 30 ⁇ g; isocratic operation: 30 min.
- the SEC chromatogram and the molecular weight Marker SEC chromatogram of the BT001002 obtained by coupling the antibody with TL003 and the antibody are shown in Figures 7 and 8, respectively.
- the molecular weight Marker molecular weight marker it is confirmed that the main peak of the coupled product has a molecular weight of about 150 kD, that is, the antibody and TL003.
- BT001002 obtained by coupling with the antibody, the light and heavy chains were not separated, and the antibody remained in the overall structure.
- the SEC chromatogram of BT001004 obtained by coupling TL019 with antibody is shown in Fig. 9. According to the SEC retention time and peak area ratio, it is confirmed that the molecular weight of the main coupling product is about 150 kD, that is, BT001004 obtained by coupling TL019 with the antibody, and the antibody remains. The complete structure.
- the SEC chromatogram of BT001012 obtained by coupling TL024 with antibody is shown in Figure 34. According to the SEC retention time and peak area ratio, it was confirmed that the molecular weight of the main coupling product was about 150 kD, that is, BT001012 obtained by coupling TL024 with the antibody, and the antibody remained. The complete structure.
- the SEC chromatogram of BT001013 obtained by coupling TL048 with antibody is shown in Fig. 35. According to the SEC retention time and peak area ratio, it is confirmed that the molecular weight of the main coupling product is about 150 kD, that is, BT001013 obtained by coupling TL048 with the antibody, and the antibody remains. The complete structure.
- the SEC chromatogram of BT001018 obtained by coupling TL030 to the antibody is shown in Figure 36. According to the SEC retention time and peak area ratio, it was confirmed that the molecular weight of the main coupling product was about 150 kD, that is, BT001018 obtained by coupling TL030 with the antibody, and the antibody remained. The complete structure.
- the SEC chromatogram of BT001021 obtained by coupling TL033 with antibody is shown in Figure 37. According to the SEC retention time and peak area ratio, it was confirmed that the molecular weight of the main coupling product was about 150 kD, that is, BT001021 obtained by coupling TL033 with the antibody, and the antibody remained. The complete structure.
- the SEC chromatogram of BT001023 obtained by coupling TL035 with antibody is shown in Figure 38. According to the SEC retention time and peak area ratio, it was confirmed that the molecular weight of the main coupling product was about 150 kD, that is, BT001023 obtained by coupling TL035 with the antibody, still retaining the antibody. The complete structure.
- the SEC chromatogram of BT001042 obtained by coupling TL051 with antibody is shown in Figure 39. According to the SEC retention time and peak area ratio, it was confirmed that the molecular weight of the main coupling product was about 150 kD, that is, BT001042 obtained by coupling TL051 with the antibody, and the antibody remained. The complete structure.
- the SEC chromatogram of BT001043 obtained by coupling TL052 with antibody is shown in Figure 40. According to the SEC retention time and peak area ratio, it was confirmed that the molecular weight of the main coupling product was about 150 kD, that is, BT001043 obtained by coupling TL052 with the antibody, and the antibody remained. The complete structure.
- the SEC chromatogram of BT001044 obtained by coupling TL053 with antibody is shown in Fig. 41. According to the ratio of SEC retention time and peak area, it was confirmed that the molecular weight of the main coupling product was about 150 kD, that is, BT001044 obtained by coupling TL053 with the antibody, and the antibody remained. The complete structure.
- the SEC chromatogram of BT001046 obtained by coupling TL055 with the antibody is shown in Fig. 42. According to the SEC retention time and peak area ratio, it was confirmed that the molecular weight of the main coupling product was about 150 kD, that is, BT001046 obtained by coupling TL055 with the antibody, and the antibody remained. The complete structure.
- the SEC chromatogram of BT001047 obtained by coupling TL056 with antibody is shown in Fig. 43. According to the SEC retention time and peak area ratio, it was confirmed that the molecular weight of the main coupling product was about 150 kD, that is, BT001047 obtained by coupling TL056 with the antibody, and the antibody remained. The complete structure.
- the tumor cells MDA-MB-468 (Trop-2 positive cell line) and HCC1806 (Trop-2 positive cell line) were cultured; the bioactive molecules and ADC molecules of the present disclosure were co-cultured with tumor cells, and then CCK8 reagent was added ( Dongren Chemical Technology Co., Ltd., Cat: CK04, Lot: JJ744), using a microplate reader (manufacturer: Molecular Devices, model: SpectraMax M2) to read (detection wavelength is 450nm), to detect the activity of dehydrogenase in mitochondria, The inhibitory effect of ADC on cell proliferation was evaluated.
- the source of tumor cells is shown in Table 1.
- Bioactive molecules or ADCs (12 concentration gradients) were diluted with the corresponding assay medium (containing 2% FBS). Tumor cells were digested by conventional methods using trypsin, cells were harvested and counted, and resuspended in the corresponding assay medium (containing 2% FBS). The diluted bioactive molecule or ADC is added to a 96-well plate and the cells are added. Then, 20 ⁇ L of CCK8 reagent was added to each well, and the reaction was carried out for 4 hours, and the microplate reader was read (detection wavelength was 450 nm). The experimental conditions and test results are shown in Tables 2 and 3.
- the test results show that the bioactive molecules have tumor cell killing effect.
- test results show that the ADC molecules obtained by the new coupling method have tumor cell killing effect. It is indicated that the ADC formed by the new coupling method can kill tumor cells, and the new coupling method is effective in ADC molecules.
- the liquid concentration is 5.44mg / ml, stored at -20 ° C, when used, diluted with saline according to the dose to obtain a test solution;
- the liquid concentration is 13.158mg/ml, stored at -20 °C, diluted with saline according to the dose when used. , obtaining a test solution;
- T-030 solid powder, prepared with a concentration of 5.2 mg / ml in 100% DMSO (Sigma), stored at -20 ° C, diluted with a physiological saline solution to obtain a test solution;
- SN-38 also can be expressed as SN38
- a solid powder prepared with a concentration of 3.23 mg/ml in 100% DMSO (Sigma), stored at -20 ° C, and diluted with a physiological saline solution to obtain a test solution.
- the dose of toxin is administered according to the equimolar ratio of the ADC sample.
- T-030, SN-38, and Immu-132 are as follows:
- mice Balb/c-nu mice (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., production license number: SCXK (Beijing) 2016-0011); gastric cancer cell line NCI-N87 (ATCC), breast cancer cell line HCC1806 (Nanjing Science).
- a tumor-bearing mouse with a tumor volume of 100 to 200 mm 3 and 6 cells/group were randomly selected (determined according to the number of samples).
- the administration volume was 10 mL/kg
- the administration route was tail vein injection
- the administration was performed twice a week.
- the tumor growth inhibition rate TGI (%) was calculated using the following formula to evaluate the antitumor efficacy of antibody drug conjugates:
- TGI (%) [1 - (V T end - V T start ) / (V C end - V C start )] * 100%
- V T is the mean tumor volume at the end of the treatment group
- V T at the beginning mean volume of tumor at the beginning of administration in the treatment group
- V C mean volume of tumor at the end of the experiment in the solvent control group
- V C start mean volume of tumor at the start of drug control group administration
- mice were used to evaluate the inhibition of tumor conjugated BT001021 on the proliferation of tumor-bearing mice by subcutaneous transplantation of human tumor cells.
- the human gastric cancer cell line NCI-N87 and the human triple negative breast cancer cell line HCC1806 were subcutaneously implanted to construct a tumor-bearing mouse model, and the tumor volume was grown to about 100 mm 3 and then randomly grouped.
- BT001021 was administered intravenously twice a week for 6 times. Tumor volume and animal body weight changes were measured twice a week, and the drug effect (antitumor effect) of antibody drug conjugates on tumor-bearing mice was evaluated.
- NCI-N87 cells were cultured in a 1640 medium containing 10% fetal bovine serum at 37 ° C, 5% CO 2 .
- NCI-N87 cells in the exponential growth phase were collected, resuspended in PBS to a suitable concentration, and inoculated into female Balb/c-nu mice to establish a gastric cancer model.
- the average tumor volume was about 90 mm 3 , they were randomly divided according to tumor size, namely saline group, BT001021 (3 mg/kg, intravenous injection, twice a week ⁇ 3 weeks), and positive drug Immu-132 (3 mg/kg).
- Intravenous injection, twice a week ⁇ 3 weeks) group, T030 group, SN38 group, the corresponding drugs were injected into the tail vein after grouping, and administered twice a week for 6 times.
- the tumor volume and body weight of the mice were observed and periodically measured after administration, and the specific results are shown in Table 4, Figures 44 and 45.
- human gastric cancer cell line NCI-N87 was used to construct a human gastric cancer subcutaneous xenograft model, and the efficacy of BT001021 in NCI-N87 human gastric cancer tumor-bearing mouse model was evaluated.
- BT001021 (3mg/kg, intravenous injection, twice a week ⁇ 3 weeks) can significantly inhibit the tumor growth of NCI-N87 gastric cancer xenograft model mice, and tumor regression and antitumor activity at the end of administration. Compared with positive Immu-132, no deaths were observed in all treatment groups during the observation period, and significant animal weight loss was observed, indicating that BT001021 had no obvious toxicity.
- HCC1806 cells were cultured in 1640 medium containing 10% fetal bovine serum at 37 ° C, 5% CO 2 .
- HCC1806 in the exponential growth phase was collected, resuspended in PBS to a suitable concentration, and inoculated into female Balb/c-nu mice to establish a breast cancer model.
- the average tumor volume was about 130 mm 3 , they were randomly grouped according to tumor size, which were saline group, BT001021 (10 mg/kg, intravenous injection, twice a week ⁇ 3 weeks), and positive drug Immu-132 (10 mg/kg).
- intravenous injection, twice a week ⁇ 3 weeks) group the corresponding drug was injected into the tail vein after grouping, twice a week for 5 times.
- the tumor volume of the mice was observed and periodically measured after administration, and the specific results are shown in Table 5, Figure 46.
- the human breast cancer cell line HCC1806 used in this experiment was used to construct a human breast cancer subcutaneous xenograft model, and the efficacy of BT001021 in the HCC1806 human breast cancer-bearing mouse model was evaluated.
- BT001021 (10 mg/kg, intravenous injection, twice a week ⁇ 3 weeks) significantly inhibited tumor growth in HCC1806 breast cancer xenograft model mice, and the antitumor activity was superior to that of positive Immu-132.
- the antibody drug of the present invention can significantly inhibit tumor growth in the mouse NCI-N87 model, which is significantly better than Immu-132 at the same dose, and no Significant weight loss and no significant drug toxicity.
- Immu-132 did not show significant inhibitory activity due to the high degree of tumor malignancy, and the dose was increased to 10 mg/kg, while BT001021 significantly inhibited tumor growth.
- the above results indicate that the BT001021 of the present invention has good pharmacological efficacy and excellent safety.
- BT001021 In the subcutaneous xenograft models of Experimental Examples 1 and 2, the antitumor activity of BT001021 was significantly better than that of Immu-132 at the same dose. It is speculated that BT001021 has the potential to treat solid tumors, and it is expected to make more BT001021 than Immu-132 in clinical practice. Patients benefit.
- Example 3 The effects of BT001021 and BT001035 on the proliferation inhibition of a tumor-bearing mouse model by subcutaneous transplantation of human tumor cells of HCC827 non-small cell lung cancer were evaluated. Specifically, in this experiment, a human tumor-bearing mouse model was constructed by subcutaneous transplantation of human non-small cell lung cancer cell line HCC827. After the tumor volume was grown to about 100 mm 3 , the cells were randomly divided into groups, and BT001021 and BT001035 were administered intravenously after grouping. Times, a total of 6 times, twice a week to measure tumor volume and animal body weight changes, calculate the efficacy of BT001021 and BT001035 on tumor-bearing mice (tumor inhibition effect).
- HCC827 cells were cultured in a 1640 medium containing 10% fetal bovine serum at 37 ° C, 5% CO 2 . HCC827 cells in the exponential growth phase were collected, resuspended in PBS to a suitable concentration, and subcutaneously inoculated into female Balb/c-nu mice to establish a lung cancer xenograft model. When the average tumor volume was about 80 mm3, the tumors were randomly divided into normal saline group, positive drug Immu-132 (10 mg/kg, IV, BIW ⁇ 3W) group, BT001021 (10 mg/kg, IV, BIW ⁇ 3W).
- BT001035 (10mg/kg, IV, BIW ⁇ 3W) group
- the corresponding drugs were injected into the tail vein after grouping, and administered twice a week for 6 times.
- the tumor volume and body weight of the mice were observed and periodically measured after administration, and the specific results are shown in Table 6, Figure 47A, and Figure 47B.
- BT001021 and BT001035 can significantly inhibit the tumor growth of HCC827 non-small cell lung cancer xenograft model mice, and tumor regression occurs at the end of administration.
- the antitumor activity is better than the positive group Immu-132, and all treatment groups are observed during the observation period. Animal-free death and significant animal weight loss did not show significant drug toxicity, and the mice were well tolerated for each evaluation drug during treatment.
- BT001021 and BT001035 In this subcutaneous xenograft model, the antitumor activities of BT001021 and BT001035 were significantly better than Immu-132 at the same dose. It is speculated that BT001021 and BT001035 have the potential to treat solid tumors, and it is expected that BT001021 and BT001035 will be clinically compared with Immu-132. More patients benefit.
- BT001036 inhibited tumor growth of tumor-bearing mice by subcutaneous transplantation of human tumor cells.
- a human tumor-bearing mouse model of subcutaneously transplanted human gastric cancer cell line NCI-N87 was constructed, and the tumor volume was grown to about 140 mm 3 , and then randomly grouped, and BT001036 was administered intravenously after grouping, twice a week. A total of 6 times. Tumor volume and animal body weight changes were measured twice a week, and the drug effect (antitumor effect) of antibody drug conjugates on tumor-bearing mice was evaluated.
- NCI-N87 cells were cultured in a 1640 medium containing 10% fetal bovine serum at 37 ° C, 5% CO 2 .
- NCI-N87 cells in the exponential growth phase were collected, resuspended in PBS to a suitable concentration, and subcutaneously inoculated into female Balb/c-nu mice to establish a gastric cancer xenograft model.
- the average tumor volume was about 140 mm 3
- the tumors were randomly divided into normal saline group, BT001036 (1.5 mg/kg, IV, BIW ⁇ 3W) group, BT001036 (3 mg/kg, IV, BIW ⁇ 3W) group.
- a subcutaneously transplanted human gastric cancer cell line NCI-N87 was used to construct a human gastric cancer subcutaneous xenograft model, and the efficacy of BT001036 in the NCI-N87 human gastric cancer tumor-bearing mouse model was evaluated.
- mice The effect of BT001021 on the proliferation inhibition of a tumor-bearing mouse model by subcutaneous transplantation of human tumor cells of MDA-MB-231 breast cancer was evaluated. Specifically, in this experiment, a human tumor-bearing mouse model was constructed by subcutaneous transplantation of human breast cancer cell line MDA-MB-231. After the tumor volume was grown to about 130 mm 3 , the cells were randomly divided into groups, and BT001021 was administered intravenously after grouping. Times, a total of 6 times, while measuring tumor volume and animal body weight changes, calculate the efficacy of BT001021 on tumor-bearing mice (tumor inhibition effect).
- NCI-MDA-MB-231 cells were cultured in RPMI 1640 medium containing 10% fetal calf serum at 37 ° C, 5% CO 2 .
- MDA-MB-231 cells in the exponential growth phase were collected, resuspended in PBS to a suitable concentration, and subcutaneously inoculated into female Balb/c-nu mice to establish a lung cancer xenograft model.
- the average tumor volume was about 130 mm 3
- the tumors were randomly divided into normal saline group and BT001021 (3 mg/kg) group.
- the corresponding drugs were injected into the tail vein after grouping, and the drug was administered twice a week for 6 times.
- the tumor volume and body weight of the mice were observed and periodically measured after administration, and the specific results are shown in Table 8, Figures 49A and 49B.
- BT001021 can significantly inhibit the tumor growth of MDA-MB-231 breast cancer xenograft model mice, and tumor regression occurred at the end of the drug administration. All the treatment groups showed no animal death and significant animal weight loss during the observation period, no performance. Significant drug toxicity was observed, and the mice were well tolerated for each of the evaluated drugs during the treatment.
- BT001021 had significant anti-tumor activity. All the treatment groups showed no animal death and significant animal weight loss during the observation period, and showed no obvious drug toxicity. The mice were well tolerated for each evaluation drug during the treatment period. .
- the liquid concentration is 20mg/ml, stored at -20 ° C, and diluted with a physiological saline solution to obtain a test solution;
- T-030 was formulated into 1 mg/ml with dimethyl sulfoxide and diluted with physiological saline according to the dose to obtain a test solution.
- mice Balb/c-nu mice (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., production license number: SCXK (Beijing) 2016-0011); gastric cancer cell line NCI-N87 (ATCC).
- a tumor-bearing mouse with a tumor volume of 100 to 200 mm 3 in a random group (determining the number of samples according to the number of samples) was selected, 4 cells/group, and the administration route was a single administration of tail vein injection.
- NCI-N87 cells were cultured in a 1640 medium containing 10% heat-inactivated fetal bovine serum at 37 ° C, 5% CO 2 .
- NCI-N87 cells in the exponential growth phase were collected, resuspended in PBS to the appropriate concentration, and subcutaneously inoculated into Balb/c-nu mice to establish a lung cancer xenograft model.
- the average tumor volume was about 100-200 mm 3
- the tumors were randomly divided into normal saline group, T-030 (0.23 mg/kg, intravenous injection, single administration) group, BT001021 (10 mg/kg, intravenous injection).
- T-030 0.23 mg/kg, intravenous injection, single administration
- BT001021 10 mg/kg, intravenous injection
- Serum and tumor tissues were collected from T-030 group at 1h, 2h, 4h, 8h, 24h and 72h after administration (T-030 was not detected in serum and tumor tissues 72h after administration, so it was not administered after administration Serum and tumor tissues were collected at 168h, and serum and tumor tissues were collected at 1h, 2h, 4h, 8h, 24h, 72h and 168h after administration.
- the serum and tumor concentrations of T-030 were detected by LC-MS/MS. The specific results are shown in Table 9.
- the dose of T-030 (0.23 mg/kg) was converted in an equimolar amount according to the dose of BT001021 (10 mg/kg).
- BT001021 (10mg / kg) administration group AUC last in tumors and serum were 850.1h * ng / ml and 174.97h * ng / ml
- T- 030 administration group AUC last in tumors and serum were 3.85 h*ng/ml and 5.58h*ng/ml
- the comparison of the three showed that the exposure of T-030 in the BT001021 administration group was significantly higher than that in the T-030 administration group.
- the exposure of active biomolecule T-030 in tumors of BT001021 group was significantly higher than that in serum.
- the exposure of biomolecules in T-030 group was basically the same in serum and tumor, indicating antibody drug conjugate ( BT001021) has strong tumor tissue targeting.
- the C max of the active biomolecule T-030 in tumor and serum in the BT001021 (10 mg/kg) administration group was 7.82 ng/ml and 11.7 ng/ml, respectively, and the active biomolecule T in the tumor and serum of the T-030 administration group.
- the Cmax of -030 was 1.20 ng/ml and 1.81 ng/ml, respectively, indicating that the antibody drug conjugate (BT001021) has a higher concentration of active biomolecule (T-030) in tumor tissues and serum.
- BT001021 (10mg / kg) administration group active biological molecule in the tumor T-030 to T 1/2 to 93.14h, T-030 tumors in the group administered active biological molecule in T-030 to T 1/2 2.55h .
- BT001021 has significant tumor tissue targeting and good pharmacokinetic properties compared to the corresponding active biomolecule (T-030).
- human gastric cancer cell line NCI-N87 to Balb/c-nu mice were subcutaneously transplanted to construct a tumor-bearing mouse model, and the tumor volume was grown to 100-200 mm 3 , and then randomly grouped, and a single intravenous administration of BT001021 after grouping and Immu-132.
- concentrations of active biomolecules T-030 and SN-38 corresponding to BT001021 and Immu-132 in tumor tissues and serum were determined, and the pharmacokinetic behavior of antibody-conjugated drugs BT001021 and Immu-132 in tumor-bearing mice was evaluated.
- the liquid concentration is 20mg/ml, stored at -20 ° C, and diluted with a physiological saline solution to obtain a test solution;
- Immu-132 was diluted with physiological saline according to the dose to obtain a test solution.
- mice Balb/c-nu mice (Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., production license number: SCXK (Beijing) 2016-0011); gastric cancer cell line NCI-N87 (ATCC).
- a tumor-bearing mouse with a tumor volume of 100 to 200 mm 3 in a random group (determining the number of samples according to the number of samples) was selected, 4 cells/group, and the administration route was a single administration of tail vein injection.
- NCI-N87 cells were cultured in a 1640 medium containing 10% heat-inactivated fetal bovine serum at 37 ° C, 5% CO 2 .
- NCI-N87 cells in the exponential growth phase were collected, resuspended in PBS to the appropriate concentration, and subcutaneously inoculated into Balb/c-nu mice to establish a lung cancer xenograft model.
- the average tumor volume was about 100-200 mm 3 , they were randomly divided into BT001021 (5 mg/kg, intravenous, single administration) group and Immu-132 (5 mg/kg, intravenous injection, single administration) according to tumor size.
- the corresponding drugs were injected into the tail vein, and serum and tumor tissues were collected at 2h, 24h, 48h and 72h after administration.
- the concentrations of T-030 or SN-38 in serum and tumor were detected by LC-MS/MS.
- Table 10 Pharmacokinetic parameters of T-030 and SN-38 in tumor and serum after intravenous administration of BT001021 and Immu-132 in tumor-bearing mice
- BT001021 administration group AUC last small molecule toxins in tumor and serum were 427.2h * ng / ml, and 115.3h * ng / ml
- Immu- 132 administration group AUC last small molecule toxins in tumor and serum were 116.8h*ng/ml and 422.7h*ng/ml.
- BT001021 group administered a small molecule toxin in the tumor C max of 6.8ng / ml
- Immu-132 administration group of small molecule toxin in the tumor C max respectively 2.8ng / ml. .
- the above results indicate that BT001021 has better tumor tissue targeting and better pharmacokinetic properties than Immu-132, and has a better therapeutic window.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
时间(分钟) | 1 | 7 | 8 | 9 | 13 |
流动相A(体积%) | 90 | 20 | 20 | 90 | 90 |
流动相B(体积%) | 10 | 80 | 80 | 10 | 10 |
时间(分钟) | 2 | 20 | 22 | 25 | 26 | 30 |
流动相A(体积%) | 80 | 60 | 10 | 10 | 80 | 80 |
流动相B(体积%) | 20 | 40 | 90 | 90 | 20 | 20 |
时间(分钟) | 1 | 7 | 8 | 9 | 13 |
流动相A(体积%) | 90 | 20 | 20 | 90 | 90 |
流动相B(体积%) | 10 | 80 | 80 | 10 | 10 |
时间(分钟) | 2 | 20 | 22 | 25 | 26 | 30 |
流动相A(体积%) | 80 | 60 | 10 | 10 | 80 | 80 |
流动相B(体积%) | 20 | 40 | 90 | 90 | 20 | 20 |
细胞名称 | 肿瘤类型 | 来源 |
MDA-MB-468 | 乳腺癌 | 康诺泰 |
HCC1806 | 乳腺癌 | 南京科佰生物 |
Claims (91)
- 式(I)所示化合物或其药学上可接受的盐,T-[L 1-(L 2) m1-(L 3) m2-(L 4) m3-E]-G式(I)其中,T为生物活性分子片段,优选具有抗肿瘤生物活性的分子片段;L 1选自氨基酸、2-10个氨基酸组成的肽、寡糖、-(CH 2) t1-、-(CH 2CH 2O) t1-(CH 2) t2-、其中,各R、R’、R 1和R 2各自独立地为H(氢)、D(氘)、卤素、羧酸、磺酸、氰基、C 1-6烷基、卤代C 1-6烷基、氰基取代的C 1-6烷基(例如-CH 2CN)、C 1-6烷氧基、C 2-10烯基、C 2-10炔基、C 3-6环烷基、6-10元芳基或5-12元杂芳基,各Z 1各自独立地为氨基酸或2-10个氨基酸组成的肽,各t 1和t 2各自独立地为0、1、2、3、4、5或6,各x 1和x 2各自独立地为0、1、2、3、4、5或6,各x 3独立地为0、1、2、3或4,并且L 1的1位置处与T相连;L 2选自氨基酸、2-10个氨基酸组成的肽、寡糖、-(CH 2) t1-、-(CH 2CH 2O) t1-(CH 2) t2-、 其中,R 3、R 4、R 5和R 6各自独立地选自H(氢)、D(氘)、卤素、羧酸、磺酸、CN、C 1-6烷基、卤代C 1-6烷基、氰基取代的C 1-6烷基、C 1-6烷氧基、C 2-10烯基、C 2-10炔基和C 3-6环烷基,或者,R 3、R 4或R 5、R 6或R 3、R 5连同其所连接的碳原子形成3-8元环,t 1和t 2各自独立地为0、1、2、3、4、5或6,y 1和y 2各自独立地为0、1、2、3、4、5、6、7、8、9或10,并且L 2的1位置处与L 1相连;L 3选自任选地被一个或多个R 7取代的下列基团:氨基、3-8元环烷基、3-8元脂杂环基、6-12元桥杂环基、6-12元螺杂环基、6-12元稠杂环基、6-10元芳基、5-12元杂芳基和3-8元环烷基-W-;其中,W为氧或NR 8,R 7独立地选自H(氢)、D(氘)、卤素、=O、CN、羧基、磺酸基、C 1-6烷基、卤代C 1-6烷基、氰基取代的C 1-6烷基、C 1-6烷氧基、C 2-10烯基和C 2-10炔基,R 8独立地选自H(氢)、D(氘)、C 1-6烷基、C 3-6环烷基、C 1-6烷氧基和氰基C 1-2烷基,并且L 3的1位置处与L 2相连;L 4选自 其中,Z 5优选自C 2-6烯烃、C 2-6炔烃、酰胺基、砜基、亚砜基、6-10元芳基、5-6元杂芳基;Z 2选自C 1-6亚烷基、C 2-10亚烯基、C 2-10亚炔基、C 3-8亚环烷基、6-10元芳基和5-14元杂芳基;R 9选自H(氢)、C 1-6烷基;Z 3不存在或者选自C 1-6亚烷基、卤代C 1-6亚烷基和烷氧基取代的C 1-6亚烷基;或者,R 9与Z 3连同其所连接的氮原子形成4-8元杂环基;α独立地为0、1、2、3、4、5或6;并且L 4的2位置处与E相连;E选自任选被一个或多个R 12取代的下列基团:嘧啶、喹唑啉和吡咯并[2,3-d]嘧啶;其中,R 12独立地选自H(氢)、D(氘)、卤素、CN、硝基、C 1-6烷基和卤代C 1-6烷基;G为亲核取代反应的离去基团;m 1、m 2和m 3各自独立地为0、1、2、3、4、5、6、7、8、9或10。
- 权利要求1的化合物或其药学上可接受的盐,其中,L 1选自Val、Cit、Phe、Lys、D-Val、Leu、Gly、Ala、Asn、2-5个氨基酸组成的肽、 其中,各R、R’、R 1和R 2各自独立地为H(氢)、D(氘)、C 1-6烷基、C 2-10烯基、C 2-10炔基或C 3-6环烷基,Z 1为Val、Cit、Phe、Lys、D-Val、Leu、Gly、Ala、Asn、Val-Cit、Cit-Val、Cit-Ala、Val-Ala、Lys-Val、Val-Lys(Ac)、Phe-Lys、Phe-Lys(Ac)、D-Val-Leu-Lys、Gly-Gly-Arg或Ala-Ala-Asn,x 1为0、1、2或3,x 3为0、1、2、3或4。
- 权利要求1-2任一项所述的化合物或其药学上可接受的盐,其中,L 1选自Val、Cit、Phe、Lys、D-Val、Leu、Gly、Ala、Asn、Cit-Val、Val-Ala、Lys-Val、Val-Lys(Ac)、Phe-Lys、Phe-Lys(Ac)、D-Val-Leu-Lys、Gly-Gly-Arg、Ala-Ala-Asn、 其中,R、R’和R 1各自独立地为H(氢)、D(氘)、C 1-6烷基、C 2-10烯基、C 2-10炔基或C 3-6环烷基,Z 1为Val、Cit、Phe、Lys、D-Val、Leu、Gly、Ala、Asn、Val-Cit、Cit-Val、Cit-Ala、Val-Ala、Lys-Val、Val-Lys(Ac)、Phe-Lys、Phe-Lys(Ac)、D-Val-Leu-Lys、Gly-Gly-Arg或Ala-Ala-Asn,x 1和x 3各自独立的为0、1、2或3。
- 权利要求1-7任一项所述的化合物或其药学上可接受的盐,其中,L 2选自Val、Cit、Phe、Lys、D-Val、Leu、Gly、Ala、Asn、Val-Cit、Cit-Val、Val-Ala、Lys-Val、Val-Lys(Ac)、Phe-Lys、Phe-Lys(Ac)、D-Val-Leu-Lys、Gly-Gly-Arg、Ala-Ala-Asn、 其中,R 3、R 4、R 5和R 6各自独立地选自H(氢)、D(氘)、卤素、羧酸、磺酸、CF 3、CN、CH 2CN、C 1-4烷基、C 1-4烷氧基、C 2-6烯基、C 2-6炔基和C 3-6环烷基,y 1和y 2各自独立地为0、1、2、3、4、5、6、7或8,并且L 2的1位置处与L 1相连;m 1为0、1或2。
- 权利要求1-11任一项所述的化合物或其药学上可接受的盐,其中,L 3选自任选地被一个或多个R 7取代的下列基团:氨基、3-8元环烷基、3-8元脂杂环基、6-12元桥杂环基、6-12元螺杂环基、6-12元稠杂环基6-10元芳基、5-12元杂芳基和3-8元环烷基-W-;其中,W为氧或NR 8,R 7独立地选自H(氢)、D(氘)、卤素、=O、CF 3、CN、CH 2CN、羧基、磺酸基、C 1-4烷基、C 1-4烷氧基、C 2-6烯基和C 2-6炔基;优选地,所述3-8元脂杂环基、6-12元桥杂环基、6-12元螺杂环基或6-12元稠杂环基含有一个或多个氮原子;优选地,所述3-8元脂杂环基、6-12元桥杂环基、6-12元螺杂环基或6-12元稠杂环基含有一个或多个季铵化的氮原子;优选地,所述3-8元脂杂环基、6-12元桥杂环基、6-12元螺杂环基或6-12元稠杂环基含有一个或多个氮原子,其中,至少一个氮原子被=O取代;R 8独立地选自H(氢)、D(氘)、C 1-6烷基、C 2-6烯基、C 3-6炔基、C 3-6环烷基、C 1-6烷氧基和氰基C 1-2烷基;m 2为0、1、2或3。
- 权利要求1-12任一项所述的化合物或其药学上可接受的盐,其中,L 3选自任选地被一个或多个R 7取代的下列基团:氨基、3-6元脂杂环基和5-10元杂芳基;其中,R 7独立地选自H(氢)、D(氘)、卤素、=O、CF 3、CN、CH 2CN、羧基、磺酸基、C 1-4烷基、C 1-4烷氧基、C 2-6烯基和C 2-6炔基;优选地,所述3-6元脂杂环基含有一个或多个氮原子;优选地,所述3-6元脂杂环基含有一个或多个季铵化的氮原子;优选地,所述3-6元脂杂环基含有一个或多个氮原子,其中,至少一个氮原子被=O取代;m 2为0、1或2。
- 权利要求1-13任一项所述的化合物或其药学上可接受的盐,其中,L 3选自任选地被一个或多个R 7取代的5-6元杂芳基;其中,R 7独立地选自H(氢)、D(氘)、卤素、=O、CF 3、CN、CH 2CN、羧基、磺酸基、C 1-4烷基、C 1-4烷氧基、C 2-6烯基和C 2-6炔基;m 2为1。
- 权利要求1-14任一项所述的化合物或其药学上可接受的盐,其中,L 3选自任选地被一个或多个R 7取代的下列基团:氨基、N-甲基哌啶、吡唑和三氮唑;其中,R 7独立地选自H(氢)、D(氘)、卤素、=O、CF 3、CN、CH 2CN、羧基、磺酸基、C 1-4烷基、C 1-4烷氧基、C 2-6烯基和C 2-6炔基;m 2为0或1。
- 权利要求1-15任一项所述的化合物或其药学上可接受的盐,其中,L 3选自:三氮唑;m 2为0或1。
- 权利要求1-22任一项的化合物或其药学上可接受的盐,其中,E选自任选被一个或多个R 12取代的嘧啶;其中,R 12独立地选自H(氢)、D(氘)。
- 权利要求1-23任一项所述的化合物或其药学上可接受的盐,其中,G选自卤素、OMs、OTs、OTf、硝基、以及任选被一个或多个R 13取代的下列基团:烷基硫醚基、芳基硫醚基、杂芳基硫醚基、烷基亚砜基、芳基亚砜基、杂芳基亚砜基、烷基磺酰基、芳基磺酰基或杂芳基磺酰基;其中,R 13独立地选自H(氢)、D(氘)、卤素、CN、硝基、C 1-6烷基、卤代C 1-6烷基、C 1-6烷氧基、6-10元芳基和5-12元杂芳基。
- 权利要求1-24任一项所述的化合物或其药学上可接受的盐,其中,G选自F、Cl、Br、I、OMs、OTs、OTf、甲磺酰基、乙磺酰基、对甲苯磺酰基和萘磺酰基。
- 权利要求1-25任一项所述的化合物或其药学上可接受的盐,其中,G选自F、Cl、Br、OMs、OTs、甲磺酰基和对甲苯磺酰基。
- 权利要求1-26任一项所述的化合物或其药学上可接受的盐,其中,G选自Cl和甲磺酰基。
- 权利要求1-39任一项所述的化合物或其药学上可接受的盐,其中,T为生物活性分子片段,所述生物活性分子选自金属配合物,例如金属铂配合物(例如奥沙利铂)、金属金配合物;糖肽类抗生素,例如博来霉素或平阳霉素;DNA拓扑异构酶抑制剂,例如拓扑异构酶I抑制剂(例如喜树碱、羟基喜树碱、9-氨基喜树碱、SN-38、伊立替康、拓扑替康、贝洛替康或卢比替康),拓扑异构酶II抑制剂(例如放线菌素D、阿霉素、多柔比星、多卡米星,柔红霉素、米托蒽醌、鬼臼毒素或依托泊苷);干扰DNA合成药物,例如甲氨蝶呤、5-氟尿嘧啶、阿糖胞苷、吉西他滨、巯嘌呤、喷司他丁、氟达拉滨、克拉屈滨或奈拉滨;作用于结构蛋白的药物,例如微管蛋白抑制剂,长春花生物碱类、长春新碱、长春碱、紫杉醇、多西他赛或卡巴他赛;肿瘤信号通路抑制剂,例如丝氨酸/苏氨酸激酶抑制剂、酪氨酸激酶抑制剂、天冬氨酸激酶抑制剂或组氨酸激酶抑制剂;蛋白酶体抑制剂;组蛋白去乙酰化酶抑制剂;肿瘤新生血管生成抑制剂;细胞周期蛋白抑制剂;美登素衍生物;卡里奇霉素衍生物;奥瑞他汀衍生物;Pyrrolobenzodiazepine dimers(PBD)衍生物;美法仑;丝裂霉素C;苯丁酸氮芥;以及其它抑制肿瘤细胞生长、促进肿瘤细胞凋亡或坏死的活性物质。
- 一种偶联物,其含有生物活性分子、连接体和靶向部分,所述靶向部分通过活性基团(例如巯基)与所述连接体连接形成偶联物。
- 权利要求55的偶联物,其结构如式(II)所示:{T-[L 1-(L 2) m1-(L 3) m2-(L 4) m3-E]} γ-A式(II)其中,A为靶向部分(例如小分子配体、蛋白质、多肽、非蛋白质试剂(例如糖、RNA或DNA));γ选自1-10之间的整数或小数;优选地,γ选自5-8之间的整数或小数(例如5、6、7或8);其余基团如权利要求1-54任一项所定义。
- 权利要求55-56任一项所述的偶联物,其中,A的靶标选自表皮生长因子、Trop-2、CD37、HER2、CD70、EGFRvIII、Mesothelin、Folate eceoptor1、Mucin 1、CD138、CD20、CD19、CD30、SLTRK6、Nectin 4、Tissue factor、Mucin16、Endothelinreceoptor、STEAP1、SLC39A6、Guanylylcyclase C、PSMA、CCD79b、CD22、Sodium phosphate cotransporter 2B、GPNMB、Trophoblast glycoprotein、AGS-16、EGFR、CD33、CD66e、CD74、CD56、PD-L1、TACSTD2、DR5、E16、STEAP1、0772P、MPF、Napi3b、Sema 5b、PSCA hlg、ETBR、MSG783、STEAP2、TrpM4、CRIPTO、CD21、CD79b、FcRH2、NCA、MDP、IL20Rα、Brevican、EphB2R、ASLG659、PSCA、GEDA、BAFF-R、CD22、CD79a、CXCR5、HLA-DOB、P2X5、CD72、LY64、FcRH1、IRTA2、TENB2、整合素α5β6,α4β7、FGF2、FGFR2、Her3、CD70、CA6、DLL3、DLL4、P-cadherin、EpCAM、pCAD、CD223、LYPD3、LY6E、EFNA4、ROR1、SLITRK6、5T4、ENPP3、SLC39A6、Claudin18.2、BMPR1B、E16、STEAP1、Tyro7、0772P、MPF、Napi3b、Sema 5b、PSCA hlg、ETBR、MSG783、STEAP2、TrpM4、CRIPTO、CD21、CD79b、FcRH2、NCA、MDP、IL20Rα、Brevican、EphB2R、ASLG659、PSCA、GEDA、CD22、CD79a、CXCR5、HLA-DOB、P2X5、CD72、LY64、FcRH1、IRTA2,c-Met,ApoE、CD1lc、CD40、CD45(PTPRC)、CD49D(ITGA4)、CD80、CSF1R、 CTSD、GZMB、Ly86、MS4A7、PIK3AP1、PIK3CD、CCR5、IFNG、IL10RA1、IL-6、ACTA2、COL7A1、LOX、LRRC15、MCPT8、MMP10、NOG、SERPINEl、STAT1、TGFBR1、CTSS、PGF、VEGFA、C1QA、C1QB、ANGPTL4、EGLN、ANGPTL4、EGLN3、BNIP3、AIF1、CCL5、CXCL10、CXCL11、IFI6、PLOD2、KISS1R、STC2、DDIT4、PFKFB3、PGK1、PDK1、AKR1C1、AKR1C2、CADM1、CDH11、COL6A3、CTGF、HMOX1、KRT33A、LUM、WNT5A、IGFBP3、MMP14、CDCP1、PDGFRA、TCF4、TGF、TGFB1、TGFB2、CDl lb、ADGRE1、EMR2、TNFRSF21、UPK1B、TNFSF9、MMP16、MFI2、IGF-1R、RNF43、NaPi2b、BCMA和TENB2。
- 权利要求55-57任一项所述的偶联物,其中,A为小分子配体例如叶酸衍生物、谷氨酸脲衍生物、生长抑素衍生物、芳基磺酰胺类衍生物(例如碳酸酐酶IX抑制剂)、连接两个脂肪族吲哚的多烯、花青染料和IR-783或其衍生物。
- 权利要求55-59任一项所述的偶联物,其中,A为抗体,例如单克隆抗体或其抗原结合片段,其中,所述单克隆抗体或其抗原结合片段包括Fab、Fab′、F(ab′) 2、Fd、Fv、dAb、互补决定区片段、单链抗体(例如, scFv)、非人抗体、人源化抗体、嵌合抗体、全人抗体、前抗(Probody)、双特异性抗体或多特异性抗体。
- 权利要求55-60任一项所述的偶联物,其中,A为抗Her 2的单克隆抗体或抗Trop-2的单克隆抗体,优选地,所述抗Trop-2的单克隆抗体选自Sacituzumab抗体、抗体M1、M2或M3;优选地,所述抗Her 2的单克隆抗体选自曲妥珠单抗、帕妥珠单抗;其中,所述抗体Sacituzumab的重链具有如SEQ ID No.:19所示的氨基酸序列;轻链具有如SEQ ID No.:20所示的氨基酸序列;所述抗体M1的重链可变区具有如SEQ ID No.:11所示的氨基酸序列;轻链可变区具有如SEQ ID No.:12所示的氨基酸序列;所述抗体M2的重链可变区具有如SEQ ID No.:13所示的氨基酸序列;轻链可变区具有如SEQ ID No.:14所示的氨基酸序列;所述抗体M3的重链可变区具有如SEQ ID No.:15所示的氨基酸序列;轻链可变区具有如SEQ ID No.:16所示的氨基酸序列;所述抗体M1、M2和M3的重链恒定区具有如SEQ ID No.:10所示的氨基酸序列;轻链恒定区具有如SEQ ID No.:9所示的氨基酸序列。
- 权利要求55-61任一项所述的偶联物,其中,A为抗Her 2的单克隆抗体或抗Trop-2的单克隆抗体,优选地,抗Trop-2的单克隆抗体选自Sacituzumab抗体,抗Her 2的单克隆抗体选自曲妥珠单抗、帕妥珠单抗。
- 权利要求55-62任一项所述的偶联物,其中,A选自识别细胞表面整联蛋白受体的RGD肽;识别细胞表面生长因子受体的生长因子例如EGF、PDGF或VEGF;以及能识别功能性细胞表面纤溶酶原活化因子、蛙皮素、缓激肽、生长抑素或前列腺特异性膜抗原受体的肽。
- 权利要求55-63任一项所述的偶联物,其中,A选自CD40配体、CD30配体、OX40配体、PD-1配体、ErbB配体、Her2配体、TACSTD2配体和DR5配体。
- 权利要求55-80任一项的偶联物的制备方法,包括将式(I)化合物的连接体与靶向部分的活性基团进行偶联的步骤。
- 权利要求81的偶联物的制备方法,包括将式(I)化合物的连接体与靶向部分形成C-S键的步骤。
- 权利要求81-82任一项偶联物的制备方法,所述偶联物靶向部分,为抗Her 2的单克隆抗体或抗Trop-2的单克隆抗体,或其活性片段或变体;优选的,抗Trop-2的单克隆抗体选自Sacituzumab抗体、抗体M1、M2或M3,抗Her 2的单克隆抗体选自曲妥珠单抗、帕妥珠单抗。
- 权利要求81-83任一项偶联物的制备方法,所述偶联物靶向部分,为抗Her 2的单克隆抗体或抗Trop-2的单克隆抗体,或其活性片段或变体;优选的,抗Trop-2的单克隆抗体选自Sacituzumab抗体,抗Her 2的单克隆抗体选自曲妥珠单抗、帕妥珠单抗。
- 权利要求81-84任一项的偶联物的制备的制备方法,所述偶联物靶向部分与式(I)化合物的物质的量之比为1∶(1-20);优选地,所述偶联在水和/或有机溶剂中进行;优选地,所述有机溶剂选自N,N-二甲基甲酰胺、二甲基亚砜、N-甲基吡咯烷酮、腈类(例如乙腈)、醇类(例如甲醇、乙醇)及其任意组合。
- 权利要求81-85任一项偶联物的制备方法,还包括将偶联产物进行纯化的步骤;优选地,通过层析方法对偶联产物进行纯化;优选的,所述的层析方法包括离子交换层析、疏水层析、反相层析或亲和层析中的一种或多种。
- 药物组合物,其包含权利要求1-54任一项的化合物或或其药学上可接受的盐,或权利要求55-80任一项的偶联物,以及一种或多种药用辅料。
- 权利要求1-54任一项的化合物或其药学上可接受的盐或权利要求55-80任一项的偶联物或权利要求87的药物组合物在制备治疗与细胞活动异常相关的疾病(例如癌症疾病)的药物中的用途。
- 权利要求1-54任一项的化合物或其药学上可接受的盐或权利要求55-80任一项的偶联物或权利要求87的药物组合物用于治疗与细胞活动异常相关的疾病(例如癌症疾病)中的用途。
- 权利要求88或89所述的用途,其中所述癌症疾病选自实体瘤或非实体瘤;例如选自食管癌(例如食管腺癌和食管鳞状细胞癌)、脑瘤、肺癌(例如小细胞性肺癌和非小细胞性肺癌)、鳞状上皮细胞癌、膀胱癌、胃癌、卵巢癌、腹膜癌、胰腺癌、乳腺癌、头颈癌、子宫颈癌、子宫内膜癌、结直肠癌、肝癌、肾癌、非霍奇金淋巴瘤、中枢神经系统肿瘤(例如神经胶质瘤、多形性胶质母细胞瘤、胶质瘤或肉瘤)、前列腺癌和甲状腺癌。
- 治疗与细胞活动异常相关的疾病(例如癌症疾病)的方法,包括给有此需要的个体有效剂量的权利要求1-54任一项的化合物或其药学上可接受的盐或权利要求55-80任一项的偶联物或权利要求87的药物组合物。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3080236A CA3080236A1 (en) | 2017-12-15 | 2018-12-10 | Bioactive molecule conjugate, preparation method and use thereof |
US16/758,980 US11970506B2 (en) | 2017-12-15 | 2018-12-10 | Bioactive molecule conjugate, preparation method and use thereof |
KR1020207010986A KR20200099123A (ko) | 2017-12-15 | 2018-12-10 | 생체활성 접합체, 이의 제조 방법 및 용도 |
CN201880069543.5A CN111295389B (zh) | 2017-12-15 | 2018-12-10 | 生物活性物偶联物及其制备方法和用途 |
EP18888623.8A EP3725798A4 (en) | 2017-12-15 | 2018-12-10 | BIOACTIVE CONJUGATE, METHOD FOR ITS MANUFACTURING AND USES |
JP2020521429A JP7446993B2 (ja) | 2017-12-15 | 2018-12-10 | 生物活性分子コンジュゲート、その調製法及び使用 |
US18/155,650 US20230357259A1 (en) | 2017-12-15 | 2023-01-17 | Bioactive conjugate, preparation method therefor and use thereof |
JP2023221143A JP2024038168A (ja) | 2017-12-15 | 2023-12-27 | 生物活性分子コンジュゲート、その調製法及び使用 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711347535.6 | 2017-12-15 | ||
CN201711347535 | 2017-12-15 | ||
CN201810230346.9 | 2018-03-20 | ||
CN201810230346 | 2018-03-20 | ||
CN201811071947 | 2018-09-14 | ||
CN201811071947.6 | 2018-09-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/758,980 A-371-Of-International US11970506B2 (en) | 2017-12-15 | 2018-12-10 | Bioactive molecule conjugate, preparation method and use thereof |
US18/155,650 Division US20230357259A1 (en) | 2017-12-15 | 2023-01-17 | Bioactive conjugate, preparation method therefor and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019114666A1 true WO2019114666A1 (zh) | 2019-06-20 |
Family
ID=66819957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/120125 WO2019114666A1 (zh) | 2017-12-15 | 2018-12-10 | 生物活性物偶联物及其制备方法和用途 |
Country Status (7)
Country | Link |
---|---|
US (2) | US11970506B2 (zh) |
EP (1) | EP3725798A4 (zh) |
JP (2) | JP7446993B2 (zh) |
KR (1) | KR20200099123A (zh) |
CN (5) | CN113603703A (zh) |
CA (1) | CA3080236A1 (zh) |
WO (1) | WO2019114666A1 (zh) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020156189A1 (zh) * | 2019-01-30 | 2020-08-06 | 四川科伦博泰生物医药股份有限公司 | 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途 |
CN112390885A (zh) * | 2019-08-12 | 2021-02-23 | 凯惠科技发展(上海)有限公司 | 一种trop2抗体及其制备方法、其偶联物和应用 |
EP3617221A4 (en) * | 2017-04-19 | 2021-04-14 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | CYTOTOXIN AND CONJUGATE, USES THEREOF AND MANUFACTURING PROCESSES THEREFORE |
WO2021148003A1 (zh) * | 2020-01-22 | 2021-07-29 | 上海森辉医药有限公司 | 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用 |
WO2021147993A1 (zh) * | 2020-01-22 | 2021-07-29 | 江苏恒瑞医药股份有限公司 | 抗trop-2抗体-依喜替康类似物偶联物及其医药用途 |
CN113181373A (zh) * | 2021-05-10 | 2021-07-30 | 深圳安特生物医药科技有限公司 | 一种抗体药物偶联制剂及其制备方法和应用 |
WO2022057651A1 (zh) | 2020-09-16 | 2022-03-24 | 四川科伦博泰生物医药股份有限公司 | 抗Nectin-4抗体、包含所述抗体的缀合物及其应用 |
WO2022170971A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州宜联生物医药有限公司 | 生物活性物偶联物及其制备方法和用途 |
WO2022184082A1 (en) * | 2021-03-03 | 2022-09-09 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates comprising an anti-bcma antibody |
WO2022228497A1 (zh) * | 2021-04-30 | 2022-11-03 | 四川科伦博泰生物医药股份有限公司 | 药物在治疗肿瘤疾病中的应用 |
WO2022253035A1 (zh) * | 2021-06-02 | 2022-12-08 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物及其制备方法和用途 |
WO2023016488A1 (zh) * | 2021-08-13 | 2023-02-16 | 昆山新蕴达生物科技有限公司 | 一种基于微管抑制剂的抗体偶联药物 |
WO2023030064A1 (zh) * | 2021-09-01 | 2023-03-09 | 四川科伦博泰生物医药股份有限公司 | 一种提高抗体药物偶联物产品质量的方法 |
WO2023065594A1 (zh) | 2021-10-19 | 2023-04-27 | 宝船生物医药科技(上海)有限公司 | 抗cd47-cldn18.2双特异性抗体及其用途 |
WO2023098515A1 (zh) * | 2021-12-02 | 2023-06-08 | 四川科伦博泰生物医药股份有限公司 | 一种药物-接头偶联物的制备方法 |
JP2023525120A (ja) * | 2020-05-15 | 2023-06-14 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | 抗体薬物複合体、その調製方法、およびその使用 |
WO2023201268A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating tumor antigen expressing cancers |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023221975A1 (zh) * | 2022-05-18 | 2023-11-23 | 苏州宜联生物医药有限公司 | 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
WO2024012524A1 (zh) * | 2022-07-14 | 2024-01-18 | 苏州宜联生物医药有限公司 | 抗体药物偶联物及其制备方法和用途 |
US11970506B2 (en) | 2017-12-15 | 2024-04-30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive molecule conjugate, preparation method and use thereof |
WO2024097812A1 (en) | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Therapy for treating bladder cancer |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230079096A (ko) * | 2020-09-30 | 2023-06-05 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항체-약물 접합체를 포함하는 약제학적 조성물 및 약제학적 조성물의 용도 |
CN117279664A (zh) | 2021-04-10 | 2023-12-22 | 普方生物制药美国公司 | Folr1结合剂、其偶联物及其使用方法 |
EP4326768A1 (en) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
CN114106088A (zh) * | 2021-04-28 | 2022-03-01 | 联宁(苏州)生物制药有限公司 | 基于溴甲基吡嗪的药物偶联物及adc |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
WO2023122228A1 (en) * | 2021-12-23 | 2023-06-29 | Adcentrx Therapeutics Inc. | Novel auristatin analogs and immunoconjugates thereof |
WO2023134706A1 (zh) * | 2022-01-13 | 2023-07-20 | 四川科伦博泰生物医药股份有限公司 | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 |
WO2023143208A1 (zh) * | 2022-01-26 | 2023-08-03 | 苏州宜联生物医药有限公司 | 一种药物连接体偶联物的制备方法 |
WO2023143154A1 (zh) * | 2022-01-28 | 2023-08-03 | 四川科伦博泰生物医药股份有限公司 | 一种药物组合物及其制备方法和应用 |
WO2023155808A1 (zh) * | 2022-02-16 | 2023-08-24 | 苏州宜联生物医药有限公司 | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 |
WO2023231988A1 (zh) * | 2022-05-30 | 2023-12-07 | 苏州宜联生物医药有限公司 | 一种药物连接体偶联物的制备方法及其中间体 |
WO2024002042A1 (zh) * | 2022-06-27 | 2024-01-04 | 百奥泰生物制药股份有限公司 | 治疗实体瘤的方法 |
WO2024012566A2 (en) * | 2022-07-15 | 2024-01-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibody, linkers, payload, conjugates and applications thereof |
WO2024027708A1 (zh) * | 2022-08-02 | 2024-02-08 | 诺纳生物(苏州)有限公司 | Msln抗体药物偶联物 |
WO2024078586A1 (en) | 2022-10-14 | 2024-04-18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody-drug conjugate binding to human ptk7 and method for preparation and use thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US7517964B2 (en) | 2002-03-01 | 2009-04-14 | Immunomedics, Inc. | RS7 antibodies |
US7560111B2 (en) | 2004-07-22 | 2009-07-14 | Genentech, Inc. | HER2 antibody composition |
US20120237518A1 (en) | 2010-06-10 | 2012-09-20 | Kyowa Hakko Kirin Co., Ltd | Anti-trop-2 antibody |
CN103319599A (zh) | 2013-05-27 | 2013-09-25 | 上海交联药物研发有限公司 | 一种抗人ErbB2抗体—美登木素偶联物及其应用 |
CN103476941A (zh) | 2010-04-12 | 2013-12-25 | 索伦托治疗有限公司 | 展示抗体的方法 |
WO2014144878A2 (en) * | 2013-03-15 | 2014-09-18 | The Scripps Research Institute | Novel thiol & amino modifying reagents for protein chemistry and methods of use thereof |
WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
WO2016142049A1 (en) | 2015-03-09 | 2016-09-15 | Heidelberg Pharma Gmbh | Amatoxin-antibody conjugates |
WO2018025168A1 (en) | 2016-08-03 | 2018-02-08 | Pfizer Inc. | Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP9300587A0 (en) * | 1992-11-12 | 1995-05-05 | Glaxo Inc | Water soluble camptothecin derivatives. |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
AU689131B2 (en) | 1993-10-01 | 1998-03-26 | Teikoku Hormone Mfg. Co., Ltd. | Novel peptide derivative |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
US8609105B2 (en) | 2008-03-18 | 2013-12-17 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
WO2011097627A1 (en) | 2010-02-08 | 2011-08-11 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 161p2f10b proteins |
CA2852860C (en) | 2011-11-17 | 2020-06-09 | Matthew David DOROSKI | Cytotoxic peptides and antibody drug conjugates thereof |
CN104662000B (zh) | 2012-05-15 | 2018-08-17 | 索伦托医疗有限公司 | 药物偶联物及其偶联方法和用途 |
US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
JP6366111B2 (ja) * | 2012-12-13 | 2018-08-01 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 有効性の改善および毒性の減少のための、抗体およびsn−38からなるイムノコンジュゲートの投薬 |
CN105407891A (zh) * | 2013-07-23 | 2016-03-16 | 免疫医疗公司 | 具有cl2a接头的抗体-sn-38免疫缀合物 |
EP3226909A1 (en) * | 2014-12-03 | 2017-10-11 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
EP3954394A1 (en) | 2015-06-19 | 2022-02-16 | Centurion BioPharma Corporation | Delivery systems for controlled drug release |
EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
WO2017031034A2 (en) * | 2015-08-14 | 2017-02-23 | Rc Biotechnologies, Inc. | Covalent linkers in antibody-drug conjugates and methods of making and using the same |
CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
CN107029244B (zh) | 2016-02-04 | 2021-04-27 | 浙江昭华生物医药有限公司 | 抗her2抗体-药物偶联物及其应用 |
JP2020512314A (ja) | 2017-03-27 | 2020-04-23 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | サシツズマブゴビテカンとRAD51阻害剤を用いたTrop−2発現トリプルネガティブ乳癌の治療 |
CA3065919A1 (en) * | 2017-06-07 | 2018-12-13 | Silverback Therapeutics, Inc. | Antibody construct conjugates |
US11970506B2 (en) * | 2017-12-15 | 2024-04-30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive molecule conjugate, preparation method and use thereof |
CN110903395A (zh) * | 2018-09-14 | 2020-03-24 | 四川科伦博泰生物医药股份有限公司 | 抗体、偶联物及其制备方法和用途 |
-
2018
- 2018-12-10 US US16/758,980 patent/US11970506B2/en active Active
- 2018-12-10 CN CN202111110831.0A patent/CN113603703A/zh active Pending
- 2018-12-10 CN CN202111113700.8A patent/CN113698414A/zh active Pending
- 2018-12-10 CN CN201880069543.5A patent/CN111295389B/zh active Active
- 2018-12-10 JP JP2020521429A patent/JP7446993B2/ja active Active
- 2018-12-10 WO PCT/CN2018/120125 patent/WO2019114666A1/zh unknown
- 2018-12-10 CN CN202111110433.9A patent/CN113651831A/zh active Pending
- 2018-12-10 KR KR1020207010986A patent/KR20200099123A/ko unknown
- 2018-12-10 CA CA3080236A patent/CA3080236A1/en active Pending
- 2018-12-10 EP EP18888623.8A patent/EP3725798A4/en active Pending
- 2018-12-10 CN CN202111114512.7A patent/CN113683622A/zh active Pending
-
2023
- 2023-01-17 US US18/155,650 patent/US20230357259A1/en active Pending
- 2023-12-27 JP JP2023221143A patent/JP2024038168A/ja active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US7517964B2 (en) | 2002-03-01 | 2009-04-14 | Immunomedics, Inc. | RS7 antibodies |
US7560111B2 (en) | 2004-07-22 | 2009-07-14 | Genentech, Inc. | HER2 antibody composition |
CN103476941A (zh) | 2010-04-12 | 2013-12-25 | 索伦托治疗有限公司 | 展示抗体的方法 |
US20120237518A1 (en) | 2010-06-10 | 2012-09-20 | Kyowa Hakko Kirin Co., Ltd | Anti-trop-2 antibody |
WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
WO2014144878A2 (en) * | 2013-03-15 | 2014-09-18 | The Scripps Research Institute | Novel thiol & amino modifying reagents for protein chemistry and methods of use thereof |
CN103319599A (zh) | 2013-05-27 | 2013-09-25 | 上海交联药物研发有限公司 | 一种抗人ErbB2抗体—美登木素偶联物及其应用 |
WO2016142049A1 (en) | 2015-03-09 | 2016-09-15 | Heidelberg Pharma Gmbh | Amatoxin-antibody conjugates |
WO2018025168A1 (en) | 2016-08-03 | 2018-02-08 | Pfizer Inc. | Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates |
Non-Patent Citations (16)
Title |
---|
"Genebank", Database accession no. X03363 |
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883 |
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
DICK, L.W. ET AL., BIOTECHNOL. BIOENG., vol. 100, pages 1132 - 1143 |
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 |
LI, XIULING ET AL.: "Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues", BIOCONJUGATE CHEMISTRY, vol. 26, no. 11, 18 November 2015 (2015-11-18), pages 2243 - 2248, XP055416982, DOI: doi:10.1021/acs.bioconjchem.5b00244 * |
LIANG, XIAOFEI ET AL.: "Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3- (trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL- ABL-053) as a Potent, Selective, and Orally Available BCR-ABUSRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, 31 December 2016 (2016-12-31), pages 1984 - 2004, XP055603365, DOI: doi:10.1021/acs.jmedchem.5b01618 * |
MARKS ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 222, 1991, pages 581 - 597 |
MORRISON ET AL., PNAS, vol. 81, 1984, pages 6851 - 6855 |
PATTERSON, J.T. ET AL.: "Improving the Serum Stability of Site-Specific Antibody Conjugates with Sulfone Linkers", BIOCONJUGATE CHEMISTRY, vol. 25, no. 8, 20 August 2014 (2014-08-20), pages 1402 - 1407, XP055338868, DOI: doi:10.1021/bc500276m * |
PRESTA, CURR OP STRUCT BWL, vol. 2, 1992, pages 593 - 596 |
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329 |
SEMBA ET AL., PNAS, vol. 82, 1985, pages 6497 - 6501 |
TODA, N. ET AL.: "Rapid, Stable, Chemoselective Labeling of Thiols with Julia-Kocienski-Like Reagents: A Serum-Stable Alternative to Maleimide-Based Protein Conjugation", ANGEWANDTE CHEMI INTERNATIONAL EDITION, vol. 52, no. 48, 2 October 2013 (2013-10-02), pages 12592 - 12596, XP055416940, DOI: doi:10.1002/anie.201306241 * |
YAMAMOTO ET AL., NATURE, vol. 319, 1986, pages 230 - 234 |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11207420B2 (en) | 2017-04-19 | 2021-12-28 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Cytotoxin and conjugate, uses of same and preparation method therefor |
EP3617221A4 (en) * | 2017-04-19 | 2021-04-14 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | CYTOTOXIN AND CONJUGATE, USES THEREOF AND MANUFACTURING PROCESSES THEREFORE |
US11970506B2 (en) | 2017-12-15 | 2024-04-30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive molecule conjugate, preparation method and use thereof |
WO2020156189A1 (zh) * | 2019-01-30 | 2020-08-06 | 四川科伦博泰生物医药股份有限公司 | 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途 |
CN112390885A (zh) * | 2019-08-12 | 2021-02-23 | 凯惠科技发展(上海)有限公司 | 一种trop2抗体及其制备方法、其偶联物和应用 |
CN112390885B (zh) * | 2019-08-12 | 2024-01-19 | 凯惠科技发展(上海)有限公司 | 一种trop2抗体及其制备方法、其偶联物和应用 |
WO2021148003A1 (zh) * | 2020-01-22 | 2021-07-29 | 上海森辉医药有限公司 | 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用 |
CN114846021A (zh) * | 2020-01-22 | 2022-08-02 | 江苏恒瑞医药股份有限公司 | 抗trop-2抗体-依喜替康类似物偶联物及其医药用途 |
CN114845739A (zh) * | 2020-01-22 | 2022-08-02 | 上海森辉医药有限公司 | 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用 |
EP4095148A4 (en) * | 2020-01-22 | 2023-07-26 | Jiangsu Hengrui Medicine Co., Ltd. | ANTI-TROP-2 ANTIBODY EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF |
WO2021147993A1 (zh) * | 2020-01-22 | 2021-07-29 | 江苏恒瑞医药股份有限公司 | 抗trop-2抗体-依喜替康类似物偶联物及其医药用途 |
JP7407973B2 (ja) | 2020-05-15 | 2024-01-04 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | 抗体薬物複合体、その調製方法、およびその使用 |
JP2023525120A (ja) * | 2020-05-15 | 2023-06-14 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | 抗体薬物複合体、その調製方法、およびその使用 |
WO2022057651A1 (zh) | 2020-09-16 | 2022-03-24 | 四川科伦博泰生物医药股份有限公司 | 抗Nectin-4抗体、包含所述抗体的缀合物及其应用 |
JP7458686B2 (ja) | 2020-09-16 | 2024-04-01 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | 抗ネクチン-4抗体、それを含むコンジュゲート、及びその適用 |
WO2022170971A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州宜联生物医药有限公司 | 生物活性物偶联物及其制备方法和用途 |
CN115279417A (zh) * | 2021-02-09 | 2022-11-01 | 苏州宜联生物医药有限公司 | 生物活性物偶联物及其制备方法和用途 |
WO2022184082A1 (en) * | 2021-03-03 | 2022-09-09 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates comprising an anti-bcma antibody |
WO2022228497A1 (zh) * | 2021-04-30 | 2022-11-03 | 四川科伦博泰生物医药股份有限公司 | 药物在治疗肿瘤疾病中的应用 |
CN113181373B (zh) * | 2021-05-10 | 2024-03-01 | 深圳安特生物医药科技有限公司 | 一种抗体药物偶联制剂及其制备方法和应用 |
CN113181373A (zh) * | 2021-05-10 | 2021-07-30 | 深圳安特生物医药科技有限公司 | 一种抗体药物偶联制剂及其制备方法和应用 |
WO2022253035A1 (zh) * | 2021-06-02 | 2022-12-08 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物及其制备方法和用途 |
WO2023016488A1 (zh) * | 2021-08-13 | 2023-02-16 | 昆山新蕴达生物科技有限公司 | 一种基于微管抑制剂的抗体偶联药物 |
WO2023030064A1 (zh) * | 2021-09-01 | 2023-03-09 | 四川科伦博泰生物医药股份有限公司 | 一种提高抗体药物偶联物产品质量的方法 |
WO2023065594A1 (zh) | 2021-10-19 | 2023-04-27 | 宝船生物医药科技(上海)有限公司 | 抗cd47-cldn18.2双特异性抗体及其用途 |
WO2023098515A1 (zh) * | 2021-12-02 | 2023-06-08 | 四川科伦博泰生物医药股份有限公司 | 一种药物-接头偶联物的制备方法 |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2023201268A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating tumor antigen expressing cancers |
WO2023221975A1 (zh) * | 2022-05-18 | 2023-11-23 | 苏州宜联生物医药有限公司 | 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
WO2024012524A1 (zh) * | 2022-07-14 | 2024-01-18 | 苏州宜联生物医药有限公司 | 抗体药物偶联物及其制备方法和用途 |
WO2024097812A1 (en) | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Therapy for treating bladder cancer |
Also Published As
Publication number | Publication date |
---|---|
EP3725798A1 (en) | 2020-10-21 |
KR20200099123A (ko) | 2020-08-21 |
US11970506B2 (en) | 2024-04-30 |
JP2021506743A (ja) | 2021-02-22 |
CN113603703A (zh) | 2021-11-05 |
US20200347075A1 (en) | 2020-11-05 |
CN113698414A (zh) | 2021-11-26 |
JP2024038168A (ja) | 2024-03-19 |
EP3725798A4 (en) | 2021-11-10 |
CN111295389B (zh) | 2021-10-22 |
CN113651831A (zh) | 2021-11-16 |
CA3080236A1 (en) | 2019-06-20 |
CN113683622A (zh) | 2021-11-23 |
US20210101906A2 (en) | 2021-04-08 |
US20230357259A1 (en) | 2023-11-09 |
JP7446993B2 (ja) | 2024-03-11 |
CN111295389A (zh) | 2020-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019114666A1 (zh) | 生物活性物偶联物及其制备方法和用途 | |
US11505617B2 (en) | Benzodiazepine derivatives | |
WO2014145090A1 (en) | Biologically active molecules, conjugates thereof, and therapeutic uses | |
TW201427694A (zh) | 親水性自消耗連接子及彼等之共軛物 | |
WO2019149116A1 (zh) | 制备偶联物的方法 | |
US11207420B2 (en) | Cytotoxin and conjugate, uses of same and preparation method therefor | |
WO2019154120A1 (zh) | 细胞毒性剂及其偶联物、其制备方法及用途 | |
WO2022253035A1 (zh) | 抗体药物偶联物及其制备方法和用途 | |
CN116036303A (zh) | 一种抗体-药物偶联物及其制备方法和应用 | |
WO2023207773A1 (en) | Ligand-drug conjugate of camptothecin analogs, intermediates, preparation method therefor, pharmaceutical composition and application thereof | |
WO2023155808A1 (zh) | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 | |
WO2023222019A1 (zh) | 配体药物偶联物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18888623 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020521429 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3080236 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018888623 Country of ref document: EP Effective date: 20200715 |